0001213900-26-036520 | S-4/A | XBRL Viewer

Print Document

Related Party Balances and Transactions - Schedule of Related Parties Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current
Allowance for credit loss			$ (521,007)
Convertible notes to a related party
Convertible notes to a related party - Current	$ 3,418,500	$ 3,238,500
Loan from related parties			2,500,000
Issuance of Convertible Note to related parties			3,000,000
Loan to related parties			92,459
Healthcare services income			431,378
Libra Sciences Limited [Member]
Current
Amounts due from related parties	522,192	522,192
Convertible notes to a related party
Loan to related parties			92,459
Interest income			8,963
Administrative management services			9,615
Related Party [Member]
Current
Amounts due from related parties
Allowance for credit loss	(522,192)	(522,192)
Current
Amounts due to related parties, current	79,180	79,644
Aeneas Group Limited [Member]
Current
Amounts due to related parties, current	79,180	79,180
Convertible notes to a related party
Loan from related parties			2,500,000
Settlement of loan from a related party through issuance of Convertible Note			3,000,000
Interest expenses			71,123
Ian Huen [Member]
Current
Amounts due to related parties, current		464
Jurchen Investment Corporation [Member]
Convertible notes to a related party
Convertible notes to a related party - Current	3,418,500	3,238,500
Issuance of Convertible Note to related parties			3,000,000
Interest expenses	180,000	180,000	58,500
Aenco Technologies Ltd [Member]
Convertible notes to a related party
Interest expenses			(13,234)
Talem Medical Group Limited [Member]
Convertible notes to a related party
Loan repayment and interest received from a related party			611,641
Interest income			4,637
CGY Investments Limited [Member]
Convertible notes to a related party
Consultant, secondment, management and administrative services fees			153,640
ACC Medical Limited [Member]
Convertible notes to a related party
Consultant, secondment, management and administrative services fees			138,768
Aeneas Management Limited [Member]
Convertible notes to a related party
Healthcare services income			$ 961

Income Taxes - Schedule of Income Taxes Paid (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Income Taxes Paid [Line Items]
Total income taxes paid
Hong Kong [Member]
Schedule of Income Taxes Paid [Line Items]
Total income taxes paid
Singapore [Member]
Schedule of Income Taxes Paid [Line Items]
Total income taxes paid
Other Jurisdictions [Member]
Schedule of Income Taxes Paid [Line Items]
Total income taxes paid

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Stockholders’ Equity - Schedule of Stock Option Activity (Details) - Stock Option Plan [Member] - DiamiR Biosciences Corp. [Member] - Share-Based Payment Arrangement, Option [Member] - $ / shares		12 Months Ended
	May 31, 2023	May 31, 2025	May 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number, Granted			153,000
Weighted Average Exercise Price, Granted			$ 0.01
Number, Exercised
Weighted Average Exercise Price, Exercised
Number, Expired or forfeited			(198,500)
Weighted Average Exercise Price, Expired or forfeited			$ 4.95
Number of share options, Outstanding, Ending	557,450	511,950	511,950
Weighted average exercise price, Outstanding, Ending	$ 6.04	$ 4.66	$ 4.66
Remaining contractual term in years, Outstanding, Ending		5 years 6 months
Number, Exercisable, Balance		263,450
Weighted Average Exercise Price, Exercisable, Balance		$ 4.96
Weighted Average Remaining Life, Exercisable, Balance		4 years

Accounts Payable and Accrued Expenses

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Accounts Payable and Accrued Expenses [Line Items]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Research and development expenses payable	$	830,189	$	778,205
Professional fees payable		185,247		127,031
Others		56,279		13,375
	$	1,071,715	$	918,611

DiamiR Biosciences Corp. [Member]

Accounts Payable and Accrued Expenses [Line Items]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

	November 30, 2025		May 31, 2025
Outside services	$	643,784	$	220,411
Employee compensation		19,248		5,884
Other		10,364		5,563
Total	$	673,396	$	231,858

NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

	May 31, 2025		May 31, 2024
Outside services	$	220,411	$	123,065
Employee compensation		5,884		12,285
Other		5,563		13,298
Total	$	231,858	$	148,648

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Schedule of Accounts Payable and Accrued Expenses [Abstract]
Research and development expenses payable	$ 830,189	$ 778,205
Professional fees payable	185,247	127,031
Others	56,279	13,375
Accounts payable and accrued expenses	$ 1,071,715	$ 918,611

Commitments and Contingencies (Details) - USD ($)		12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Aug. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Milestone payments			$ 61,123	$ 50,000
Common stock received	$ 500,000
Exercise price (in Dollars per share)	$ 0.01	$ 2
Gross proceeds	$ 4,000,000
Cash fee	250,000
Purchase of warrants	$ 250,000

Net Loss Per Share

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Net Loss Per Share [Line Items]

NET LOSS PER SHARE

19. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted loss per share:

	Year ended December 31, 2025			Year ended December 31, 2024			Year ended December 31, 2023
Numerator:
Net loss attributable to Aptorum Group Limited	$	(1,363,270	)	$	(4,267,806	)	(2,824,647	)
Denominator:
Basic and diluted weighted average shares outstanding		7,351,784			5,453,103		4,521,133

Net loss per share attributable to Aptorum Group Limited(1)
Basic and diluted loss per share	$	(0.19	)	$	(0.78	)	(0.62	)

Basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation of diluted loss per share in loss periods as their effect would be anti-dilutive. For the year ended December 31, 2025, 2024 and 2023, the total number of share options, warrants and convertible notes excluded from the calculation of diluted earnings per share due to their anti-dilutive nature, are 3,452,457, 1,392,277 and 1,293,723, respectively.

DiamiR Biosciences Corp. [Member]

Net Loss Per Share [Line Items]

NET LOSS PER SHARE

NOTE 12 — LOSS PER SHARE

The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive in the six months ended November 30:

	2025	2024
Stock options	441,750	511,950
Restricted stock	88,000	88,000
Warrants	—	29,336

Additional shares are issuable under the Company’s convertible notes, the amount of which is dependent on future events.

NOTE 13 — LOSS PER SHARE

The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive:

	2025	2024
Stock options	511,950	511,950
Restricted stock	88,000	88,000
Warrants	—	29,336

Additional shares are issuable under the Company’s convertible notes, the amount of which is dependent on future events.

Convertible Notes Payable - Schedule of Interest Expenses (Details) - Previously Reported [Member] - DiamiR Biosciences Corp. [Member] - USD ($)	6 Months Ended		12 Months Ended
	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024
Schedule of Interest Expenses [Line Items]
Interest on notes	$ 25,607	$ 19,490	$ 38,508	$ 23,232
Amortization of discount	31,550	19,349	$ 43,538	$ 25,367
Total	$ 57,157	$ 38,839

- Definition

Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-24

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483013/835-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-3

+ Details

Loss Per Share - Schedule of Antidilutive Common Stock Equivalents (Details) - DiamiR Biosciences Corp. [Member] - shares	6 Months Ended		12 Months Ended
	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024
Stock options [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares	441,750	511,950	511,950	511,950
Restricted Stock [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares	88,000	88,000	88,000	88,000
Warrants [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares		29,336		29,336

Other Receivables and Prepayments (Tables)

12 Months Ended

Dec. 31, 2025

Other Receivables and Prepayments [Abstract]

Schedule of Other Receivables and Prepayments

Other receivables and prepayments as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Prepaid insurance		17,490		17,794
Prepaid service fee		44,810		50,538
Rental deposits		71,823		4,206
Other receivables		—		4,545
Other deposits		5,510		8,233
	$	139,633	$	85,316

Other Receivables and Prepayments (Details) - USD ($)	12 Months Ended
Other Receivables and Prepayments (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Other Receivables and Prepayments [Abstract]
Write-off of other receivables and prepayments		$ 45,677	$ 62,369

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2025	May 31, 2025
Subsequent Events [Line Items]
SUBSEQUENT EVENTS	22. SUBSEQUENT EVENTS The Group evaluates all events and transactions that occur after December 31, 2025, there is no subsequent event occurred that would require recognition or disclosure in the Group’s consolidated financial statements.
DiamiR Biosciences Corp. [Member]
Subsequent Events [Line Items]
SUBSEQUENT EVENTS		NOTE 16 — SUBSEQUENT EVENTS In June 2025, DiamiR amended the convertible note with Kira Sheinerman, one of its founders and the Executive Director, such that the founder loaned us additional $150,000. In July 2025, the Company entered into a definitive merger agreement with Aptorum Group Limited, a publicly traded Cayman Islands company. Pursuant to the merger agreement, if completed, shareholders of the Company would receive shares of the acquirer’s common stock in a share exchange. Accounting for the merger, if consummated, is not complete. Under the merger agreement, the Company’s outstanding convertible notes are expected to be converted to shares of common stock. Concurrent with the execution of the merger agreement, the companies entered into a management service agreement and a license agreement through earlier of the closing of the merger or December 31, 2025 under which the Company will provide certain development services. On July 4, 2025, H.R.1, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBB eliminates the requirement under Internal Revenue Code Section 174 to capitalize and amortize U.S.-based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred, among other provisions. The Company is currently evaluating the impact on its consolidated financial statements of the provisions of the OBBBA, which may result in a significant reduction of recorded income tax liabilities. The provisions were not effective as of May 31, 2025 and their effects, if any, are expected to be recorded in the Company’s consolidated financial statements for the year ending May 31, 2026. On July 7, 2025, DiamiR entered into a financial advisory agreement with H.C. Wainwright & Co., LLC (“Wainwright”), with Wainwright to act as exclusive financial advisor to DiamiR in connection with the merger with Aptorum. As compensation for its services, upon the consummation of the Merger, Wainwright will receive common stock purchase warrants to purchase up to a number of shares of common stock of the combined company equal to $500,000 divided by the closing price of the combined company’s common stock on the date of consummation of the Merger, which warrants shall have an exercise price of $0.01 per share and a term of exercise of five years. In the event that DiamiR (or the combined company) consummates one or more financing transactions, with gross proceeds of at least $4,000,000 following the execution of the Merger Agreement through and including the consummation of the Merger and within 90 days thereafter, Wainwright shall receive a cash fee of $250,000, which cash fee shall be paid in lieu of a number of warrants equal to $250,000. The Executive Director and co-founder of DiamiR, is currently a managing director of Wainwright. The Company has evaluated subsequent events through October 6, 2025, the date these financial statements were available to be issued.

Revenue

12 Months Ended

Dec. 31, 2025

Revenue [Abstract]

REVENUE

5. REVENUE

During the second quarter of 2023, the Group made a decision to streamline its operations by terminating clinic services and suspending non-lead R&D projects. No revenue was generated for the year ended December 31, 2025 and 2024.

For the year ended December 31, 2023, all revenue came from provision of healthcare services in Hong Kong.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Organization (Details)		6 Months Ended	12 Months Ended
Organization (Details)	Jul. 14, 2025	Nov. 30, 2025	Dec. 31, 2025	May 31, 2025	Mar. 31, 2026
Organization (Details) [Line Items]
Entity Incorporation, Date of Incorporation			Sep. 13, 2010
Capital stock percentage	70.00%
Equity holders stock percentage	30.00%
DiamiR Biosciences Corp. [Member] \| Share Exchange Agreement [Member]
Organization (Details) [Line Items]
Shares issued and outstanding, percentage				100.00%
Ian Huen [Member] \| Subsequent Event [Member]
Organization (Details) [Line Items]
Owns percentage					87.00%
DiamiR, LLC [Member] \| DiamiR Biosciences Corp. [Member]
Organization (Details) [Line Items]
Ownership interest percent		100.00%

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	Nov. 30, 2025	May 31, 2025
Schedule of Convertible Notes Payable [Line Items]
Convertible notes payable	$ 1,252,125	$ 957,662
Executive director [Member]
Schedule of Convertible Notes Payable [Line Items]
Convertible notes payable	1,060,565	872,245
Former Chief Scientific Officer [Member]
Schedule of Convertible Notes Payable [Line Items]
Convertible notes payable	89,782	85,417
Investor [Member]
Schedule of Convertible Notes Payable [Line Items]
Convertible notes payable	$ 101,778

Income Taxes - Schedule of Income/(Loss) Before Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Income/(Loss) Before Income Tax Expense [Line Items]
Loss before income tax expense	$ (1,376,430)	$ (4,157,737)	$ (4,340,975)
Hong Kong [Member]
Schedule of Income/(Loss) Before Income Tax Expense [Line Items]
Loss before income tax expense	(1,409,614)	(3,944,692)	(1,297,897)
Singapore [Member]
Schedule of Income/(Loss) Before Income Tax Expense [Line Items]
Loss before income tax expense	111,972	(252,611)	(2,956,296)
Other Jurisdictions [Member]
Schedule of Income/(Loss) Before Income Tax Expense [Line Items]
Loss before income tax expense	$ (78,788)	$ 39,566	$ (86,782)

- Definition

Amount after tax of income (loss) from continuing operations attributable to the parent.

+ References

+ Details

Summary of Significant Accounting Policies

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Summary of Significant Accounting Policies [Line Items]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of presentation and consolidation

The consolidated financial statements of the Group are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United Stated Securities and Exchange Commission (the “SEC”), and include the accounts of the Group, its direct and indirect wholly and majority owned subsidiaries. In accordance with the provisions of Accounting Standards Codification (“ASC”) 810, Consolidation, the Group also consolidate any variable interest entity (“VIE”) of which the Group is the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Group does not consolidate a VIE in which the Group has a majority ownership interest when we are not considered the primary beneficiary. The Group has determined that the Group is the primary beneficiary of the VIE (see Note 13, Variable Interest Entity). The Group evaluate its relationships with the VIE on an ongoing basis to determine whether it becomes the primary beneficiary. All material intercompany balances and transactions have been eliminated in preparation of the consolidated financial statements.

Non-controlling interests

Non-controlling interests are recognized to reflect the portion of the equity of majority-owned subsidiaries which are not attributable, directly or indirectly, to the controlling shareholder. Non-controlling interests are classified as a separate line item in the equity section of the Group’s consolidated balance sheets and have been separately disclosed in the Group’s consolidated statements of operations and comprehensive loss and consolidated statements of equity to distinguish the interests from that of the Group.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as income and expenses during the reporting period. Actual results could differ from those estimates. There is no significant accounting estimate.

Foreign currency translation and transaction

USD is the reporting currency. The functional currency of subsidiaries in the Cayman Islands, Seychelles, Samoa and the United States are USD, the functional currency of subsidiaries in Hong Kong is Hong Kong Dollars (“HKD”), the functional currency of a subsidiary in Singapore is Singapore Dollars (“SGD”) and the functional currency of a subsidiary in the United Kingdom is Great British Pound (“GBP”). An entity’s functional currency is the currency of the primary economic environment in which it operates, normally that is the currency of the environment in which it primarily generates and expends cash. The management considered various indicators, such as cash flows, market expenses, financing and inter-company transactions and arrangements in determining the Group’s functional currency.

In the consolidated financial statements, the financial information of the Company and its subsidiaries, which use HKD, SGD and GBP as their functional currency, has been translated into USD. Assets and liabilities are translated from each subsidiary’s functional currency at the exchange rates on the balance sheet dates, equity amounts are translated at historical exchange rates, and revenues, expenses, gains, and losses are translated using the average exchange rates for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income or loss in the consolidated statements of operations and comprehensive income or loss.

Cash and cash equivalents

Cash and cash equivalents consists of cash on hand, bank deposits and time deposits with an original maturity of three months or less at the date of purchase.

Accounts receivable and amounts due from related parties

Accounts receivable and amounts due from related parties are stated at the original amount less an allowance for credit losses, if any, based on a review of all outstanding amounts at period end. An allowance is estimated in accordance with ASC Topic 326, Credit Losses and records the allowance for credit losses as an offset to accounts receivable or amounts due from related parties, and the expected credit losses charged to the allowance is included in other operating expenses in the consolidated statements of operations and comprehensive loss. In determining expected credit losses, the Group considers the historical level of credit losses, current economic trends, and reasonable and supportable forecasts that affect the collectability of the future cash flows. As of December 31, 2025 and 2024, $522,191 and $522,191 allowance for credit losses were made. During December 31, 2025, 2024 and 2023, $nil, $nil and $522,191 of allowance for credit losses were made.

Long-term investments, net

The Group’s long-term investments consist of equity method investment in common stocks and non-marketable investments in non-redeemable preferred shares of privately-held companies that are not required to be consolidated under the variable interest or voting models. Long-term investments are classified as non-current assets on the consolidated balance sheets as those investments do not have stated contractual maturity dates.

Non-marketable investments

The non-marketable equity securities not accounted for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date. The Group also makes a qualitative assessment of whether the investment is impaired at each reporting date. If a qualitative assessment indicates that the investment is impaired, the Group has to estimate the investment’s fair value in accordance with the principles of ASC 820. If the fair value is less than the investment’s carrying value, the Group recognizes an impairment loss in earnings equal to the difference between the carrying value and fair value.

Equity method investment — Fair value option

The Group elects the fair value option for an investment that would otherwise be accounted for using the equity method of accounting. Such election is irrevocable and is applied on an investment by investment basis at initial recognition. The fair value of such investments is based on quoted prices in an active market, if any, or recent orderly transactions for identical or similar investment of the same issuer. Changes in the fair value of these equity method investments are recognized in other income (expenses), net in the consolidated statements of operations and comprehensive loss.

Fair value measurement

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market participants would use when pricing the asset or liability.

As a basis for considering such assumptions, a three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:

• Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

• Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

• Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The hierarchy requires the Group to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables represent the fair value hierarchy of the Group’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and there is no such financial liabilities measured at fair value on a recurring basis as of December 31, 2024.

	As of December 31, 2025
	Fair Value Measurement at the Reporting Date using
	Quoted price in active markets for identical assets Level 1		Significant other observable inputs Level 2		Significant unobservable inputs Level 3		Total
Financial liabilities:
Warrant liabilities		—		—		306,000		306,000
Total	$	—	$	—	$	306,000	$	306,000

The Group has determined that the carrying value of the Group’s cash and cash equivalents, other receivables and prepayments, amounts due to related parties, accounts payable and accrued expenses, convertible notes to a related party approximate fair value due to the short-term nature of these assets and liabilities.

Property and equipment, net

Property and equipment, net, is stated at cost less accumulated depreciation and impairment losses. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major additions to physical properties are capitalized.

Assets under construction are stated at cost less impairment losses. Cost comprises of cost of laboratory equipment delivered but not ready to be used, together with interest expense capitalized during the period of construction or installation and testing. Capitalization of these costs ceases and the asset concerned is transferred to the appropriate fixed assets category when substantially all the activities necessary to prepare the asset for its intended use are completed.

Depreciation of property and equipment is provided using the straight-line method over their estimated useful lives:

Computer equipment		3 years
Furniture, fixture, and office and medical equipment		5 years
Leasehold improvements		Shorter of the remaining lease terms or 5 years
Laboratory equipment		5 years
Motor vehicle		5 years

Upon sale or disposal, the applicable amounts of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or credited to operating expenses.

Intangible assets, net

Finite-lived intangible assets are carried at cost less accumulated amortization and impairment if any. The finite intangible assets are amortized over their estimated useful life, which is the period over which the assets are expected to contribute directly or indirectly to the future cash flows of the Group.

The Group’s intangible assets mainly consist of computer software and is amortized over its useful life. The estimated useful life is generally 5 years. The Group will reassess the remaining useful life on annual basis.

Impairment of long-lived assets

The Group reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events occur, the Group compares the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over the fair value of the assets, using the expected future discounted cash flows.

Convertible notes

The Group evaluates and accounts for conversion options embedded in convertible notes in accordance with ASC 815 “Derivatives and Hedging Activities”.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Group accounts for the convertible notes as a single unit of account, unless the conversion feature requires bifurcation and recognition as derivatives. Additionally, the Group uses the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of potential share settlement for instruments that may be settled in cash or shares.

Operating leases

At the inception of a contract, the Group determines if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Group’s option to extend (or not to terminate) the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.

The Group has elected not to recognize right-of-use assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases on a straight-line basis over the lease terms.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Group’s own ordinary shares and whether the warrant holders could potentially require “net cash

settlement” in a circumstance outside of the Group’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the consolidated statements of operations.

For equity-classified warrants that contain redemption features not solely within the control of the Company, the Company evaluates whether temporary equity classification is required pursuant to ASC 480-10-S99-3A. When temporary equity classification is required, the initial amount presented in temporary equity is based on the redemption provisions of the instrument. If the redemption event is contingent and not probable of occurring, no subsequent adjustment to the temporary equity amount is required pursuant to S99-3A Paragraph 15.

Issuance costs

Specific incremental costs directly attributable to an offering of securities are allocated among the freestanding financial instruments issued in the transaction. The Company allocates issuance costs in proportion to the allocation of proceeds between the freestanding financial instruments. Issuance costs allocated to liability-classified instruments that are subsequently measured at fair value through earnings are recognized in earnings in the period incurred. Issuance costs allocated to equity-classified instruments are charged to additional paid-in capital.

Revenue recognition

Revenues are derived from healthcare services rendered to patients for healthcare consultation and medical treatment. Revenue is reported at the amount that reflects the consideration to which the Group expects to be entitled in exchange for providing healthcare services.

The Group recognizes revenue as its performance obligations are completed. Healthcare services are treated as a single performance obligation satisfied at a point in time because the performance obligations are generally satisfied over a period of less than one day.

Cost of healthcare services

Cost of healthcare services rendered represents cost in relation to the medical services provided including the compensation of the physicians, cost of pharmaceutical supplies and medicine and write-down of inventories.

Research and development expenses

Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including amortization of the patent license, depreciation of laboratory equipment, costs of engaging external consultants, advisors and contracted research organization to conduct preclinical development activities and trials, payroll expenses to research and development staff, sponsored research expenses to universities and research institutions, and impairment of patent license and laboratory equipment.

Government Subsidies

The Company’s subsidiaries received government subsidies from certain local governments. The Company’s government subsidies consisted of specific subsidies that are subsidies from the local government for a specific purpose, such as subsidies for research and development. The Company recorded specific subsidies as other income which is included in the consolidated statements of income upon receipt as further performance by the Company is not required. The government subsidies were approximately $nil, $0.9 million and $0.1 for the years ended December 31, 2025, 2024 and 2023, respectively.

Share-based compensation

The Group uses the fair value method of accounting for the share options granted to directors, employees, external consultants and advisors to measure the cost services received in exchange for the share based awards. The fair value of share option awards with only service condition is estimated on the grant or offering date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires inputs such as the risk-free interest rate, expected term and expected volatility. These inputs are subjective and generally require significant judgment. The resulting cost is recognized over the period during which a director, employee, external consultant or advisor is required to provide service in exchange for the awards, usually the vesting period, which is generally from 9.5 months to 21.5 months. Share-based compensation expense is recognized on a graded vesting basis, net of actual forfeitures in the period.

Share-based compensation expense is recorded in cost of healthcare services, research and development expenses, general and administrative fees and legal and professional fees in the consolidated statements of operations and comprehensive loss. Warrants issued to placement agents or other non-employees in exchange for services rendered in connection with equity offerings are accounted for under ASC 718 and classified as equity when the criteria for equity classification are met. Such warrants are measured at their grant date fair value using the Black-Scholes option pricing model and recognized as issuance costs of the related offering.

In accordance with ASC 718, modifications to stock-based awards are accounted for as exchanges of the original awards for new awards. The incremental fair value, which is the difference between the fair value of the modified award and the original award immediately before modification, is measured at the modification date. This incremental fair value is recognized immediately as compensation cost for vested awards. For unvested awards, the incremental compensation cost, along with any remaining unrecognized compensation cost of the original award, is recognized over the remaining requisite vesting period.

Income taxes

The Group accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are determined based on differences between the financial carrying amounts of existing assets and liabilities and their tax bases. Income taxes are provided for in accordance with the laws of the relevant taxing authorities.

A valuation allowance is provided for deferred tax assets if it is more likely than not that these items will either expire before the Group is able to realize their benefits, or that future deductibility is uncertain. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

Uncertain tax positions

The Group accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. The Group recognizes interest on non-payment of income taxes and penalties associated with tax positions when a tax position does not meet more likely than not thresholds be sustained under examination. The tax returns of the Group’s Hong Kong subsidiaries are subject to examination by the relevant tax authorities. According to the Hong Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed or has been assessed at less than the proper amount, the statute of limitation is extended to ten years if the underpayment of taxes is due to fraud or willful evasion. According to United Kingdom, Singapore and the United States, trading losses are available to be carried forward indefinitely. The Group did not have any material interest or penalties associated with tax positions for the years ended December 31, 2025, 2024 and 2023, and did not have any significant unrecognized uncertain tax positions as of December 31, 2025 and 2024. The Group does not believe that its assessment regarding unrecognized tax benefits will materially change over the next twelve months.

Comprehensive income or loss

Certain changes in assets and liabilities are reported as separate components of the equity section of the consolidated balance sheets, such items, along with net income or loss, are components of comprehensive income or loss. The components of other comprehensive income or loss consist of exchange differences on translation of foreign operations.

Net income or loss per share

Basic net income or loss per share is computed by dividing net income or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income or loss per share reflects the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation of diluted loss per share in loss periods as their effect would be anti-dilutive.

Segment reporting

The Group uses the management approach to determine operating segment. The management approach considers the internal organization and reporting used by the Group’s chief operating decision maker (‘‘CODM’’) for making decisions, allocation of resource and assessing performance.

The Group operates and manages its business as a single operating and reportable segment. The Group’s CODM has been identified as the Chief Executive Officer who reviews the consolidated net income (loss) when making decisions about allocating resources and assessing performance of the Group. Significant segment expenses are the same as these presented under the operating costs and expenses in the consolidated statements of operations, and the difference between net revenue less the significant segment expenses and consolidated net income are the other segment items. The CODM reviews and utilizes these financial metrics together with non-financial metrics to make operation decisions, such as the determination of the fee rate at which the Company charges for its services and the allocation of budget between operating costs and expense.

The Group’s long-lived assets are substantially all located in Hong Kong and substantially all of the Group’s revenues are derived from within Hong Kong. Therefore, no geographical segments are presented.

Concentration of credit risk

Financial assets which potentially subject the Group to concentrations of credit risk consist principally of bank deposits and balances.

The Group takes on exposure to credit risk on cash balances majority held with HSBC for the purposes of payments of Group expenses. The risk of default is considered minimal as the Group considers HSBC is well established with high credit rating.

Recently adopted accounting pronouncements

In December 2023, the FASB issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the transparency and decision usefulness of income tax disclosures. The amendments address more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in this ASU are effective for public business entities for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. The Group adopted ASU 2023-09 from January 1, 2025 on a retrospective basis. The adoption of ASU2023-09 did not have material impact on the Company’s consolidated balance sheets, statements of operations and comprehensive loss, changes in equity and cash flows, but resulted in expanded income tax disclosures in Note 11 to the consolidated financial statements.

Recently issued accounting standards which have not yet been adopted

ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), was issued in November 2024, which requires disclosure in the notes to the financial statements, of disaggregated information about certain costs and expenses that are included in expense line items on the face of the income statement. The requirements of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this standard will have on its Consolidated Financial Statements and disclosures.

The Group does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.

DiamiR Biosciences Corp. [Member]

Summary of Significant Accounting Policies [Line Items]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of DiamiR Biosciences Corp. and its wholly-owned subsidiary, DiamiR, LLC (collectively referred to as the “Company”). There are no material intercompany transactions.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of six months or less when purchased to be cash equivalents. The Company had no cash equivalents as of November 30, 2025 and May 31, 2025.

Related Parties

Parties are considered related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged. See note 8, Convertible Notes Payable.

Research and Development Expenses

research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 730, Research and Development.

Equipment

Equipment is carried at cost and depreciated on a straight-line basis over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

Accounting for Income Taxes

The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax liabilities and assets are determined based on the difference between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company estimates the degree to which tax assets and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction. A valuation allowance for such tax assets and loss carryforwards is provided when it is determined to be more likely than not that the benefit of such deferred tax asset will not be realized in future periods. Tax benefits of operating loss carryforwards are evaluated on an ongoing basis, including a review of historical and projected future operating results, the eligible carryforward period, and other circumstances. If it becomes more likely than not that a tax asset will be used, the related valuation allowance on such assets would be reduced.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurement and Disclosures, requires all entities to disclose the fair value of financial instruments, both assets and liabilities for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of November 30, 2025 and May 31, 2025, the recorded values of cash, accounts receivable, accounts payable and accrued expenses, and convertible note payable to founder approximate the fair values due to the short-term nature of the instruments. See note 8, Convertible Notes Payable.

The Company determines the fair value of financial and non-financial assets using the highest-level inputs available in the fair value hierarchy, which establishes six levels of inputs that may be used to measure fair value as follows:

		Level 1:		Inputs that reflect unadjusted quoted prices in active markets that are accessible for identical assets or liabilities;
		Level 2:		Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and
		Level 3:		Unobservable inputs that are supported by little or no market activity.

Since inception, the Company has made certain fair value estimates that are not recurring, generally related to share values and expected volatility, compensation expense and interest expense. Such estimates involve management’s review of available information of comparable companies and are therefore, generally unobservable Level 3 inputs.

Concentrations of Credit Risk

Cash, cash equivalents and accounts receivable potentially subject the Company to concentration of credit risk. Cash and cash equivalents are held at U.S. FDIC-insured financial institutions and the amounts on deposit are sometimes above the FDIC insured limits of up to $250,000 per account.

Intangible Assets

The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not subject to amortization.

Impairment of Long-lived Assets

The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are not limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; (iv) or, expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. The Company recorded no impairment charges in the six months ended November 30, 2025 and November 30, 2024.

Patent Costs

The Company has no experience or historical data to support a probable future economic benefit for the arising patent application, filing and prosecution costs. Therefore, patent costs were expensed as incurred. Should the Company experience a legal cost to defend the patent in the future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit of the patent. Costs related to an unsuccessful outcome would be expensed.

Revenue

Grant revenue — Government assistance

The Company’s primary source of revenue has been grant revenue from non-customers. The Company applies the provisions of ASC Topic 958, Not-For-Profit Entities, applicable to contributions received and recognizes grant revenue as qualified expenses are incurred. In the years ended May 31, 2025 and 2024, all grant revenue was received from the National Institutes of Health (“NIH”). As of May 31, 2025, the Company has used all funding available under the grants.

Under these NIH grants, the Company received funds monthly on a cost-reimbursement basis for agreed-upon direct and indirect costs for specific research and development activities, together with a specified fee. Allowable direct costs included personnel costs, fees for laboratory and other contract services and supplies, among others.

The Company was responsible for performing research and development activities but was not required to achieve any specified identified results. Accordingly, these grants did not contain general payback provisions. However, the Company’s performance, costs and compliance are subject to periodic review and audit and the Company may be required to repay funds already received in the event of noncompliance. Grant-years ending after May 31, 2024 remained subject to review as of November 30, 2025.

Revenue from customers

The Company recognizes service revenue from customers in accordance with FASB Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when (or as) customers obtain control of promised goods or services, in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenues when (or as) the Company satisfies a performance obligation. The Company applies the provisions of ASC 606 to an arrangement when a substantive contract exists and collectability is probable.

The Company’s deferred revenue represents amounts invoiced in excess of revenue earned and relates to fees for the Company’s laboratory testing services. The deferred revenue is expected to be recognized as revenue within a year, as samples are tested in accordance with customer specifications. There is no variable consideration. Customer acquisition costs are not significant.

Contract assets and deferred revenues related to contracts with customers consist of the following as of November 30, 2025 and May 31, 2025:

	Contract assets						Contract liabilities Deferred revenue
	Contract costs		Unbilled revenue		Total		Contract liabilities Deferred revenue
May 31, 2024	$	—	$	—	$	—	$	—
Net change due to billings		—		—		—		43,982
Revenue recognized		—		—		—		—
May 31, 2025		—		—		—		43,982
Net change due to billings		—		86,373		86,373		—
Revenue recognized		—		86,373		86,373		43,982
November 30, 2025	$	—	$	—	$	—	$	—

Other income

In the six months ended November 30, 2025, the Company’s other revenue consists of fees received under a management services agreement with Aptorum Group Ltd. (“Aptorum”). In July 2025, the Company entered into a definitive merger agreement with Aptorum. Concurrent with the execution of the merger agreement, the companies entered into a management services agreement under which the Company will provide certain development and management services through earlier of a closing of the merger or December 31, 2025. The services to be provided by the Company under the agreement are employee services that do not vary significantly in nature on a periodic basis and the Company recognizes income in equal monthly amounts. As of November 30, 2025, $88,700 of management services revenue is included in accounts receivable.

Accounting for Derivative Financial Instruments

The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity (“ASC Topic 815-40”) and ASC Topic 470, Debt. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company has no financial instruments meeting the criteria for derivative accounting as of November 30, 2025 and May 31, 2025.

Stock Based Compensation

The Company accounts for share-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all share-based payments including share options. The fair value method requires the Company to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur.

Leases

The Company accounts for its operating leases under ASC 842, Leases. Accordingly, the Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

Convertible Notes Payable

Debt issuance costs and discounts (premiums) related to notes payable are reported as direct deductions (increases) to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition (reduction) to interest expense.

Segment Information

FASB ASC 280, Segment Reporting (“ASC 280”), establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company performs research and development activities of its own and for others substantially in one location using resources common to internal research activities and revenue-producing services, which have been limited to date. Accordingly, the Company’s chief operating decision maker (“CODM”), the Executive Chairman, manages the Company’s business activities as a single operating and reportable segment at the consolidated level using cash flow and EBITDA measures to allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (personnel, other research and development, and general and administrative) at the consolidated level to manage the Company’s operations. Other segment items included in consolidated net income are depreciation and amortization, stock based compensation, interest expense and the provision for income taxes.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 requires additional disclosure of certain amounts included in the expense captions presented on the condensed consolidated statement of operations as well as disclosures about selling expenses. The ASU is effective on a prospective basis, with the option for retrospective application, for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted for annual financial statements that have not yet been issued. The Company is currently evaluating the impact of ASU 2024-03 on its condensed consolidated financial statements and related disclosures.

There are no other recently issued accounting pronouncements that the Company believes might have a material impact on its financial position or results of operations.

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Principles of Consolidation

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of May 31, 2025 and May 31, 2024.

Related Parties

Research and Development Expenses

The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical study costs, contracted services, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 730, Research and Development.

Property and Equipment

resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

Accounting for Income Taxes

Fair Value of Financial Instruments

ASC 820, Fair Value Measurement and Disclosures, requires all entities to disclose the fair value of financial instruments, both assets and liabilities for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of May 31, 2025 and 2024, the recorded values of cash, accounts receivable, accounts payable and accrued expenses, and convertible note payable to founder approximate the fair values due to the short-term nature of the instruments. See note 8, Convertible Notes Payable — Founder.

The Company determines the fair value of financial and non-financial assets using the highest level inputs available in the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

		Level 1:		Inputs that reflect unadjusted quoted prices in active markets that are accessible for identical assets or liabilities;
		Level 2:		Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and
		Level 3:		Unobservable inputs that are supported by little or no market activity.

Concentrations of Credit Risk

Intangible Assets

Impairment of Long-lived Assets

Patent Costs

The Company has no experience or historical data to support a probable future economic benefit for the arising patent application, filing and prosecution costs. Therefore, patent costs were expensed as a general and administrative expense as incurred. Should the Company experience a legal cost to defend the patent in the future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit of the patent. Costs related to an unsuccessful outcome would be expensed.

Revenue

Grant revenue

The Company was responsible for performing research and development activities but ws not required to achieve any specified identified results. Accordingly, these grants did not contain general payback provisions. However, the Company’s performance, costs and compliance are subject to periodic review and audit and the Company may be required to repay funds already received in the event of noncompliance. Grant-years ending after May 31, 2024 remained subject to review as of May 31, 2025.

As of May 31, 2025 and 2024, respectively, the Company had $0 and $89,281 of unbilled revenue related to grants, representing grant costs incurred, which were reimbursed in future periods

Revenue from customers

The Company recognizes revenue from customers in accordance with FASB Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when (or as) customers obtain control of promised goods or services, in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenues when (or as) the Company satisfies a performance obligation. The Company applies the provisions of ASC 606 to an arrangement when a substantive contract exists and collectability is probable.

Contract assets and deferred revenues related to contracts with customers consist of the following as of May 31, 2025 and May 31, 2024:

	Contract assets				Contract liability
	Contract costs		Unbilled revenue		Total		Deferred revenue
May 31, 2023	$	—	$	—	$	—	$	—
Net change due to billings		—		—		—		—
Revenue recognized		—		—		—		—
May 31, 2024		—		—		—		—
Net change due to billings		—		—		—		43,982
Revenue recognized		—		—		—		—
May 31, 2025	$	—	$	—	$	—	$	43,982

Other revenue

In the year ended May 31, 2025, the Company’s other revenue consists of nonrecurring fees earned under a material transfer agreement with a non-customer. The Company recognized other revenue upon shipment of the subject materials.

Accounting for Derivative Financial Instruments

Stock Based Compensation

Leases

estimated present value of unpaid lease payments over the lease term. The Company uses an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

Convertible Notes Payable

In August 2020, the FASB issued ASU No. 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) — “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. The amendments in this update were effective for public entities that are smaller reporting companies, as defined by the Securities and Exchange Commission (“SEC”), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted the pronouncement early on a fully retrospective basis prior to the year ended May 31, 2024 and has not recognized calculated beneficial conversion features in its notes payable.

Segment Information

Recently Issued Accounting Pronouncements

There are no other recently issued accounting pronouncements that the Company believes might have a material impact on its financial position or results of operations.

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Net operating losses carryforwards	$ 15,365,786	$ 15,107,318
Depreciation and amortization	86,843	128,896
Impairment loss on assets	537,830	537,830
Total Deferred tax asset	15,990,459	15,774,044
Valuation allowance	(15,990,459)	(15,774,044)	$ (17,407,156)	$ (15,705,088)
Deferred tax asset, net of valuation allowance

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Nov. 30, 2025	Nov. 30, 2024	Dec. 31, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net loss			$ (1,376,430)		$ (4,157,737)		$ (4,340,975)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation					255,046		1,125,254
Issuance cost in relation to warrant			153,189
Change in fair value of warrant liability			(690,000)
Share-based compensation							1,265,189
Loss on investments in marketable securities, net							9,266
Unrealized loss (gain) from fair value change of the long-term investments, net							(6,431,088)
Impairment loss of long-term investment					1,000,000		77,200
(Gain) loss on disposal of long-lived assets					(58,621)		110,852
Impairment loss on long-lived assets					1,699,481		750,381
Allowance for credit loss of due from a related party							521,007
Write-off of prepayment and other receivables					45,677		62,369
Write-off of accounts receivable					6,280
Write-down of inventories							13,206
Gain on disposal of subsidiaries					(703)
Amortization of right-of-use assets					50,520		252,345
Interest expense and accretion of convertible debts			180,000		180,000		45,266
Reversal of deferred cash bonus							(1,646,228)
Changes in operating assets and liabilities
Accounts receivable					41,349		126,717
Inventories							14,516
Other receivables and prepayments			17,506		291,078		227,457
Long-term deposits							29,106
Amounts due from related parties					961		63,050
Amounts due to related parties			(464)		464		(8,524)
Accounts payable and accrued expenses			(28,368)		(422,705)		398,635
Operating lease liabilities			(91,979)		(120,824)		(389,365)
Net cash used in operating activities			(1,836,546)		(1,189,734)		(7,724,364)
Cash flows from investing activities
Purchases of property and equipment							(3,015)
Proceeds from disposal of property and equipment					58,621		15,385
Proceeds from sales of investment securities							93,215
Loan to a related party							(92,459)
Repayment of loan and interest from a related party							611,641
Net cash provided by investing activities					58,621		624,767
Cash flows from financing activities
Loan from related parties							2,500,000
Proceeds from issuance of Class A Ordinary Shares, and warrant			2,000,000				1,575,562
Exercise of share options							16,506
Payments related to offering costs			(284,001)
Repayment of bank loan							(3,000,000)
Proceeds from issuance of convertible notes							3,000,000
Proceeds from issuance of Class A Ordinary Shares			3,070,000
Payments related to offering costs			(370,800)
Net cash provided by financing activities			4,415,199				4,092,068
Net increase (decrease) in cash			2,578,653		(1,131,113)		(3,007,529)
Cash and cash equivalents – Beginning of year			874,238		2,005,351		5,012,880
Cash and cash equivalents – End of year			3,452,891		874,238		2,005,351
Supplemental disclosures of cash flow information
Interest paid							94,108
Non-cash operating, investing and financing activities
Reclassification of placement agent warrant redemption amount			47,000
Right-of-use assets obtained in exchange for new operating lease liabilities							338,525
Convertible notes converted to Class A Ordinary Shares							6,000,000
Settlement of deferred cash bonus by issuance of share options					$ 451,660		$ 3,078,196
DiamiR Biosciences Corp
Cash flows from operating activities
Net loss	$ (409,955)	$ (282,532)		$ (743,235)		$ (614,405)
Reconciliation of net loss to net cash used in operating activities:
Deferred offering costs expensed				150,526
Noncash lease expense	18,925	18,378		(1,830)		(8,450)
Amortization of note discount	31,550	19,349		43,538		25,367
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation	9,772	10,155		20,828		20,052
Share-based compensation		20,418		24,312		194,846
Changes in operating assets and liabilities
Accounts receivable	(131,091)	85,086		89,281		(89,281)
Prepaid expenses	40,945	(36,514)		(77,036)		(89,334)
Accounts payable and accrued expenses	441,538	12,941		83,210		108,997
Accrued interest	25,607	15,617		34,634		23,232
Deferred revenue	(43,982)			43,982
Income taxes payable	(176,002)	9,445		16,483		112,947
Operating lease liabilities	(22,315)	(18,204)		1,867		7,115
Net cash used in operating activities	(215,008)	(145,861)		(313,440)		(308,914)
Cash flows from investing activities
Purchases of property and equipment	(6,938)					(1,278)
Net cash provided by investing activities	(6,938)					(1,278)
Cash flows from financing activities
Proceeds from notes payable	250,000	200,000		300,000		200,000
Net cash provided by financing activities	250,000	200,000		300,000		200,000
Net increase (decrease) in cash	28,054	54,139		(13,440)		(110,192)
Cash and cash equivalents – Beginning of year	56,836	70,276		70,276		180,468
Cash and cash equivalents – End of year	84,890	124,415		56,836		70,276
Non-cash investing and financing activities:
Discounts on note payable to founder	12,694	24,970		34,692		35,063
Supplemental disclosures of cash flow information
Interest paid
Cash paid for taxes				$ 1,456		$ 1,456

Accounts Payable and Accrued Expenses (Tables)

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Accounts Payable and Accrued Expenses (Tables) [Line Items]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Research and development expenses payable	$	830,189	$	778,205
Professional fees payable		185,247		127,031
Others		56,279		13,375
	$	1,071,715	$	918,611

DiamiR Biosciences Corp. [Member]

Accounts Payable and Accrued Expenses (Tables) [Line Items]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

	November 30, 2025		May 31, 2025
Outside services	$	643,784	$	220,411
Employee compensation		19,248		5,884
Other		10,364		5,563
Total	$	673,396	$	231,858

Accounts payable and accrued expenses consist of the following:

	May 31, 2025		May 31, 2024
Outside services	$	220,411	$	123,065
Employee compensation		5,884		12,285
Other		5,563		13,298
Total	$	231,858	$	148,648

Accounting Policies, by Policy (Policies)

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Accounting Policies, by Policy (Policies) [Line Items]

Principles of presentation and consolidation

Non-controlling interests

Use of estimates

Foreign currency translation and transaction

Cash and cash equivalents

Cash and cash equivalents consists of cash on hand, bank deposits and time deposits with an original maturity of three months or less at the date of purchase.

Accounts receivable and amounts due from related parties

Long-term investments, net

Non-marketable investments

Equity method investment — Fair value option

Fair value measurement

As a basis for considering such assumptions, a three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:

• Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

	As of December 31, 2025
	Fair Value Measurement at the Reporting Date using
	Quoted price in active markets for identical assets Level 1		Significant other observable inputs Level 2		Significant unobservable inputs Level 3		Total
Financial liabilities:
Warrant liabilities		—		—		306,000		306,000
Total	$	—	$	—	$	306,000	$	306,000

Property and equipment, net

Depreciation of property and equipment is provided using the straight-line method over their estimated useful lives:

Computer equipment		3 years
Furniture, fixture, and office and medical equipment		5 years
Leasehold improvements		Shorter of the remaining lease terms or 5 years
Laboratory equipment		5 years
Motor vehicle		5 years

Intangible assets, net

Impairment of long-lived assets

Convertible notes

The Group evaluates and accounts for conversion options embedded in convertible notes in accordance with ASC 815 “Derivatives and Hedging Activities”.

Cost of healthcare services

Research and development expenses

Government Subsidies

Share-based compensation

Income taxes

Uncertain tax positions

Comprehensive income or loss

Net income or loss per share

Segment reporting

Concentration of credit risk

Financial assets which potentially subject the Group to concentrations of credit risk consist principally of bank deposits and balances.

Recently adopted accounting pronouncements

Recently issued accounting standards which have not yet been adopted

The Group does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.

DiamiR Biosciences Corp. [Member]

Accounting Policies, by Policy (Policies) [Line Items]

Principles of presentation and consolidation

Principles of Consolidation

Use of estimates

Use of Estimates

Cash and cash equivalents

Cash and Cash Equivalents

Property and equipment, net

Equipment

Property and Equipment

Intangible assets, net

Intangible Assets

Impairment of long-lived assets

Impairment of Long-lived Assets

Convertible notes

Convertible Notes Payable

Revenue recognition

Revenue

Grant revenue — Government assistance

Revenue from customers

Contract assets and deferred revenues related to contracts with customers consist of the following as of November 30, 2025 and May 31, 2025:

	Contract assets						Contract liabilities Deferred revenue
	Contract costs		Unbilled revenue		Total		Contract liabilities Deferred revenue
May 31, 2024	$	—	$	—	$	—	$	—
Net change due to billings		—		—		—		43,982
Revenue recognized		—		—		—		—
May 31, 2025		—		—		—		43,982
Net change due to billings		—		86,373		86,373		—
Revenue recognized		—		86,373		86,373		43,982
November 30, 2025	$	—	$	—	$	—	$	—

Other income

Revenue

Grant revenue

As of May 31, 2025 and 2024, respectively, the Company had $0 and $89,281 of unbilled revenue related to grants, representing grant costs incurred, which were reimbursed in future periods

Revenue from customers

Contract assets and deferred revenues related to contracts with customers consist of the following as of May 31, 2025 and May 31, 2024:

	Contract assets				Contract liability
	Contract costs		Unbilled revenue		Total		Deferred revenue
May 31, 2023	$	—	$	—	$	—	$	—
Net change due to billings		—		—		—		—
Revenue recognized		—		—		—		—
May 31, 2024		—		—		—		—
Net change due to billings		—		—		—		43,982
Revenue recognized		—		—		—		—
May 31, 2025	$	—	$	—	$	—	$	43,982

Other revenue

Research and development expenses

Research and Development Expenses

Share-based compensation

Stock Based Compensation

Income taxes

Accounting for Income Taxes

Segment reporting

Segment Information

Concentration of credit risk

Concentrations of Credit Risk

Recently adopted accounting pronouncements

Recently Issued Accounting Pronouncements

There are no other recently issued accounting pronouncements that the Company believes might have a material impact on its financial position or results of operations.

Recently Issued Accounting Pronouncements

There are no other recently issued accounting pronouncements that the Company believes might have a material impact on its financial position or results of operations.

Related Parties

Fair Value of Financial Instruments

		Level 1:		Inputs that reflect unadjusted quoted prices in active markets that are accessible for identical assets or liabilities;
		Level 2:		Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and
		Level 3:		Unobservable inputs that are supported by little or no market activity.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurement and Disclosures, requires all entities to disclose the fair value of financial instruments, both assets and liabilities for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of May 31, 2025 and 2024, the recorded values of cash, accounts receivable, accounts payable and accrued expenses, and convertible note payable to founder approximate the fair values due to the short-term nature of the instruments. See note 8, Convertible Notes Payable — Founder.

		Level 1:		Inputs that reflect unadjusted quoted prices in active markets that are accessible for identical assets or liabilities;
		Level 2:		Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and
		Level 3:		Unobservable inputs that are supported by little or no market activity.

Intangible assets, net

Intangible Assets

Patent Costs

The Company has no experience or historical data to support a probable future economic benefit for the arising patent application, filing and prosecution costs. Therefore, patent costs were expensed as a general and administrative expense as incurred. Should the Company experience a legal cost to defend the patent in the future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit of the patent. Costs related to an unsuccessful outcome would be expensed.

Accounting for Derivative Financial Instruments

Stock Based Compensation

Leases

Property and Equipment, Net (Details) - USD ($)	12 Months Ended
Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024	Dec. 31, 2023
Property and Equipment, Net [Line Items]
Depreciation expense			$ 235,827		$ 1,041,234
Impairment loss
Gain on disposal of medical equipment			58,621		79,822
DiamiR Biosciences Corp. [Member]
Property and Equipment, Net [Line Items]
Depreciation expense		$ 20,828		$ 20,052
Research and Development Expense [Member]
Property and Equipment, Net [Line Items]
Impairment loss			1,421,782
Other Operating Expenses [Member]
Property and Equipment, Net [Line Items]
Impairment loss			$ 5,520		$ 28,128

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	May 31, 2025	May 31, 2024
Convertible Notes Payable [Line Items]
Convertible notes payable	$ 957,662	$ 614,182
Executive Officer [Member]
Convertible Notes Payable [Line Items]
Convertible notes payable	872,245	536,861
Former Chief Scientific Officer [Member]
Convertible Notes Payable [Line Items]
Convertible notes payable	$ 85,417	$ 77,321

Non-Controlling Interest (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Nov. 30, 2024	Mar. 31, 2023	Feb. 01, 2023
Non-Controlling Interest [Line Items]
Share issued					122
Total deficit value (in Dollars)					$ 67,766
Class A Ordinary Shares [Member]
Non-Controlling Interest [Line Items]
Ordinary shares	6,346,823	3,811,823		70,430
Class B Ordinary Shares [Member]
Non-Controlling Interest [Line Items]
Ordinary shares	1,796,934	1,796,934
Scipio [Member] \| Class A Ordinary Shares [Member]
Non-Controlling Interest [Line Items]
Ordinary shares			10,000
Scipio [Member] \| Class B Ordinary Shares [Member]
Non-Controlling Interest [Line Items]
Ordinary shares			5,850,000
Aptorum Medical Limited [Member] \| Minimum [Member]
Non-Controlling Interest [Line Items]
Equity interest percentage					91.00%
Aptorum Medical Limited [Member] \| Maximum [Member]
Non-Controlling Interest [Line Items]
Equity interest percentage					90.00%

Intangible Assets, Net (Details) - USD ($)	12 Months Ended
Intangible Assets, Net (Details) - USD ($)	Dec. 31, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024	Dec. 31, 2023	Nov. 30, 2025
Intangible Assets, Net [Line Items]
Amortization expenses for finite-lived intangible assets			$ 19,219
Intangible assets
DiamiR Biosciences Corp. [Member]
Intangible Assets, Net [Line Items]
Impairment loss on intangible assets
Intangible assets		$ 197,761				$ 197,761
Research and Development Expense [Member]
Intangible Assets, Net [Line Items]
Impairment loss on intangible assets					$ 519,496
Other Operating Expenses [Member]
Intangible Assets, Net [Line Items]
Impairment loss on intangible assets			$ 128,128		$ 1,841

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 24: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 27: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 28: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details

Warrants (Tables)

12 Months Ended

Dec. 31, 2025

Warrants [Abstract]

Schedule of Fair Value of Investor Warrants

The fair value of the Investor Warrants was determined using a binomial option pricing model with the following inputs:

	As of October 14, 2025			As of December 31, 2025
Stock price	$	1.59		$	1.06
Exercise price	$	2.00		$	2.00
Expected term		2.5 years			1.93 years
Risk-free rate		3.49	%		3.48	%
Expected volatility		58.80	%		58.10	%
Dividend rate		0.00	%		0.00	%
Dilution factor		1			1
Fair value per share	$	0.498		$	0.153

Long-Term Investment - Schedule of Unrealized Gains and Losses (Details) - USD ($)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Schedule Of Unrealized Gains And Losses [Abstract]

Upward adjustments

^[1]

$ 6,431,088

Impairment

^[2]

(1,000,000)

Total unrealized (loss) gain from fair value change of non-marketable investments, net

$ (1,000,000)

$ 6,431,088

[1]

The Group holds 622,600 Series B preferred stock of Alzheon, Inc. (“Alzheon”) with initial cost of $2.6 million with unit price of $4.11, which represents 240,773 common stock converted as a conversion rate of $10.63. Pursuant to ASC 321-10-35-2, as the investment in Alzheon lacks readily determinable fair values, the Group elects to account for this investment using the measurement alternative. The Group reviews Alzehon’s available financial information and adjusts the carrying value of its investment based on preferred stock issuances reflected therein, which were deemed as observable price changes in orderly transactions for the identical or similar investment of the same issuer. During the year ended December 31, 2022, Alzheon issued its Series D preferred stock at $36.00 per share for aggregate gross proceeds of $50 million. During the year ended December 31, 2023, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds of $45 million. During the year ended December 31, 2024, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds of $78 million. During the year ended December 31, 2025, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds of $5 million. Aside from the conversion price of the conversion rights being different, the other key terms, including liquidation right, conversion right, voting power, dividend right and redemption right are aligned for Series B, Series D and Series E convertible preferred stocks. The Group determines the Series D and Series E convertible preferred stocks financings are orderly transactions between market participants for the identical or a similar investment of the same issuer and recorded as an upward in the carrying value of the security measured in accordance with paragraph 321-10-35-2 to reflect the current fair value of the security as of the date that the observable transaction for the similar security took place. The Group made an upward adjustment of $6,108,872, from $2,558,886 to $8,667,758, based on Series D convertible preferred stock financing for the year ended December 31, 2022, and made an upward adjustment of $6,431,088, from $8,667,758 to $15,098,846, based on Series E convertible preferred stock financing for the year ended December 31, 2023. No such upward adjustments were made during the years ended December 31, 2025 and 2024. The Group conducts a quarterly assessment to determine whether impairment exists in Alzheon’s equity securities, considering, among other factors, the nature of the securities, financial condition of Alzheon and expected future cash flows. No impairment indicator was identified, and no impairment was made during the years ended December 31, 2025 and 2024. The carrying value of the investment with Alzheon was $15,098,846 as of December 31, 2025 and 2024. As of December 31, 2025 and 2024, this investment was pledged for a convertible note issued to a related party (Note 15).

[2]

The Group holds 3,333,333 Series B preferred stock of Investee B with initial cost of $1.0 million at a purchase price of $0.30 per unit. There was no observable orderly transactions of identical or similar securities from the same issuer. The Group monitored the financial statements of the Investee B. The Group recorded $1 million impairment for this investment in the year ended December 31, 2024 since the Group considered the investees’ ability to continue as a going concern and the investment is not recoverable. The carrying value of this investment was $nil as of December 31, 2025 and 2024, respectively. The Group did not sell or transfer any non-marketable investments or record any realized gains or losses for the non-marketable investments measured at fair value on a non-recurring basis during the years ended December 31, 2025, 2024 and 2023.

Accounts Receivable (Tables)

6 Months Ended

Nov. 30, 2025

DiamiR Biosciences Corp. [Member]

Accounts Receivable (Tables) [Line Items]

Schedule of Accounts Receivable

Accounts receivable consists of the following:

	November 30, 2025		May 31, 2025
Contracts with customers	$	42,391	$	—
Management services revenue from Aptorum		88,700		—
Total	$	131,091	$	—

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2025

May 31, 2025

Property and Equipment, Net (Tables) [Line Items]

Schedule of Property and Equipment

Property and equipment as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Computer equipment	$	69,291	$	69,291
Furniture, fixture, and office and medical equipment		32,435		32,435
Leasehold improvements		108,187		108,187
Laboratory equipment		4,335,722		4,335,722
Motor vehicle		239,093		239,093
		4,784,728		4,784,728
Less: accumulated depreciation		4,784,728		4,784,728
Property and equipment, net	$	—	$	—

DiamiR Biosciences Corp. [Member]

Property and Equipment, Net (Tables) [Line Items]

Schedule of Property and Equipment

Property and equipment, net, consists of the following:

	Estimated Life	May 31, 2025			May 31, 2024
Laboratory equipment	5 years	$	88,388		$	88,388
Furniture	7 years		11,780			11,780
Computer equipment	3 years		5,176			5,176
Total property and equipment			105,344			105,344
Accumulated depreciation			(85,315	)		(64,487	)
Property and equipment, net		$	20,029		$	40,857

Share Based Compensation - Schedule of the Option Activity (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of the Option Activity [Line Items]
Number of share options, Outstanding, Ending			427,060	272,126
Weighted average exercise price, Outstanding, Ending			$ 3.59	$ 21.54
Remaining contractual term in years, Outstanding, Ending			9 years 3 months 10 days	10 years 9 months 29 days
Aggregate Intrinsic value, Outstanding, Ending
Number of share options, Outstanding, Granted			403,820
Weighted average exercise price, Granted			$ 2.68
Number of share options, Outstanding, Exercised		(427,060)	(791)
Weighted average exercise price, Exercised		$ 1.49	$ 20.9
Aggregate Intrinsic value, Exercised		$ 1,436,963
Number of share options, Outstanding, Modified			(248,095)
Weighted average exercise price, Modified			$ 21.74
Number of share options, Outstanding, Exercisable			420,157
Weighted average exercise price, Exercisable			$ 3.43
Remaining contractual term in years, Exercisable			9 years 5 months 1 day
Aggregate Intrinsic value, Exercisable
Number of share options, Vested			420,157
Weighted average exercise price, Vested			$ 3.43

Defined Contribution Plan (Details) - USD ($)	12 Months Ended
Defined Contribution Plan (Details) - USD ($)	May 31, 2025	May 31, 2024
DiamiR Biosciences Corp. [Member]
Defined Contribution Plan [Line Items]
Defined contribution plan cost	$ 5,948	$ 12,711

Commitments and Contingencies - Schedule of Milestone Payments that the Group is Required to Pay up to Different Achievements (Details)	Dec. 31, 2025 USD ($)
Drug molecules: up to the conditions and milestones of
Contingent milestone payments, subtotal	$ 8,720,000
From entering phase 1 to before first commercial sale [Member]
Drug molecules: up to the conditions and milestones of
Contingent milestone payments, subtotal	920,000
First commercial sale [Member]
Drug molecules: up to the conditions and milestones of
Contingent milestone payments, subtotal	800,000
Net sales amount more than certain threshold in a year [Member]
Drug molecules: up to the conditions and milestones of
Contingent milestone payments, subtotal	$ 7,000,000

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2025

Intangible Assets, Net [Abstract]

Schedule of Intangible Assets

	December 31, 2025		December 31, 2024
Gross carrying amount
Prepaid patented licenses	$	200,000	$	200,000
Computer software		223,858		223,858
		423,858		423,858
Less: accumulated amortization
Prepaid patented licenses		200,000		200,000
Computer software		223,858		223,858
		423,858		423,858
Intangible assets, net
Prepaid patented licenses		—		—
Computer software		—		—
Intangible assets, net	$	—	$	—

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	12 Months Ended
	May 31, 2025	May 31, 2024
Schedule of Unrecognized Tax Benefits [Line Items]
Unrecognized tax benefits, Beginning balance	$ 372,544	$ 217,239
Gross increases – tax positions in current period	49,626	155,305
Unrecognized tax benefits, Ending balance	$ 422,170	$ 372,544

Document And Entity Information	12 Months Ended
Document And Entity Information	Dec. 31, 2025
Document Information Line Items
Entity Central Index Key	0001734005
Amendment Description	Amendment No. 2
Document Type	S-4/A
Entity Registrant Name	Aptorum Group Limited
Entity Incorporation, State or Country Code	E9
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Amendment Flag	true

Consolidated Statements of Changes in Equity - USD ($)

Common Stock

Class A

Common Stock

Class B

Common Stock

Diamir Biosciences Corp.

Additional Paid in Capital

Diamir Biosciences Corp.

Additional Paid in Capital

Accumulated Deficit

Diamir Biosciences Corp.

Accumulated Deficit

Accumulated Other Comprehensive income (loss) Amount

Non- controlling interests Amount

Diamir Biosciences Corp.

Total

Balance at Dec. 31, 2022

$ 13,269,528

$ 22,437,754

$ 45,308,080

$ (65,337,075)

$ 33,807

$ (7,878,789)

$ 7,833,305

Balance (in Shares) at Dec. 31, 2022

1,326,953

2,243,776

Adjustment for change of par value

$ (13,269,514)

$ (22,437,732)

35,707,246

Issuance of shares to non-controlling interest

67,766

(67,766)

Issuance of shares in exchange of share options and settlement of liabilities

$ 1

3,078,195

3,078,196

Issuance of shares in exchange of share options and settlement of liabilities (in Shares)

70,430

Issuance of shares for share-based compensation

$ 1

176,263

176,264

Issuance of shares for share-based compensation (in Shares)

65,770

Issuance of shares

$ 2

1,575,560

1,575,562

Issuance of shares (in Shares)

215,959

Stock compensation expense

1,088,925

Conversion of convertible notes

$ 13

5,999,987

6,000,000

Conversion of convertible notes (in Shares)

1,250,000

Exercise of share options

16,506

Exercise of share options (in Shares)

^[1]

791

Rounding up for reverse stock split

Rounding up for reverse stock split (in Shares)

8,018

Exchange difference on translation of foreign operations

(44,430)

Net loss

(2,824,647)

(1,516,328)

(4,340,975)

Balance at Dec. 31, 2023

$ 31

$ 22

93,018,528

(68,161,722)

(10,623)

(9,462,883)

15,383,353

Balance (in Shares) at Dec. 31, 2023

2,937,921

2,243,776

Balance at May. 31, 2023

$ 4,441

$ 4,440,256

$ (4,464,931)

$ (20,234)

Balance (in Shares) at May. 31, 2023

4,440,891

Stock compensation expense

194,846

Discount on note payable to founder

35,063

Net loss

(614,405)

Balance at May. 31, 2024

$ 4,441

4,670,165

(5,079,336)

(404,730)

Balance (in Shares) at May. 31, 2024

4,440,891

Balance at Dec. 31, 2023

$ 31

$ 22

93,018,528

(68,161,722)

(10,623)

(9,462,883)

15,383,353

Balance (in Shares) at Dec. 31, 2023

2,937,921

2,243,776

Conversion of Class B Ordinary Shares to Class A Ordinary Shares

$ 4

$ (4)

Conversion of Class B Ordinary Shares to Class A Ordinary Shares (in Shares)

446,842

(446,842)

Disposal of NCI

4,639

(4,639)

Exercise of share options

$ 2

451,658

451,660

Exercise of share options (in Shares)

427,060

Exchange difference on translation of foreign operations

99,785

Net loss

(4,267,806)

110,069

(4,157,737)

Balance at Dec. 31, 2024

$ 37

$ 18

93,474,825

(72,429,528)

89,162

(9,357,453)

11,777,061

Balance (in Shares) at Dec. 31, 2024

3,811,823

1,796,934

Balance at May. 31, 2024

$ 4,441

4,670,165

(5,079,336)

(404,730)

Balance (in Shares) at May. 31, 2024

4,440,891

Stock compensation expense

20,418

Discount on note payable to founder

24,970

Net loss

(282,532)

Balance at Nov. 30, 2024

$ 4,441

4,715,553

(5,361,868)

(641,874)

Balance (in Shares) at Nov. 30, 2024

4,440,891

Balance at May. 31, 2024

$ 4,441

4,670,165

(5,079,336)

(404,730)

Balance (in Shares) at May. 31, 2024

4,440,891

Stock compensation expense

24,312

Discount on note payable to founder

34,692

Net loss

(743,235)

Balance at May. 31, 2025

$ 4,441

4,729,169

(5,822,571)

(1,088,961)

Balance (in Shares) at May. 31, 2025

4,440,891

Balance at Dec. 31, 2024

$ 37

$ 18

93,474,825

(72,429,528)

89,162

(9,357,453)

11,777,061

Balance (in Shares) at Dec. 31, 2024

3,811,823

1,796,934

Placing of Class A Ordinary Shares

$ 15

2,699,185

2,699,200

Placing of Class A Ordinary Shares (in Shares)

^[1]

1,535,000

Issuance of Class A Ordinary Shares and Investor Warrants, net of issuance costs

$ 10

873,178

873,188

Issuance of Class A Ordinary Shares and Investor Warrants, net of issuance costs (in Shares)

^[1]

1,000,000

Accretion of redemption value to contingently redeemable warrants

(47,000)

Exchange difference on translation of foreign operations

(181,472)

Net loss

(1,363,270)

(13,160)

(1,376,430)

Balance at Dec. 31, 2025

$ 62

$ 18

$ 97,000,188

$ (73,792,798)

$ (92,310)

$ (9,370,613)

$ 13,744,547

Balance (in Shares) at Dec. 31, 2025

^[1]

6,346,823

1,796,934

Balance at May. 31, 2025

$ 4,441

4,729,169

(5,822,571)

(1,088,961)

Balance (in Shares) at May. 31, 2025

4,440,891

Discount on note payable to founder

12,694

Net loss

(409,955)

Balance at Nov. 30, 2025

$ 4,441

$ 4,741,863

$ (6,232,526)

$ (1,486,222)

Balance (in Shares) at Nov. 30, 2025

4,440,891

[1]	All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED’s 1 for 10 reverse stock split, which was effective on January 23, 2023.

Warrants (Details)	1 Months Ended	12 Months Ended
Warrants (Details)	Oct. 31, 2025 USD ($) $ / shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Oct. 14, 2025	Oct. 10, 2025	Aug. 31, 2025 $ / shares
Warrants [Line Items]
Warrant price per share (in Dollars per share) \| $ / shares		$ 2					$ 0.01
Expire term		20 months				24 months
Fair value of warrant liability (in Dollars)		$ (690,000)
Amount of warrant redemption (in Dollars)		47,000
Placement Agent Warrants [Member]
Warrants [Line Items]
Purchase of warrants (in Dollars)	$ 60,180
Fair value of warrant liability (in Dollars)		$ 23,606
Class A Ordinary Shares [Member]
Warrants [Line Items]
Purchase of warrants (in Dollars)	$ 2,000,000
Warrant price per share (in Dollars per share) \| $ / shares	$ 2.5
Class A Ordinary Shares [Member] \| Warrant [Member]
Warrants [Line Items]
Warrants outstanding (in Shares) \| shares		2,060,180
Weighted-average exercise price (in Dollars per share) \| $ / shares		$ 2.01
Weighted-average remaining contractual term		1 year 10 months 24 days
Stock Price [Member]
Warrants [Line Items]
Fair value of the warrant liability		1.06			1.59
Stock Price [Member] \| Placement Agent Warrants [Member]
Warrants [Line Items]
Fair value of the warrant liability		1.59
Stock Price [Member] \| Black-Scholes Option Pricing Model [Member]
Warrants [Line Items]
Fair value of the warrant liability		1.59
Exercise price [Member]
Warrants [Line Items]
Fair value of the warrant liability		2			2
Exercise price [Member] \| Placement Agent Warrants [Member]
Warrants [Line Items]
Fair value of the warrant liability		2.5
Exercise price [Member] \| Black-Scholes Option Pricing Model [Member]
Warrants [Line Items]
Fair value of the warrant liability		2.5
Expected Term [Member]
Warrants [Line Items]
Fair value of the warrant liability		1.93			2.5
Expected Term [Member] \| Placement Agent Warrants [Member]
Warrants [Line Items]
Fair value of the warrant liability		2.5
Expected Term [Member] \| Black-Scholes Option Pricing Model [Member]
Warrants [Line Items]
Fair value of the warrant liability		2.5
Risk-Free Rate [Member]
Warrants [Line Items]
Fair value of the warrant liability		3.48			3.49
Risk-Free Rate [Member] \| Placement Agent Warrants [Member]
Warrants [Line Items]
Fair value of the warrant liability		3.48
Risk-Free Rate [Member] \| Black-Scholes Option Pricing Model [Member]
Warrants [Line Items]
Fair value of the warrant liability		3.48
Expected Volatility [Member] \| Placement Agent Warrants [Member]
Warrants [Line Items]
Fair value of the warrant liability		100
Expected Volatility [Member] \| Black-Scholes Option Pricing Model [Member]
Warrants [Line Items]
Fair value of the warrant liability		58.8

Segment Information

12 Months Ended

May 31, 2025

DiamiR Biosciences Corp. [Member]

Segment Information [Line Items]

SEGMENT INFORMATION

NOTE 15 — SEGMENT INFORMATION

Segment revenue and expenses are as follows in the years ended May 31, 2025 and 2024.

	2025			2024
Revenue	$	631,729		$	1,319,531
Research and development
Salaries and benefits		449,344			692,875
Consultants and contractors		176,935			278,837
Stock based compensation		24,312			182,912
Other R&D		—			2,236
Total research and development		650,591			1,156,860
General and administrative
Salaries and benefits		105,761			117,883
Consultants and contractors		213,509			292,234
Stock based compensation		—			11,934
Patents		44,363			30,167
Depreciation		20,828			20,052
Offering costs		150,526			—
Rent and facilities		53,483			55,600
Other		35,918			86,204
Total general and administrative		624,388			614,074
Interest expense		82,046			48,599
Income taxes		17,939			114,403
Net loss	$	(743,235	)	$	(614,405	)

Other general and administrative expenses include software services, statutory and licensing fees, insurance and office expenses, among others.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Income Taxes - Schedule of Provision For Income Taxes (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	6 Months Ended		12 Months Ended
	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024
Current:
Federal			$ 16,483	$ 112,947
State			1,456	1,456
Total current			17,939	114,403
Deferred:
Federal
State
Total deferred
Total provision for income taxes	$ (174,546)	$ 10,901	$ 17,939	$ 114,403

Lease - Schedule of Maturity Analysis of Operating Leases Liabilities (Details)	Dec. 31, 2025 USD ($)
Schedule of Maturity Analysis of Operating Leases Liabilities [Abstract]
2026	$ 24,573
Total future undiscounted cash flow	24,573
Less: Discount on operating lease liabilities	(145)
Present value of operating lease liabilities	$ 24,428

Long-Term Investment

12 Months Ended

Dec. 31, 2025

Long-Term Investment [Abstract]

LONG-TERM INVESTMENT

4. LONG-TERM INVESTMENT

As of December 31, 2025 and 2024, the Group’s long-term investment consists of non-marketable investments with carrying value of $15,098,846 and equity method investment at fair value option with carrying value of $nil.

Non-marketable investments

The Group’s non-marketable investments are investments in privately held companies without readily determinable fair values. The carrying value of the non-marketable investments are adjusted based on price changes from observable transactions of identical or similar securities of the same issuer (referred to as the measurement alternative) or for impairment if the carrying amount of the non-marketable investments may not be fully recoverable. Any changes in carrying value are recorded within other income (expenses), net in the consolidated statements of operations and comprehensive loss.

The following table summarizes the total carrying value of the non-marketable investments held as of December 31, 2025 and 2024 including cumulative unrealized upward adjustments and impairment made to the initial cost basis of the investments:

	December 31, 2025									December 31, 2024
	Cost basis		Upward adjustments		Impairment			Carrying value		Cost basis		Upward adjustments		Impairment			Carrying value
Investment A(1)	$	2,558,886	$	12,539,960	$	—		$	15,098,846	$	2,558,886	$	12,539,960	$	—		$	15,098,846
Investment B(2)		1,000,000		—		(1,000,000	)		—		1,000,000		—		(1,000,000	)		—
Investment C		520,821		—		(520,821	)		—		520,821		—		(520,821	)		—
	$	4,079,707	$	12,539,960	$	(1,520,821	)	$	15,098,846	$	4,079,707	$	12,539,960	$	(1,520,821	)	$	15,098,846

The following is a summary of annual upward or downwards adjustments and impairment recorded in other income (expenses), net, and included as adjustments to the carrying value of non-marketable investments held as of December 31, 2025, 2024 and 2023 based on the observable price in an orderly transaction for the same or similar security of the same issuers:

	Year ended December 31, 2025		Year ended December 31, 2024			Year ended December 31, 2023
Upward adjustments(1)	$	—	$	—		$	6,431,088
Impairment(2)		—		(1,000,000	)		—
Total unrealized (loss) gain from fair value change of non-marketable investments, net	$	—	$	(1,000,000	)	$	6,431,088

(1) The Group holds 622,600 Series B preferred stock of Alzheon, Inc. (“Alzheon”) with initial cost of $2.6 million with unit price of $4.11, which represents 240,773 common stock converted as a conversion rate of $10.63. Pursuant to ASC 321-10-35-2, as the investment in Alzheon lacks readily determinable fair values, the Group elects to account for this investment using the measurement alternative. The Group reviews Alzehon’s available financial information and adjusts the carrying value of its investment based on preferred stock issuances reflected therein, which were deemed as observable price changes in orderly transactions for the identical or similar investment of the same issuer.

During the year ended December 31, 2022, Alzheon issued its Series D preferred stock at $36.00 per share for aggregate gross proceeds of $50 million. During the year ended December 31, 2023, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds of $45 million. During the year ended December 31, 2024, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds of $78 million. During the year ended December 31, 2025, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds of $5 million. Aside from the conversion price of the conversion rights being different, the other key terms, including liquidation right, conversion right, voting power, dividend right and redemption right are aligned for Series B, Series D and Series E convertible preferred stocks. The Group determines the Series D and Series E convertible preferred stocks financings are orderly transactions between market participants for the identical or a similar investment of the same issuer and recorded as an upward in the carrying value of the security measured in accordance with paragraph 321-10-35-2 to reflect the current fair value of the security as of the date that the observable transaction for the similar security took place.

The Group made an upward adjustment of $6,108,872, from $2,558,886 to $8,667,758, based on Series D convertible preferred stock financing for the year ended December 31, 2022, and made an upward adjustment of $6,431,088, from $8,667,758 to $15,098,846, based on Series E convertible preferred stock financing for the year ended December 31, 2023. No such upward adjustments were made during the years ended December 31, 2025 and 2024.

The Group conducts a quarterly assessment to determine whether impairment exists in Alzheon’s equity securities, considering, among other factors, the nature of the securities, financial condition of Alzheon and expected future cash flows. No impairment indicator was identified, and no impairment was made during the years ended December 31, 2025 and 2024. The carrying value of the investment with Alzheon was $15,098,846 as of December 31, 2025 and 2024.

As of December 31, 2025 and 2024, this investment was pledged for a convertible note issued to a related party (Note 15).

(2) The Group holds 3,333,333 Series B preferred stock of Investee B with initial cost of $1.0 million at a purchase price of $0.30 per unit. There was no observable orderly transactions of identical or similar securities from the same issuer. The Group monitored the financial statements of the Investee B. The Group recorded $1 million impairment for this investment in the year ended December 31, 2024 since the Group considered the investees’ ability to continue as a going concern and the investment is not recoverable. The carrying value of this investment was $nil as of December 31, 2025 and 2024, respectively.

The Group did not sell or transfer any non-marketable investments or record any realized gains or losses for the non-marketable investments measured at fair value on a non-recurring basis during the years ended December 31, 2025, 2024 and 2023.

Equity method investment, fair value option

In December 2021, one of the Group’s subsidiaries, Libra Sciences Limited (“Libra”, formerly known as Aptorum Pharmaceutical Development Limited), issued Class A and Class B ordinary shares to various parties in exchange of licenses or cash. Each Class A share of Libra is entitled to 1 vote while each Class B share of Libra is entitled to 10 votes. Upon the share issuance, the Group was holding 97.27% economic interest and 31.51% voting power in Libra. The Group lost the controlling interest in Libra because it was transferred to a third party, and therefore deconsolidated Libra. However, the Group still owns 97.27% economic interest and 31.51% voting power, which is deemed as having significant influence over Libra. As a result, the Group’s investment in Libra is subject to the equity method of accounting. The Group assessed that the fair value option can better reflect the true value of Libra. Pursuant to ASC 825 — Financial Instruments (“ASC 825”), the Group elected to apply the fair value option for its investments in Libra and will remeasure its investments in Libra at fair value every reporting period. The initial carrying value of the investment was $77,200. For the year ended December 31, 2023, the Group has determined that the carrying value of the investment is not recoverable and this condition is determined to be other-than-temporary. Consequently, an impairment for the investment of $nil, $nil and $77,200 has been recognized as of December 31, 2025, 2024 and 2023.

The Company’s involvement with Libra includes equity ownership as mentioned in above and also amounts due from Libra as disclosed in note 12. The primary risks associated with this involvement include potential financial losses due to Libra’s operational performance or inability to generate sufficient cash flows. The Company’s maximum exposure to loss resulting from its involvement with Libra is nil for the year ended December 31, 2025 and December 31, 2024 which was the amount due from Libra.

Share Based Compensation (Tables)

12 Months Ended

Dec. 31, 2025

Share Based Compensation [Abstarct]

Schedule of the Option Activity

A summary of the option activity for the years ended December 31, 2025, 2024 and 2023 changes during the period are presented below:

	Number of share options(1)		Weighted average exercise price $	Remaining contractual term in years	Aggregate Intrinsic value
Outstanding, January 1, 2025	—		—	—
Outstanding, December 31, 2025	—		—	—	—
Exercisable, December 31, 2025	—		—	—	—
Vested, December 31, 2025	—		—	—	—

Outstanding, January 1, 2024	427,060		3.59	9.28
Exercised	(427,060	)	1.49		1,436,963
Outstanding, December 31, 2024	—		—	—	—
Exercisable, December 31, 2024	—		—	—	—

Outstanding, January 1, 2023	272,126		21.54	10.83
Granted	403,820		2.68
Exercised	(791	)	20.90		—
Modified	(248,095	)	21.74
Outstanding, December 31, 2023	427,060		3.59	9.28	—
Exercisable, December 31, 2023	420,157		3.43	9.42	—

Share Based Compensation

12 Months Ended

Dec. 31, 2025

Share Based Compensation [Abstarct]

SHARE BASED COMPENSATION

17. SHARE BASED COMPENSATION

Share option plan

On October 13, 2017, the Group adopted the 2017 Share Option Plan (the “Option Plan”) and on November 5, 2021, the Group amended the Option Plan. A total of 550,000 Class A Ordinary Shares (subject to subsequent adjustments described more fully below) may be issued pursuant to awards under the Option Plan. Subsequent adjustments include that on each January 1, starting with January 1, 2020, an additional number of shares equal to the lesser of (i) 2% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate preceding December 31, and (ii) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in all cases to adjustments as provided in Section 10 of the Option Plan. Awards will be made pursuant to agreements and may be subject to vesting and other restrictions as determined by the board of directors.

153,146 options were granted on March 8, 2022 to directors, employees, external consultants and advisors of the Group with an exercise price of $13.4 per share, which was based on the average closing price of the shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant date. 74,881 options vest on January 1, 2023 and expire on December 31, 2033; 74,906 options vest on January 1, 2024 and expire on December 31, 2034; 1,866 options vest on June 8, 2022 and expire on June 7, 2033; and 1,493 options vest on July 14, 2022 and expire on July 13, 2033.

On March 31, 2023, the Group entered into exchange agreements and cancelled 177,667 existing vested and unvested share options held by related parties option holders and cancelled the Group’s obligations for deferred cash bonus payables of $3.1 million by granting of 403,820 share options (“New Options”) with 6 months vesting period. The New Options’ exercise price was $2.68 per share, which was based on the last closing price of the shares

traded on the NASDAQ stock exchange on the grant date. All options fully vested on October 1, 2023 and expires on September 30, 2033. On March 31, 2023, the Group entered into supplemental agreements with the same related parties option holders to provide additional cash compensation to cover the exercise price of the New Options. On March 31, 2023, the Group entered into exchange agreements and cancelled 70,428 existing vested and unvested share options held by non-related parties option holders and cancelled the Group’s obligations for deferred cash bonus payables of $1.6 million by issuance of 70,430 fully vested Class A Ordinary Shares. The Group accounted for this exchange for both related parties and non-related parties share option holders as a modification to share based compensation which required the remeasurement of existing share options value at the time of the modification. The total incremental cost as a result of the modification was $0.7 million.

A summary of the option activity for the years ended December 31, 2025, 2024 and 2023 changes during the period are presented below:

	Number of share options(1)		Weighted average exercise price $	Remaining contractual term in years	Aggregate Intrinsic value
Outstanding, January 1, 2025	—		—	—
Outstanding, December 31, 2025	—		—	—	—
Exercisable, December 31, 2025	—		—	—	—
Vested, December 31, 2025	—		—	—	—

Outstanding, January 1, 2024	427,060		3.59	9.28
Exercised	(427,060	)	1.49		1,436,963
Outstanding, December 31, 2024	—		—	—	—
Exercisable, December 31, 2024	—		—	—	—

Outstanding, January 1, 2023	272,126		21.54	10.83
Granted	403,820		2.68
Exercised	(791	)	20.90		—
Modified	(248,095	)	21.74
Outstanding, December 31, 2023	427,060		3.59	9.28	—
Exercisable, December 31, 2023	420,157		3.43	9.42	—

(1) All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED’s 1 for 10 reverse stock split, which was effective on January 23, 2023.

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model under the following assumptions.

Placement agent warrants

In connection with the October 2025 Offering (see Note 16), the Company issued warrants to purchase 60,180 Class A ordinary shares to the placement agent’s designees at an exercise price of $2.50 per share. The Placement Agent Warrants were immediately exercisable upon issuance on October 10, 2025 and expire on the earlier of 24 months from the effective date of a registration statement or October 10, 2030. The Placement Agent Warrants are accounted for under ASC 718 as share-based compensation issued in exchange for services. The grant date fair value of the Placement Agent Warrants was $23,606 which was treated as an issuance cost of the October 2025 Offering (see Note 16). The Placement Agent Warrants were classified as temporary equity under ASC 480-10-S99-3A due to certain contingent redemption provisions in the warrant. The contractual redemption amount of the Placement Agent Warrants on the issuance date was $47,000, which was reclassified from additional paid-in capital to temporary equity. Since the contingent event is not probable to occur, no subsequent remeasurement of the temporary equity amount is required. See Note 20 for additional information regarding warrants.

Organization - Schedule of Major Subsidiaries Consolidated (Details)	12 Months Ended
	Dec. 31, 2025
Aptorum Therapeutics Limited (“ATL”) [Member]
Schedule of Major Subsidiaries Consolidated [Line Items]
Incorporation date	Jun. 30, 2016
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED [Member]
Schedule of Major Subsidiaries Consolidated [Line Items]
Incorporation date	May 16, 2017
Ownership	100.00%
Place of incorporation	Hong Kong
Principle activities	Provision of management services to its holding company and fellow subsidiaries
Paths Innovations Limited [Member]
Schedule of Major Subsidiaries Consolidated [Line Items]
Incorporation date	Apr. 15, 2019
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Investment holding company
Paths Diagnostics Pte. Limited [Member]
Schedule of Major Subsidiaries Consolidated [Line Items]
Incorporation date	Jun. 05, 2019
Ownership	75.00%
Place of incorporation	Singapore
Principle activities	Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited [Member]
Schedule of Major Subsidiaries Consolidated [Line Items]
Incorporation date	Jun. 30, 2017
Ownership	80.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products

Net Loss Per Share (Details) - shares	12 Months Ended
Net Loss Per Share (Details) - shares	Dec. 31, 2025	Dec. 31, 2024
Net Loss Per Share [Abstract]
Shares excluded from anti-dilutive earning share	1,392,277	1,293,723

Basis of Presentation	6 Months Ended	12 Months Ended
Basis of Presentation	Nov. 30, 2025	May 31, 2025
DiamiR Biosciences Corp. [Member]
Basis of Presentation [Line Items]
BASIS OF PRESENTATION	NOTE 2 — BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP in the United States for complete financial statements and should be read in conjunction with the annual financial statements. The Company currently operates in one business segment focusing on the development and commercialization of methods for the early detection and monitoring of neurodegenerative diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business or separate business entities. Going Concern The Company has a limited operating history and has incurred a net loss of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively, and $409,955 in the six months ended November 30,2025. The Company used net cash $313,440 in the year ended May 31, 2025 and $215,008 in the six months ended November 30, 2025 for operating activities. Since the inception of the Company, the operations of the Company have been funded primarily through capital contributions and loans of its founders as well as grant funding, primarily received through the U.S. Department of Treasury and the National Institutes of Health (“NIH”). Management believes this capital is insufficient to fund the Company’s operations for the next twelve months. Management does not anticipate that the Company’s existing working capital alone will be sufficient to fund its operations through the successful development and commercialization of products. As a result, the Company will need to raise additional capital to fund its operations and continue to conduct activities to support its product development and commercialization activities. Management may raise additional funds by way of a public or private offering or may be awarded additional grants Management cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company’s shareholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. If the Company is not able to raise additional capital when required or on acceptable terms, the Company may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date these consolidated financial statements are available to be issued. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.	NOTE 2 — BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The Company currently operates in one business segment focusing on the development and commercialization of methods for the early detection and monitoring of neurodegenerative diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business or separate business entities. Going Concern The Company has a limited operating history and has incurred a net loss of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively, and had net cash used in operating activities of $313,440 for the year ended May 31, 2025. Since the inception of the Company, the operations of the Company have been funded primarily through capital contributions and loans of its founders as well as grant funding, primarily received through the U.S. Department of Treasury and the National Institutes of Health (“NIH”). Management believes this capital is insufficient to fund the Company’s operations for the next twelve months. Management does not anticipate that the Company’s existing working capital alone will be sufficient to fund its operations through the successful development and commercialization of products. As a result, the Company will need to raise additional capital to fund its operations and continue to conduct activities to support its product development and commercialization activities. Management may raise additional funds by way of a public or private offering or may be awarded additional grants Management cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company’s shareholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. If the Company is not able to raise additional capital when required or on acceptable terms, the Company may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date these consolidated financial statements are available to be issued. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Share Based Compensation (Details) - USD ($)									12 Months Ended
Share Based Compensation (Details) - USD ($)	Oct. 31, 2025	Jan. 01, 2024	Oct. 01, 2023	Mar. 31, 2023	Jan. 01, 2023	Jul. 14, 2022	Jun. 08, 2022	Mar. 08, 2022	Dec. 31, 2025	Dec. 31, 2024	Oct. 10, 2025	Aug. 31, 2025
Share Based Compensation [Line Items]
Outstanding percentage										2.00%
Options granted								153,146
Exercise price per share (in Dollars per share)				$ 2.68				$ 13.4
Issuance vested		74,906				1,493	1,866
Expire date		Dec. 31, 2034	Sep. 30, 2033			Jul. 13, 2033	Jun. 07, 2033
Cancelled existing vested and unvested shares				70,428
Deferred cash bonus payable (in Dollars)				$ 1.6
Share options				403,820
Vesting period				6 months
Incremental cost (in Dollars)				$ 700,000
Reverse stock split									1 for 10
Price of per share (in Dollars per share)									$ 2			$ 0.01
Warrants expiration, term									20 months		24 months
Placement Agent Warrants [Member]
Share Based Compensation [Line Items]
Issuance vested	23,606
Employees [Member]
Share Based Compensation [Line Items]
Issuance vested					74,881
Expire date					Dec. 31, 2033
Class A Ordinary Shares [Member]
Share Based Compensation [Line Items]
Issuance vested				70,430
Issuance of warrants	60,180
Price of per share (in Dollars per share)	$ 2.5
Class A Ordinary Shares [Member] \| Placement Agent Warrants [Member]
Share Based Compensation [Line Items]
Issuance vested	47,000
2017 Share Option Plan [Member] \| Class A Ordinary Shares [Member]
Share Based Compensation [Line Items]
Ordinary shares issued										550,000
Share Option Plan [Member]
Share Based Compensation [Line Items]
Cancelled existing vested and unvested shares				177,667
Deferred cash bonus payable (in Dollars)				$ 3,100,000

Net Loss Per Share (Tables)

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Net Loss Per Share (Tables) [Line Items]

Schedule of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per share:

	Year ended December 31, 2025			Year ended December 31, 2024			Year ended December 31, 2023
Numerator:
Net loss attributable to Aptorum Group Limited	$	(1,363,270	)	$	(4,267,806	)	(2,824,647	)
Denominator:
Basic and diluted weighted average shares outstanding		7,351,784			5,453,103		4,521,133

Net loss per share attributable to Aptorum Group Limited(1)
Basic and diluted loss per share	$	(0.19	)	$	(0.78	)	(0.62	)

DiamiR Biosciences Corp. [Member]

Net Loss Per Share (Tables) [Line Items]

Schedule of Antidilutive Common Stock Equivalents

The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive in the six months ended November 30:

	2025	2024
Stock options	441,750	511,950
Restricted stock	88,000	88,000
Warrants	—	29,336

The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive:

	2025	2024
Stock options	511,950	511,950
Restricted stock	88,000	88,000
Warrants	—	29,336

Intangible Assets, Net

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Intangible Assets, Net [Line Items]

INTANGIBLE ASSETS, NET

8. INTANGIBLE ASSETS, NET

	December 31, 2025		December 31, 2024
Gross carrying amount
Prepaid patented licenses	$	200,000	$	200,000
Computer software		223,858		223,858
		423,858		423,858
Less: accumulated amortization
Prepaid patented licenses		200,000		200,000
Computer software		223,858		223,858
		423,858		423,858
Intangible assets, net
Prepaid patented licenses		—		—
Computer software		—		—
Intangible assets, net	$	—	$	—

Prepaid patented licenses and computer software are finite-lived intangible assets which are amortized over their estimated useful life. Amortization expenses for finite-lived intangible assets amounted to $nil and $19,219 for the year ended December 31, 2025 and 2024 respectively.

For the year ended December 31, 2023, the Group terminated two of the licenses. For the year ended December 31, 2024, the Group terminated four of the licenses. For the year ended December 31, 2025, the Group terminated 5 of the licenses.

The Group considered that the carrying amount of these intangible assets are not recoverable and are fully impaired. As a result, the Group recorded $519,496 impairment loss on intangible assets in research and development expenses for the year ended December 31, 2023. Besides, an impairment loss related to the computer software for Hong Kong healthcare services amounted to $128,128 was recorded in research and development expenses, and $1,841 was recorded in other operating expenses for the year ended December 31, 2024 and 2023, respectively. There is no such impairment loss during the year ended December 31, 2025.

The Group does not expect any amortization expense related to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2025.

DiamiR Biosciences Corp. [Member]

Intangible Assets, Net [Line Items]

INTANGIBLE ASSETS, NET

NOTE 6 — INTANGIBLE ASSETS

In the Company’s fiscal year ended May 31, 2021, the Company acquired laboratory assets and operations, including the laboratory’s CLIA certification and its state operating licenses from a provider of molecular diagnostic tests. The Company allocated $197,761 of the total purchase price to the certification and licenses, which it considers indefinite-lived intangible assets.

NOTE 5 — INTANGIBLE ASSETS

Variable Interest Entity (Details) - USD ($)			1 Months Ended	12 Months Ended
Variable Interest Entity (Details) - USD ($)	Dec. 31, 2021	Dec. 30, 2021	Dec. 31, 2021	Dec. 31, 2025	Dec. 31, 2024	Nov. 30, 2024	Mar. 31, 2023
Variable Interest Entity [Line Items]
Variable interest primary beneficiary (in Dollars)				$ 0	$ 0
Libra [Member]
Variable Interest Entity [Line Items]
Voting right percentage				48.33%
Mios [Member]
Variable Interest Entity [Line Items]
Voting right percentage				48.39%
Scipio [Member]
Variable Interest Entity [Line Items]
Voting right percentage				48.36%
Class A Ordinary Shares [Member]
Variable Interest Entity [Line Items]
Common stock voting rights				one
Share of economic (in Shares)		1
Ordinary shares (in Shares)				6,346,823	3,811,823		70,430
Class A Ordinary Shares [Member] \| Scipio [Member]
Variable Interest Entity [Line Items]
Ordinary shares (in Shares)						10,000
Class B Ordinary Shares [Member]
Variable Interest Entity [Line Items]
Common stock voting rights			10	ten
Share of economic (in Dollars per share)		$ 0.001
Ordinary shares (in Shares)				1,796,934	1,796,934
Class B Ordinary Shares [Member] \| Scipio [Member]
Variable Interest Entity [Line Items]
Ordinary shares (in Shares)						5,850,000
Libra Sciences Limited [Member]
Variable Interest Entity [Line Items]
Ownership interest percentage	97.27%		97.27%
Libra Sciences Limited [Member] \| Group’s Subsidiaries [Member]
Variable Interest Entity [Line Items]
Voting right percentage	31.51%
Libra Sciences Limited [Member] \| Class A Ordinary Shares [Member]
Variable Interest Entity [Line Items]
Common stock voting rights		1
Libra Sciences Limited [Member] \| Class B Ordinary Shares [Member]
Variable Interest Entity [Line Items]
Common stock voting rights		10
Mios Pharmaceuticals Limited [Member]
Variable Interest Entity [Line Items]
Ownership interest percentage	97.93%		97.93%
Mios Pharmaceuticals Limited [Member] \| Group’s Subsidiaries [Member]
Variable Interest Entity [Line Items]
Voting right percentage	36.17%
Scipio Life Sciences Limited [Member]
Variable Interest Entity [Line Items]
Ownership interest percentage	97.93%		97.93%
Scipio Life Sciences Limited [Member] \| Group’s Subsidiaries [Member]
Variable Interest Entity [Line Items]
Voting right percentage	35.06%

Income Taxes - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Parentheticals) (Details)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]
Provision for income taxes at Hong Kong statutory income tax rate	(16.50%)	(16.50%)	(16.50%)

Stockholders’ Equity - Schedule of Weighted-Average Assumptions (Details) - DiamiR Biosciences Corp. [Member]	12 Months Ended
	May 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term in years	10 years
Expected volatility	81.00%
Risk-free interest rate	4.10%
Expected dividend yield	0.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Income Taxes

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Income Taxes [Line Items]

INCOME TAXES

11. INCOME TAXES

The Company and its subsidiaries file tax returns separately.

Income taxes

Cayman Islands: under the current laws of the Cayman Islands, the Company and its subsidiaries in the Cayman Islands are not subject to taxes on their income and capital gains.

Hong Kong: in accordance with the relevant tax laws and regulations of Hong Kong, a company registered in Hong Kong is subject to income taxes within Hong Kong at the applicable tax rate on taxable income. In March 2018, the Hong Kong Government introduced a two-tiered profit tax rate regime by enacting the Inland Revenue (Amendment) (No.3) Ordinance 2018 (the “Ordinance”). Under the two-tiered profits tax rate regime, the first $2 million of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity’s assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%. The subsidiaries registered in Hong Kong did not have assessable profits that were derived Hong Kong during the years ended December 31, 2025, 2024 and 2023. Therefore, no Hong Kong profit tax has been provided for in the periods presented. Our returns for 2019 and subsequent tax years remain subject to examination by Hong Kong Inland Revenue Department.

United Kingdom: in accordance with the relevant tax laws and regulations of United Kingdom, a company registered in the United Kingdom is subject to income taxes within United Kingdom at the applicable tax rate on taxable income. All the United Kingdom subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 19%. The subsidiary in United Kingdom did not have assessable profits that were derived from United Kingdom during the years ended December 31, 2025, 2024 and 2023. Therefore, no United Kingdom profit tax has been provided for in the periods presented. Our returns for 2021 and subsequent tax years remain subject to examination by the UK tax authority.

Singapore: in accordance with the relevant tax laws and regulations of Singapore, a company registered in the Singapore is subject to income taxes within Singapore at the applicable tax rate on taxable income. All the Singapore subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 17%. The subsidiary in Singapore did not have assessable profits that were derived from Singapore during the years ended December 31, 2025, 2024 and 2023. Therefore, no Singapore profit tax has been provided for in the periods presented. Our returns for 2021 and subsequent tax years remain subject to examination by the Singapore tax authority.

United States (Nevada): in accordance with the relevant tax laws and regulations of the United States, a company registered in the United States is subject to income taxes within the United States at the applicable tax rate on taxable income. All the United States subsidiaries in Nevada that are not entitled to any tax holiday were subject to income tax at a rate of 21%. The subsidiary in the United States did not have assessable profits that were derived from the United States during the years ended December 31, 2025, 2024 and 2023. Therefore, no United States profit tax has been provided for in the periods presented. Our returns for 2022 and subsequent tax years remain subject to examination by Internal Revenue Service.

Income/(loss) before income tax expense is attributable to the following geographic locations:

	Year ended December 31, 2025			Year ended December 31, 2024			Year ended December 31, 2023
Hong Kong	$	(1,409,614	)	$	(3,944,692	)	$	(1,297,897	)
Singapore		111,972			(252,611	)		(2,956,296	)
Other jurisdictions		(78,788	)		39,566			(86,782	)
Loss before income tax expense	$	(1,376,430	)		(4,157,737	)		(4,340,975	)

For the year ended December 31, 2025, 2024 and 2023, there was no current income tax expense and deferred income tax expense.

The reconciliation of income taxes expenses computed at the Hong Kong statutory tax rate applicable to income tax expense is as follows:

	Year ended December 31, 2025					Year ended December 31, 2024					Year ended December 31, 2023
Net loss before tax	$	(1,376,430	)	100	%	$	(4,157,737	)	100	%	$	(4,340,975	)	100	%
Hongkong statutory income tax rate		16.5	%				16.5	%				16.5	%
Provision for income tax benefit at Hong Kong statutory income tax rate (16.5%)		(227,110	)	16.5	%		(686,027	)	16.5	%		(716,261	)	16.5	%
Domestic tax effects
Non-taxable interest income		(13,907	)	1.0	%		(5,477	)	0.1	%		(1,071,774	)	24.7	%
Non-deductible expenses		—		0.0	%		195		0.0	%		98,704		(2.3	)%
Change in valuation allowance		223,918		(16.3	)%		702,123		(16.9	)%		1,705,603		(39.3	)%
Foreign tax effects
Cayman
– Statutory tax rate diﬀerence between Cayman and Hong Kong		16,128		(1.2	)%		(9,191	)	0.2	%		(5,078	)	0.1	%
Other foreign jurisdictions		917		0.0	%		(1,623	)	0.1	%		(11,185	)	0.3	%
Effective income tax expense	$	—		—		$	—		—		$	—		—

Income taxes paid by jurisdiction is as follows:

	Year ended December 31, 2025		Year ended December 31, 2024		Year ended December 31, 2023
Hong Kong	$	—	$	—	—
Singapore		—		—	—
Other jurisdictions		—		—	—
Total income taxes paid	$	—		—	—

Deferred tax asset, net

Deferred tax assets and deferred tax liabilities reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose and the tax bases used for income tax purpose. The following represents the tax effect of each major type of temporary difference.

	December 31, 2025			December 31, 2024
Deferred tax asset:
Net operating losses carryforwards	$	15,365,786		$	15,107,318
Depreciation and amortization		86,843			128,896
Impairment loss on assets		537,830			537,830
Total Deferred tax asset		15,990,459			15,774,044
Valuation allowance		(15,990,459	)		(15,774,044	)
Deferred tax asset, net of valuation allowance	$	—		$	—

As of December 31, 2025 and 2024, the Group had net operating losses carryforwards of $93,107,417 and $91,436,307, respectively, including its Hong Kong, Singapore, the United States, and the United Kingdom operations, which are available to reduce future taxable income and have an unlimited carryover period. For the year ended December 31, 2025, there was no net operating losses carryforwards expired, while net operating losses carryforwards of $39,489 was cancelled due to the disposal of various subsidiaries.

Valuation allowance was provided against deferred tax assets in entities where it was determined, it was more likely than not that the benefits of the deferred tax assets will not be realized. The Group had deferred tax assets which consisted of net operating losses carryforwards, which can be carried forward to offset future taxable income. The Group maintains a full valuation allowance on its net deferred tax assets. The management determines it is more likely than not that all of its deferred tax assets will not be utilized.

Changes in valuation allowance are as follows:

	December 31, 2025			December 31, 2024			December 31, 2023
Balance as of January 1	$	15,774,044		$	17,407,156		15,705,088
Additions		223,918			702,123		1,705,603
Disposal		(7,503	)		(2,335,235	)	(3,535	)
Balance as of December 31	$	15,990,459		$	15,774,044		17,407,156

Uncertain tax position

The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December 31, 2025 and 2024, the Group did not have any unrecognized uncertain tax positions. For the years ended December 31, 2025, 2024 and 2023, the Company did not incur any interest and penalties related to potential underpaid income tax expenses.

DiamiR Biosciences Corp. [Member]

Income Taxes [Line Items]

INCOME TAXES

NOTE 11 — INCOME TAXES

As of November 30, 2025 and May 31, 2025, the Company’s net deferred tax assets consisted primarily of research and development expenses and stock compensation A valuation allowance has been provided against its net deferred tax assets as, based on all available evidence, it is considered more likely than not that the deferred tax assets will not be realized in future periods.

Uncertain tax positions are evaluated based on the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustment may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue. The Company recognizes a tax benefit from an uncertain tax position when it is more-likely-than-not that it will be sustained upon examination by tax authorities.

Income tax expense in the six months ended November 30, 2024 reflects increases in unrecognized tax benefits related to current deductions for certain funded research and development expenses subject to interpretations of applicable tax law, in excess of available net operating carryforwards. Income tax expense in the six months ended November 30, 2025 reflects the reversal of prior-period provisions for such unrecognized tax benefits. On July 4, 2025, H.R.1, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBB eliminates the requirement under Internal Revenue Code Section 174 to capitalize and amortize U.S.-based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred, among other provisions.

NOTE 12 — INCOME TAXES

For the years ended May 31, 2025 and 2024, the provision for income taxes consisted of the following:

	2025		2024
Current:
Federal	$	16,483	$	112,947
State		1,456		1,456
Total current		17,939		114,403
Deferred:
Federal		—		—
State		—		—
Total deferred		—		—
Total	$	17,939	$	114,403

For the years ended May 31, 2025 and 2024, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:

	2025		2024
Income taxes at Federal statutory rate	21.0	%	21.0	%
Discounts and interest on notes	(2.4	)%	(2.1	)%
Financing costs	(4.3	)%	—	%
State taxes	—	%	(4.2	)%
Other	(2.3	)%	(1.2	)%
Change in valuation allowance	(14.3	)%	(36.3	)%
Income tax provision	(2.3	)%	(22.9	)%

The Company’s deferred tax assets and liabilities consist of the following at May 31, 2025 and 2024:

	May 31, 2025			May 31, 2024
Deferred tax assets:
Tax benefit of net operating loss carry-forward (NOL)	$	351,453		$	247,637
FIN48 reduction in NOL		(269,420	)		(219,793	)
Stock compensation		351,136			346,030
Research and development expenses		422,170			372,544
Other		1,152			2,432
Total deferred tax assets:		856,490			748,850
Deferred tax liabilities		(8,152	)		(4,583	)
Net deferred tax assets:		848,338			744,267
Valuation allowance for deferred tax assets		(848,338	)		(744,267	)
Deferred tax assets, net of valuation allowance	$	—		$	—

As of May 31, 2025 and 2024, the Company had federal net operating loss (“NOL”) carryforwards available to reduce future taxable income of approximately $1,541,000 and $1,047,000, respectively. As of May 31, 2025 and 2024, the Company had state NOL carryforwards of approximately $392,000 and $392,000, respectively. Federal NOLs of approximately $165,000 will begin to expire in 2025 and remaining Federal NOLs have an indefinite expiration period and can be utilized to offset up to 80% of future taxable income. State loss carryforwards expire between 2036 and 2044.

When realization of the deferred tax asset is more likely than not to occur, the benefit related to the deductible temporary differences attributable to operations is recognized as a reduction of income tax expense. Valuation allowances are provided against deferred tax assets when, based on all available evidence, it is considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. The Company’s valuation allowance increased by $104,071 and $181,606 in the years ended May 31, 2025 and 2024, respectively.

Unrecognized tax benefits, May 31, 2023	$	217,239
Gross increases – tax positions in current period		155,305
Unrecognized tax benefits, May 31, 2024		372,544
Gross increases – tax positions in current period		49,626
Unrecognized tax benefits, May 31, 2025	$	422,170

The gross increase in unrecognized tax benefits in the years ended May 31, 2024 and 2025 relate to expected current deductions for certain funded research and development expenses subject to interpretations of applicable tax law, in excess of available net operating carryforwards. Future changes in the unrecognized tax benefits would affect the Company’s effective tax rate. In the absence of changes in related rulings or regulations, the Company does not anticipate any such change over the next 12 months.

The Company’s policy is to recognize interest expense and penalties related to income tax matters in income tax expense. As of May 31, 2025 and 2024, accrued interest related to uncertain tax positions amounted to $20,483 and $4,000, respectively.

The Company and its subsidiary are subject to U.S. federal and state income tax, and in the normal course of business, its income tax returns are subject to examination by the relevant taxing authorities. As of May 31, 2025, the 2017 to 2025 tax years remained subject to examination.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Warrants

12 Months Ended

Dec. 31, 2025

Warrants [Abstract]

WARRANTS

20. WARRANTS

In connection with the October 2025 Offering (see Note 16), the Company issued Investor Warrants to purchase 2,000,000 Class A ordinary shares and Placement Agent Warrants to purchase 60,180 Class A ordinary shares.

The Investor Warrants are exercisable immediately at an exercise price of $2.00 per share and expire twenty-four months from the effective date of a registration statement registering for resale the ordinary shares underlying the Investor Warrants. The Investor Warrants were classified as liabilities under ASC 815 due to certain settlement provisions that preclude equity classification.

The fair value of the Investor Warrants was determined using a binomial option pricing model with the following inputs:

	As of October 14, 2025			As of December 31, 2025
Stock price	$	1.59		$	1.06
Exercise price	$	2.00		$	2.00
Expected term		2.5 years			1.93 years
Risk-free rate		3.49	%		3.48	%
Expected volatility		58.80	%		58.10	%
Dividend rate		0.00	%		0.00	%
Dilution factor		1			1
Fair value per share	$	0.498		$	0.153

Expected volatility was based on the historical volatility of comparable publicly traded companies. The Company recognized a gain of $690,000 on the change in fair value of the Investor Warrant liability for the year ended December 31, 2025, included in “Change in fair value of warrant liability” in the consolidated statements of operations.

The Placement Agent Warrants are exercisable immediately upon issuance and expire on the earlier of (i) 24 months from the effective date of a registration statement or (ii) October 10, 2030.

The grant-date fair value of the Placement Agent Warrants was $23,606, determined using the Black-Scholes option pricing model with the following inputs: stock price of $1.59, exercise price of $2.50, expected term of 2.5 years, risk-free rate of 3.48%, and expected volatility of 58.8% based on comparable public companies. The fair value of the Placement Agent Warrants was treated as an issuance cost of the October 2025 Offering (see Note 16). See Note 20 for additional information regarding warrants.

The Placement Agent Warrants were classified as temporary equity under ASC 480-10-S99-3A due to certain contingent redemption provisions in the warrant. The contractual redemption amount of the Placement Agent Warrants on the issuance date was $47,000, computed using the following contractually specified inputs: stock price of $1.59, exercise price of $2.50, expected volatility of 100%, risk-free rate of 3.48%, and remaining term of 2.5 years. This amount was reclassified from additional paid-in capital to temporary equity on the issuance date. Since the contingent event is not probable to occur, no subsequent remeasurement of the temporary equity amount is required.

As of December 31, 2025, the Company had 2,060,180 warrants outstanding to purchase Class A ordinary shares with a weighted-average exercise price of $2.01 and a weighted-average remaining contractual term of approximately 1.9 years.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 185
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-185

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 184
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-184

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 181
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-181

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 15
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480960/815-15-50-3

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 183
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-183

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C

+ Details

Other Receivables and Prepayments

12 Months Ended

Dec. 31, 2025

Other Receivables and Prepayments [Abstract]

OTHER RECEIVABLES AND PREPAYMENTS

6. OTHER RECEIVABLES AND PREPAYMENTS

Other receivables and prepayments as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Prepaid insurance		17,490		17,794
Prepaid service fee		44,810		50,538
Rental deposits		71,823		4,206
Other receivables		—		4,545
Other deposits		5,510		8,233
	$	139,633	$	85,316

For the years ended December 31, 2025, 2024 and 2023, the Group considered certain other receivables and prepayments were not recoverable and recorded write-off of other receivables and prepayments of $nil, $45,677 and $62,369, respectively.

Convertible Notes Payable (Tables) - DiamiR Biosciences Corp. [Member]

6 Months Ended

12 Months Ended

Nov. 30, 2025

May 31, 2025

Convertible Notes Payable [Line Items]

Schedule of Convertible Notes Payable

Convertible notes payable consist of the following:

	November 30, 2025		May 31, 2025
Executive director	$	1,060,565	$	872,245
Former Chief Scientific Officer		89,782		85,417
Investor		101,778		—
Total	$	1,252,125	$	957,662

Convertible notes payable consist of the following:

	May 31, 2025		May 31, 2024
Executive director	$	872,245	$	536,861
Former Chief Scientific Officer		85,417		77,321
Total	$	957,662	$	614,182

Schedule of Interest Expenses

Interest expense consists of the following in the six months ended November 30:

	2025		2024
Interest on notes	$	25,607	$	19,490
Amortization of discount		31,550		19,349
Total	$	57,157	$	38,839

Interest expense consists of the following in the years ended May 31:

	2025		2024
Interest on notes	$	38,508	$	23,232
Amortization of discount		43,538		25,367
Total	$	82,046	$	48,599

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	Dec. 31, 2025
Computer Equipment [Member]
Schedule of Estimated Useful Lives [Line Items]
Useful lives	3 years
Furniture, Fixture, and Office and Medical Equipment [Member]
Schedule of Estimated Useful Lives [Line Items]
Useful lives	5 years
Leasehold improvements [Member]
Schedule of Estimated Useful Lives [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Shorter of the remaining lease terms or 5 years
Laboratory equipment [Member]
Schedule of Estimated Useful Lives [Line Items]
Useful lives	5 years
Motor vehicle [Member]
Schedule of Estimated Useful Lives [Line Items]
Useful lives	5 years

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Nov. 30, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024
Current assets:
Cash and cash equivalents	$ 3,452,891			$ 874,238
Other receivables and prepayments	139,633			85,316
Total current assets	3,592,524			959,554
Long-term investments, net	15,098,846			15,098,846
Long-term deposits				71,823
Total Assets	18,691,370			16,130,223
Property and equipment, net
Current liabilities:
Accounts payable and accrued expenses	1,071,715			918,611
Operating lease liabilities, current	24,428			102,225
Total current liabilities	4,593,823			4,338,980
Operating lease liabilities, non-current				14,182
Total Liabilities	4,899,823			4,353,162
Commitments and contingencies
TEMPORARY EQUITY
Contingently redeemable warrants	47,000
Total temporary equity	47,000
EQUITY
Additional paid-in capital	97,000,188			93,474,825
Accumulated other comprehensive (loss) income	(92,310)			89,162
Accumulated deficit	(73,792,798)			(72,429,528)
Total stockholders’ deficit	23,115,160			21,134,514
Non-controlling interests	(9,370,613)			(9,357,453)
Total equity	13,744,547			11,777,061
Total Liabilities, Temporary Equity and Equity	18,691,370			16,130,223
Related Party
Current liabilities:
Amounts due to related parties	79,180			79,644
Convertible notes to a related party	3,418,500			3,238,500
Convertible notes to a related party	306,000
DiamiR Biosciences Corp
Current assets:
Cash and cash equivalents		$ 84,890	$ 56,836		$ 70,276
Accounts receivable		131,091			89,281
Other receivables and prepayments		5,704	46,649		120,139
Total current assets		221,685	103,485		279,696
Total Assets		481,065	384,624		579,833
Property and equipment, net		17,195	20,029		40,857
Right of use asset, net		44,424	63,349		61,519
Intangible assets		197,761	197,761		197,761
Current liabilities:
Accounts payable and accrued expenses		673,396	231,858		148,648
Operating lease liabilities, current		38,442	41,383		40,178
Deferred revenue			43,982
Total current liabilities		711,838	317,223		188,826
Commitments and contingencies
EQUITY
Preferred stock value
Ordinary shares, value		4,441	4,441		4,441
Additional paid-in capital		4,741,863	4,729,169		4,670,165
Accumulated deficit		(6,232,526)	(5,822,571)		(5,079,336)
Total stockholders’ deficit		(1,486,222)	(1,088,961)		(404,730)
Total equity		(1,486,222)	(1,088,961)		(404,730)
Total Liabilities, Temporary Equity and Equity		481,065	384,624		579,833
DiamiR Biosciences Corp \| Related Party
Current liabilities:
Operating lease liabilities, non-current		3,324	22,698		22,036
Convertible notes to a related party		1,252,125	957,662		614,182
Income taxes payable			176,002		159,519
Total Liabilities		$ 1,967,287	$ 1,473,585		$ 984,563
Class A Ordinary Shares
EQUITY
Ordinary shares, value	62			37
Class B Ordinary Shares
EQUITY
Ordinary shares, value	$ 18			$ 18

Organization (Tables)

12 Months Ended

Dec. 31, 2025

Organization [Abstract]

Schedule of Major Subsidiaries Consolidated

Below summarizes the list of the major subsidiaries consolidated as of December 31, 2025:

Name	Incorporation date	Ownership	Place of incorporation	Principle activities
Aptorum Therapeutics Limited (“ATL”)	June 30, 2016	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED	May 16, 2017	100%	Hong Kong	Provision of management services to its holding company and fellow subsidiaries
Paths Innovations Limited	April 15, 2019	100%	Cayman Islands	Investment holding company
Paths Diagnostics Pte. Limited	June 5, 2019	75%	Singapore	Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited	June 30, 2017	80%	Cayman Islands	Research and development of life science and biopharmaceutical products

Ordinary Shares (Details) - USD ($)						1 Months Ended	6 Months Ended		12 Months Ended					18 Months Ended
Ordinary Shares (Details) - USD ($)	Oct. 14, 2025	Aug. 31, 2025	Jan. 02, 2025	Jun. 28, 2023	Mar. 31, 2023	Dec. 31, 2021	Nov. 30, 2025	Nov. 30, 2024	Dec. 31, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024	Dec. 31, 2023	Nov. 30, 2025	Oct. 31, 2025	Feb. 21, 2023	Jan. 23, 2023
Ordinary Shares [Line Items]
Consolidation of authorized share capital (in Shares)																	1
Ordinary per share (in Dollars per share)																	$ 1
Shares holders upon conversion (in Shares)											446,842
Ordinary share issued (in Shares)	1
Warrant exercise price (in Dollars per share)		$ 0.01							$ 2
Warrant fair value									$ (690,000)
Expenses as incurred		$ 250,000
Shares issued value													$ 1,575,562
Investor Warrant [Member]
Ordinary Shares [Line Items]
Gross proceeds	$ 2,000,000
Allocated Liability-classified investor warrants	996,000
Allocated to the equity-classified	1,004,000
Placement Agent Warrant [Member]
Ordinary Shares [Line Items]
Net proceeds									$ 284,001,000,000
Warrant exercise price (in Dollars per share)									$ 2.5
Warrant fair value									$ 23,606
Warrant liability									141,433		11,756
Expenses as incurred									$ 142,568		$ 11,850
Convertible Notes [Member]
Ordinary Shares [Line Items]
Original principal amount				$ 3,000,000
June 2023 Notes [Member]
Ordinary Shares [Line Items]
Interest rate				7.00%
Conversion price (in Dollars per share)				$ 3
Number of shares issued for convertible debt (in Shares)				1,000,000
Employees and external consultants [Member]
Ordinary Shares [Line Items]
Issued fully vested shares (in Shares)					65,770
Issued fully vested shares (in Dollars per share)					$ 2.68
DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Ordinary per share (in Dollars per share)							$ 0.001			$ 0.001		$ 0.001		$ 0.001
Ordinary shares, shares issued (in Shares)							4,440,891			4,440,891		4,440,891		4,440,891
Interest rate										4.00%
Conversion price (in Dollars per share)							$ 1.8							$ 1.8
Number of shares issued for convertible debt (in Shares)											29,336
Exchange of warrants shares (in Shares)							29,336							29,336
Warrant exercise price (in Dollars per share)							$ 5.87							$ 5.87
Discount on note payable										$ 34,692	$ 35,063
Debt conversion converted value											$ 5.87
Shares issued for vested (in Shares)											246,000
Weighted average grant date fair value (in Dollars per share)											$ 7
Outstanding stock options (in Shares)											140,000
Stock-based compensation expense							$ 0	$ 20,418		24,312	$ 194,846
Unrecognized stock-based compensation expense related to options							0			0				$ 0
Unrecognised stock based compensation non vested										1,093,712
Restricted stock units (in Shares)													132,000
Terminated outstanding restricted stock shares (in Shares)											44,000
Unrecognized stock-based compensation expense related to restricted stock units										652,080
Debt discount							31,550	19,349		43,538		$ 25,367
Number of shares issuable in exchange (in Shares)														29,336
DiamiR Biosciences Corp. [Member] \| Founder One [Member]
Ordinary Shares [Line Items]
Shares issued value										$ 250,000
Shares issued (in Shares)										2,200,000
DiamiR Biosciences Corp. [Member] \| Founder Two [Member]
Ordinary Shares [Line Items]
Shares issued (in Shares)										2,000,000
DiamiR Biosciences Corp. [Member] \| Founders [Member]
Ordinary Shares [Line Items]
Debt discount							12,694	$ 24,970
2024 Stock Option Plan [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Options issuable (in Shares)										600,000
Shares avaliable for grant increase percentage										2.00%
2014 Stock Option Plan [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Options issuable (in Shares)										600,000
Research and Development Expense [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Stock-based compensation expense											$ 182,912
General and Administrative Expense [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Stock-based compensation expense											$ 11,934
Option [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Unrecognized stock-based compensation expense related to options							1,093,712							$ 1,093,712
October 2025 Offering [Member]
Ordinary Shares [Line Items]
Net proceeds	1,716,000
Cash issuance costs	284,001
Exchange of warrants shares (in Shares)									60,180
Grant-date fair value									$ 23,606
October 2025 Offering [Member] \| Warrant [Member]
Ordinary Shares [Line Items]
Gross proceeds	$ 2,000,000
Restricted Stock Units (RSUs) [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units							$ 652,080							$ 652,080
Maximum [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Stock options exercise price (in Dollars per share)											$ 0.01
Minimum [Member] \| DiamiR Biosciences Corp. [Member]
Ordinary Shares [Line Items]
Stock options exercise price (in Dollars per share)											7.01
Class A Ordinary Shares [Member]
Ordinary Shares [Line Items]
Consolidation of authorized share capital (in Shares)																	1
Ordinary per share (in Dollars per share)			$ 0.00001						$ 0.00001		$ 0.00001						$ 10
Additional ordinary share (in Shares)									8,018
Ordinary shares, shares issued (in Shares)					70,430				6,346,823		3,811,823
Shares holders upon conversion (in Shares)					1,250,000
Sale of common stock, shares (in Shares)	1,000,000		1,535,000
Price per share (in Dollars per share)			$ 2
Gross proceeds			$ 3,070,000
Net proceeds			$ 2,699,200
Issuance share price (in Dollars per share)	$ 2
Exchange of warrants shares (in Shares)															60,180
Warrant exercise price (in Dollars per share)															$ 2.5
Ordinary share is entitled to vote									one
Class A Ordinary Shares [Member] \| Warrant [Member]
Ordinary Shares [Line Items]
Stock options exercise price (in Dollars per share)									$ 2.01
Class A Ordinary Shares [Member] \| Option [Member]
Ordinary Shares [Line Items]
Ordinary shares to exercise option (in Shares)											427,060		791
Class A Ordinary Shares [Member] \| Maximum [Member]
Ordinary Shares [Line Items]
Ordinary per share (in Dollars per share)																$ 10
Class A Ordinary Shares [Member] \| Minimum [Member]
Ordinary Shares [Line Items]
Ordinary per share (in Dollars per share)																0.00001
Class B Ordinary Shares [Member]
Ordinary Shares [Line Items]
Consolidation of authorized share capital (in Shares)																	1
Ordinary per share (in Dollars per share)									$ 0.00001		$ 0.00001						$ 10
Ordinary shares, shares issued (in Shares)									1,796,934		1,796,934
Ordinary share is entitled to vote						10			ten
Class B Ordinary Shares [Member] \| Maximum [Member]
Ordinary Shares [Line Items]
Ordinary per share (in Dollars per share)																10
Class B Ordinary Shares [Member] \| Minimum [Member]
Ordinary Shares [Line Items]
Ordinary per share (in Dollars per share)																$ 0.00001

Lease - Schedule of Operating Leases Obligation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Lease cost
Operating lease cost		$ 50,520	$ 252,345
Short-term lease cost		3,374	65,221
Total lease cost		53,894	317,566
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$ 98,448	$ 120,824	$ 389,365
Weighted-average remaining lease term – operating leases	2 months 12 days	1 year 2 months 12 days	1 year 10 months 24 days
Weighted-average discount rate – finance leases
Weighted-average discount rate – operating leases	8.00%	8.00%	8.00%

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies [Abstract]

Schedule of Milestone Payments that the Group is Required to Pay up to Different Achievements

The aggregate amounts of the contingent milestone payments that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as of December 31, 2025 are below:

	Amount
Drug molecules: up to the conditions and milestones of
From entering phase 1 to before first commercial sale		920,000
First commercial sale		800,000
Net sales amount more than certain threshold in a year		7,000,000
Subtotal	$	8,720,000

Going Concern (Details) - USD ($)	12 Months Ended
Going Concern (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Going Concern [Abstract]
Net loss	$ (1,376,430)	$ (4,157,737)	$ (4,340,975)
Net operation cash outflow	(1,836,546)	(1,189,734)	$ (7,724,364)
Working capital	1,001,299
Accumulated deficit	$ (73,792,798)	$ (72,429,528)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19

Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 37: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 38: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-2

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Defined Contribution Plan	12 Months Ended
Defined Contribution Plan	May 31, 2025
DiamiR Biosciences Corp. [Member]
Defined Contribution Plan [Line Items]
DEFINED CONTRIBUTION PLAN	NOTE 14 — DEFINED CONTRIBUTION PLAN The Company maintains a 401K plan for the benefit of its employees. Company contributions amounted to $5,948 and $12,711 in the years ended May 31, 2025 and 2024, respectively.

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (k)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (m)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

+ Details

Convertible Note

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Convertible Note [Line Items]

CONVERTIBLE NOTE

15. CONVERTIBLE NOTE

On September 11, 2023, the Group entered into a securities purchase agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to which the Group sold a secured convertible note in the aggregate principal amount of $3,000,000 (the “Sep 2023 Notes”). The Sep 2023 Notes are convertible into the Company’s Class A Ordinary Shares and have a maturity date that is 24 months from the issuance date, although upon such date the investor has the right to extend the term of the Sep 2023 Note for twelve (12) months or more or such term subject to mutual consent. The Sep 2023 Notes have an interest rate of 6% per annum and a conversion price of $2.42 per share. The Company has the right to repay the principal amount of the Sep 2023 Notes, but in the case of such prepayment it must be paid in cash, unless otherwise agreed by both parties. The Sep 2023 Note is secured by a first priority lien and security interest on certain preferred shares that the Group owns (“Collateral”) (Note 4). Upon the Group’s disposal of all or a portion of the Collateral, the investor has the right, to request that the Group prepay the then-remaining outstanding balance of the Sep 2023 Note, in part or in full and the Group can make that payment in cash or in shares.

DiamiR Biosciences Corp. [Member]

Convertible Note [Line Items]

CONVERTIBLE NOTE

NOTE 8 — CONVERTIBLE NOTES PAYABLE

Convertible notes payable consist of the following:

	November 30, 2025		May 31, 2025
Executive director	$	1,060,565	$	872,245
Former Chief Scientific Officer		89,782		85,417
Investor		101,778		—
Total	$	1,252,125	$	957,662

In the six months ended November 30, 2025, the Company amended its outstanding convertible note (“Founder Note”) to one founder to reflect additional borrowings of $150,000 during the period. Other terms and conditions of the Founder Note were not affected. The notes call for interest at 4% per annum. The Company estimates that the nominal interest rate on the Founder Note was less than rates that may be obtained from third parties and recorded a discount of $12,694 on the additional borrowing at an estimated effective rate of 9.5%, as an addition to paid-in

capital. The Company has recorded previous discounts on its founder notes, calculated at an estimated effective rates between 9.5% and 10%, as additions to paid-in capital. Unamortized discounts presented as a deduction from the face amount of the Notes amounted to $77,475 and $96,332 as of November 30, 2025 and May 31, 2025, respectively.

In the six months ended November 30, 2025, the Company issued a convertible note (“Investor Note”) to an investor reflecting borrowings of $100,000 during the period. No payments of principal or interest on the Investor Note are required prior to maturity on December 31, 2026. The notes call for interest at 10% per annum and are convertible at a conversion price of $1.80 per share of Aptorum common stock stock upon completion of the merger with Aptorum, or upon the Company’s next equity financing involving the Company’s sale of its equity securities to third party investors at a conversion price based on the financing. Upon any conversion, all unpaid principal and accrued unpaid interest on the Investor Note will be exchanged for the Company’s securities at the lowest per unit price for securities sold to third parties in the next equity financing.

With respect to all of the Company’s convertible notes, no payments of principal or interest are required prior to maturity on December 31, 2026 and are convertible upon the Company’s next equity financing involving the Company’s sale of its equity securities to third party investors. Upon any conversion related to an equity financing, all unpaid principal and accrued unpaid interest on the Notes will be exchanged for the Company’s securities at the lowest per unit price for securities sold to third parties in the next equity financing.

In addition, the notes are due upon demand at the option of the holder when there is a liquidation event, which shall include:

(i) The closing of the sale, lease, transfer or other disposition of all or substantially all of the assets of Company or the grant of any exclusive license to any material portion of the Company’s intellectual property;

(ii) The consummation of the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold, directly or indirectly, at least fifty percent (50%) of the voting power of the capital stock of the Company or the surviving or acquiring entity);

(iii) The closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of the Company’s securities), of the Company’s securities if, after such closing, such person or group of affiliated persons would hold, directly or indirectly, fifty percent (50%) or more of the outstanding voting stock of the Company (or the surviving or acquiring entity);

(iv) An initial public offering of securities by Company or one of its subsidiaries; or

(v) A liquidation, dissolution or winding up of the Company.

Interest expense

Interest expense consists of the following in the six months ended November 30:

	2025		2024
Interest on notes	$	25,607	$	19,490
Amortization of discount		31,550		19,349
Total	$	57,157	$	38,839

NOTE 8 — CONVERTIBLE NOTES PAYABLE

Founders

Convertible notes payable consist of the following:

	May 31, 2025		May 31, 2024
Executive director	$	872,245	$	536,861
Former Chief Scientific Officer		85,417		77,321
Total	$	957,662	$	614,182

In the year ended May 31, 2024, the Company amended its outstanding convertible note (“Note”) to its executive director to reflect additional borrowings of $200,000 during the year and interest accrued to the date of the amended note. In the year ended May 31, 2025, the Company amended its outstanding convertible note (“Note”) to its executive director to reflect additional borrowings of $300,000 during the year and interest accrued to the date of the amended note. The Company estimates that the nominal interest rate on the Note is less than rates that may be obtained from third parties. The Company recorded discounts of $35,063 on the additional borrowing at an estimated effective rate of 10%, as an addition to paid-in capital. Other terms and conditions of the Note were not affected. The notes are payable in full on December 31, 2026.

No payments of principal or interest on the notes are required prior to maturity. The notes call for interest at 4% per annum, compounded monthly and are convertible, at the option of the holder, upon the Company’s next equity financing involving the Company’s sale of its equity securities to third party investors. Upon any conversion, all unpaid principal and accrued unpaid interest on the Notes will be exchanged for the Company’s securities at the lowest per unit price for securities sold to third parties in the next equity financing.

In addition, the Notes are due upon demand at the option of the holder when there is a liquidation event, which shall include:

(iv) An initial public offering of securities by Company or one of its subsidiaries; or

(v) A liquidation, dissolution or winding up of the Company.

The Company estimates that the nominal interest rate on the Notes is less than rates that may be obtained from third parties. The Company has recorded discounts on the Notes, calculated at an estimated effective rate of 10%, as an addition to paid-in capital. Unamortized discounts presented as a deduction from the face amount of the Notes amounted to $96,332 and $105,178 as of May 31, 2025 and 2024, respectively.

See Note 16 “Subsequent Events” regarding the Company’s definitive merger agreement.

Interest expense

Interest expense consists of the following in the years ended May 31:

	2025		2024
Interest on notes	$	38,508	$	23,232
Amortization of discount		43,538		25,367
Total	$	82,046	$	48,599

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	Nov. 30, 2025	May 31, 2025	May 31, 2024
Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) [Line Items]
Outside services	$ 643,784	$ 220,411
Employee compensation	19,248	5,884
Other	10,364	5,563	$ 13,298
Total	$ 673,396	$ 231,858	$ 148,648

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024	Dec. 31, 2023
Income Taxes [Line Items]
Qualifying corporations tax	8.25%
Percentage of assessable profits	16.50%
Income tax rate percentage	16.50%		16.50%		16.50%
Net operating loss carry-forwards	$ 93,107,417		$ 91,436,307
Loss carry-forward	39,489
Hong Kong [Member]
Income Taxes [Line Items]
Assessable profits rate	$ 2,000,000
Subject to income tax rate	16.50%
United Kingdom [Member]
Income Taxes [Line Items]
Income tax rate percentage	19.00%
Singapore [Member]
Income Taxes [Line Items]
Income tax rate percentage	17.00%
United States (Nevada) [Member]
Income Taxes [Line Items]
Income tax rate percentage	21.00%
DiamiR Biosciences Corp. [Member]
Income Taxes [Line Items]
Income tax rate percentage		21.00%		21.00%
Net operating loss		$ 1,541,000		$ 1,047,000
Net operating loss state		392,000		392,000
Federal NOLs		$ 165,000
Percentage rate		80.00%
Valuation allowance increase		$ 104,071		181,606
Accrued interest or penalties		$ 20,483		$ 4,000
Income tax examination, description		2017 to 2025 tax years remained subject to examination
Minimum [Member]
Income Taxes [Line Items]
Percentage of assessable profits	16.50%
Maximum [Member]
Income Taxes [Line Items]
Percentage of assessable profits	15.00%

Convertible Notes Payable - Schedule of Interest Expenses (Details) - Previously Reported [Member] - DiamiR Biosciences Corp. [Member] - USD ($)	6 Months Ended		12 Months Ended
	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024
Schedule of Interest Expenses [Line Items]
Interest on notes	$ 25,607	$ 19,490	$ 38,508	$ 23,232
Amortization of discount	$ 31,550	$ 19,349	43,538	25,367
Total			$ 82,046	$ 48,599

Convertible Note (Details) - USD ($)	6 Months Ended		12 Months Ended
Convertible Note (Details) - USD ($)	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024	Aug. 31, 2025	Sep. 11, 2023
Sep 2023 Notes [Member]
Convertible Note [Line Items]
Additional borrowings						$ 3,000,000
Debt interest rate						6.00%
Debt instrument conversion price (in Dollars per share)						$ 2.42
DiamiR Biosciences Corp. [Member]
Convertible Note [Line Items]
Debt interest rate			4.00%
Debt instrument conversion price (in Dollars per share)	$ 1.8
Additional borrowings	$ 250,000	$ 200,000	$ 300,000	$ 200,000
Debt discount	$ 77,475		$ 96,332	105,178
Effective interest rate			10.00%
Debt Instrument, Interest Rate, Basis for Effective Rate	4%
Discounts on note payable to founder	$ 12,694	$ 24,970	$ 34,692	$ 35,063
Borrowing effective rate	9.50%
Borrowings amount	$ 100,000
Percentage of voting stock after transactions	50.00%
DiamiR Biosciences Corp. [Member] \| Convertible Notes Payable [Member]
Convertible Note [Line Items]
Effective interest rate					10.00%
DiamiR Biosciences Corp. [Member] \| Third Party Investor [Member]
Convertible Note [Line Items]
Debt interest rate	10.00%
DiamiR Biosciences Corp. [Member] \| Merger or Consolidation [Member]
Convertible Note [Line Items]
Voting power percentage	50.00%
DiamiR Biosciences Corp. [Member] \| Convertible Notes Payable [Member]
Convertible Note [Line Items]
Effective interest rate	9.50%
DiamiR Biosciences Corp. [Member] \| Founders [Member] \| Convertible Notes Payable [Member]
Convertible Note [Line Items]
Additional borrowings			200,000
Debt instrument principal amount			300,000
Debt discount			$ 35,063
Effective interest rate			10.00%
DiamiR Biosciences Corp. [Member] \| Founders [Member] \| Convertible Notes Payable [Member]
Convertible Note [Line Items]
Additional borrowings	$ 150,000

Loss Per Share - Schedule of Antidilutive Common Stock Equivalents (Details) - DiamiR Biosciences Corp. [Member] - shares	6 Months Ended		12 Months Ended
	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024
Stock options [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares	441,750	511,950	511,950	511,950
Restricted stock [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares	88,000	88,000	88,000	88,000
Warrants [Member]
Schedule of Antidilutive Common Stock Equivalents [Line Items]
Antidilutive shares		29,336		29,336

Long-Term Investment (Details) - USD ($)	1 Months Ended	12 Months Ended
Long-Term Investment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Long-Term Investment [Line Items]
Long-term investment		$ 15,098,846	$ 15,098,846
Equity method investment at fair value option
Shares issued, value				$ 1,575,562
Investments
Ownership interest	97.27%
Initial carrying value of the investment	$ 77,200
Impairment investment			1,000,000	77,200
Libra [Member]
Long-Term Investment [Line Items]
Voting interest	31.51%
Business Combination, Series of Individually Immaterial Business Combinations [Member]
Long-Term Investment [Line Items]
Voting interest	31.51%
Alzheon [Member]
Long-Term Investment [Line Items]
Long-term investment		15,098,846	15,098,846
Shares issued, value		$ 2,600,000
Share price (in Dollars per share)		$ 4.11
Conversion price (in Dollars per share)		$ 10.63
Investee B [Member]
Long-Term Investment [Line Items]
Impairment value			1,000,000
Libra [Member]
Long-Term Investment [Line Items]
Ownership interest	97.27%
Impairment investment				$ 77,200
Maximum exposure to loss
Series B Preferred Stock [Member]
Long-Term Investment [Line Items]
Share price (in Dollars per share)		$ 0.3
Series B Preferred Stock [Member] \| Alzheon [Member]
Long-Term Investment [Line Items]
Shares issued (in Shares)		622,600
Series B Preferred Stock [Member] \| Investee B [Member]
Long-Term Investment [Line Items]
Shares issued (in Shares)		3,333,333
Shares issued, value		$ 1,000,000
Series D Preferred Stock [Member]
Long-Term Investment [Line Items]
Aggregate gross proceeds					$ 50,000,000
Series D Preferred Stock [Member] \| Alzheon [Member]
Long-Term Investment [Line Items]
Shares issued (in Shares)					36
Series E Convertible Preferred Stock [Member] \| Alzheon [Member]
Long-Term Investment [Line Items]
Share price (in Dollars per share)		$ 62.71	$ 62.71	$ 62.71
Aggregate gross proceeds		$ 5,000,000	$ 78,000,000	$ 45,000,000
Series D Convertible Preferred Stock [Member]
Long-Term Investment [Line Items]
Upward adjustment					$ 6,108,872
Series D Convertible Preferred Stock [Member] \| Minimum [Member]
Long-Term Investment [Line Items]
Upward adjustment					2,558,886
Series D Convertible Preferred Stock [Member] \| Maximum [Member] \| Alzheon [Member]
Long-Term Investment [Line Items]
Upward adjustment					$ 8,667,758
Series E Convertible Preferred Stock [Member]
Long-Term Investment [Line Items]
Upward adjustment				6,431,088
Series E Convertible Preferred Stock [Member] \| Minimum [Member]
Long-Term Investment [Line Items]
Upward adjustment				8,667,758
Series E Convertible Preferred Stock [Member] \| Maximum [Member]
Long-Term Investment [Line Items]
Upward adjustment				$ 15,098,846
Class B Ordinary Shares [Member]
Long-Term Investment [Line Items]
Number of votes	10	ten
Common Stock [Member] \| Alzheon [Member]
Long-Term Investment [Line Items]
Number of shares converted (in Shares)		240,773
Common Stock [Member] \| Class B Ordinary Shares [Member]
Long-Term Investment [Line Items]
Shares issued (in Shares)
Shares issued, value

Prepaid Expenses and Other Current Assets

6 Months Ended

12 Months Ended

Nov. 30, 2025

May 31, 2025

DiamiR Biosciences Corp. [Member]

Prepaid Expenses and Other Current Assets [Line Items]

PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 5 — PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

	November 30, 2025		May 31, 2025
Advances to suppliers	$	—	$	45,252
Other		5,704		1,397
Total	$	5,704	$	46,649

NOTE 4 — PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

	May 31, 2025		May 31, 2024
Deferred costs of equity financing	$	—	$	114,000
Advances to suppliers		45,252		—
Other		1,397		6,139
Total	$	46,649	$	120,139

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	Nov. 30, 2025	May 31, 2025	May 31, 2024
Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) [Line Items]
Advances to suppliers		$ 45,252
Other	5,704	1,397	6,139
Total	$ 5,704	$ 46,649	$ 120,139

Leases - Schedule of Lease Terms and Discount Rates (Details) - DiamiR Biosciences Corp. [Member]	May 31, 2025	May 31, 2024
Leases [Line Items]
Average lease term	1 year 7 months 6 days	1 year 7 months 6 days
Discount rate	10.00%	10.00%

Long-Term Investment - Schedule of Carrying Value of the Non-Marketable Investments Held (Details) - USD ($)

Dec. 31, 2025

Dec. 31, 2024

Schedule of Carrying Value of the Non-Marketable Investments Held [Line Items]

$ 4,079,707

12,539,960

(1,520,821)

15,098,846

Investment A [Member]

Schedule of Carrying Value of the Non-Marketable Investments Held [Line Items]

Cost basis

^[1]

2,558,886

Upward adjustments

^[1]

12,539,960

Impairment

^[1]

Carrying value

^[1]

15,098,846

Investment B [Member]

Schedule of Carrying Value of the Non-Marketable Investments Held [Line Items]

Cost basis

^[2]

1,000,000

Upward adjustments

^[2]

Impairment

^[2]

(1,000,000)

Carrying value

^[2]

Investment C [Member]

Schedule of Carrying Value of the Non-Marketable Investments Held [Line Items]

520,821

(520,821)

[1]

[2]

Summary of Significant Accounting Policies - Schedule of Contract Assets and Deferred Revenues (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	6 Months Ended	12 Months Ended
	Nov. 30, 2025	May 31, 2025	May 31, 2024
Schedule of Contract Assets and Deferred Revenues [Line Items]
Contract assets at beginning
Contract liabilities Deferred revenue at beginning
Contract assets Net change due to billings	86,373
Contract liabilities Deferred revenue Net change due to billings
Contract assets Revenue recognized	86,373
Contract liabilities Deferred revenue Revenue recognized
Contract assets at ending
Contract liabilities Deferred revenue at ending
Deferred Revenue [Member]
Schedule of Contract Assets and Deferred Revenues [Line Items]
Contract liabilities Deferred revenue at beginning	43,982,000,000
Contract liabilities Deferred revenue Net change due to billings		43,982,000,000
Contract liabilities Deferred revenue Revenue recognized
Contract liabilities Deferred revenue at ending		43,982,000,000
Unbilled Revenues [Member]
Schedule of Contract Assets and Deferred Revenues [Line Items]
Contract assets at beginning
Contract assets Net change due to billings	86,373
Contract assets Revenue recognized	86,373
Contract assets at ending

Accounts Receivable

6 Months Ended

Nov. 30, 2025

DiamiR Biosciences Corp. [Member]

Accounts Receivable [Line Items]

ACCOUNTS RECEIVABLE

NOTE 4 — ACCOUNTS RECEIVABLE

Accounts receivable consists of the following:

	November 30, 2025		May 31, 2025
Contracts with customers	$	42,391	$	—
Management services revenue from Aptorum		88,700		—
Total	$	131,091	$	—

Summary of Significant Accounting Policies (Details) - USD ($)		6 Months Ended	12 Months Ended
	Mar. 31, 2023	Nov. 30, 2025	Dec. 31, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]
Allowance for credit losses							$ 521,007
Allowance for credit losses							522,191
Estimated useful life			5 years
Lease term			12 months
Written-down of inventories							13,206
Vesting period term	6 months
Management approach to determine reportable segments description			The Group operates and manages its business as a single operating and reportable segment. The Group’s CODM has been identified as the Chief Executive Officer who reviews the consolidated net income (loss) when making decisions about allocating resources and assessing performance of the Group.
Executive Chairman			Chief Executive Officer
Related Parties [Member]
Summary of Significant Accounting Policies [Line Items]
Allowance for credit losses			$ 522,191		522,191
Government Subsidies [Member]
Summary of Significant Accounting Policies [Line Items]
Written-down of inventories					$ 0.9
DiamiR Biosciences Corp. [Member]
Summary of Significant Accounting Policies [Line Items]
Management approach to determine reportable segments description				The Company performs research and development activities of its own and for others substantially in one location using resources common to internal research activities and revenue-producing services, which have been limited to date.
Executive Chairman				Chief Executive Officer
Cash equivalents
FDIC insured limits				250,000
Impairment charges on long-lived assets
Management services revenue		$ 88,700
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Vesting period term			9 months 15 days
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Vesting period term			21 months 15 days
Maximum [Member] \| DiamiR Biosciences Corp. [Member]
Summary of Significant Accounting Policies [Line Items]
FDIC insured limits		$ 250,000
Unbilled Revenues [Member] \| DiamiR Biosciences Corp. [Member]
Summary of Significant Accounting Policies [Line Items]
Contract asset						$ 89,281

Revenue (Details) - USD ($)	12 Months Ended
Revenue (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue [Abstract]
Revenue			$ 431,378

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Stockholders’ Equity (Tables) - DiamiR Biosciences Corp. [Member]

12 Months Ended

May 31, 2025

Stockholders’ Equity [Line Items]

Schedule of Stock Option Activity

The following is an analysis of the stock option activity under the Plans:

	Number		Weighted Average Exercise Price		Weighted Average Remaining Life
Outstanding May 31, 2023	557,450		$	6.04
Granted	153,000			0.01
Exercised	—			—
Expired or forfeited	(198,500	)		4.95
Outstanding May 31, 2024	511,950		$	4.66
Granted	—			—
Exercised	—			—
Expired or forfeited	—			—
Outstanding May 31, 2025	511,950		$	4.66	5.5 years
Exercisable May 31, 2025	263,450		$	4.96	4.0 years

Schedule of Weighted-Average Assumptions

The weighted average grant-date fair value of stock options granted during the years ended May 31, 2024 was $7.00, based on the following weighted average assumptions:

	2024
Expected term in years	10
Expected volatility	81	%
Risk-free interest rate	4.1	%
Expected dividend yield	0	%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Long-Term Deposits (Tables)

12 Months Ended

Dec. 31, 2025

Long-Term Deposits [Abstract]

Schedule of Long-Term Deposits

Long-term deposits as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Rental deposits	$	—	$	71,823
	$	—	$	71,823

Warrants - Schedule of Fair Value of Investor Warrants (Details)	Dec. 31, 2025	Oct. 14, 2025
Stock price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.06	1.59
Exercise price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	2	2
Expected term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.93	2.5
Risk-free rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	3.48	3.49
Expected volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	58.1	58.8
Dividend rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Dilution factor [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1	1
Fair value per share [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.153	0.498

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	Nov. 30, 2025	May 31, 2025	May 31, 2024
Schedule of Accounts Payable and Accrued Expenses [Line Items]
Outside services		$ 220,411	$ 123,065
Employee compensation		5,884	12,285
Other	$ 10,364	5,563	13,298
Total	$ 673,396	$ 231,858	$ 148,648

Ordinary Shares

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Ordinary Shares [Line Items]

ORDINARY SHARES

16. ORDINARY SHARES

On January 23, 2023, the Company effectuated a 10 for 1 share consolidation of its authorized share capital, such that every 10 Class A Ordinary Shares, par value of US$1.00 per share, in the authorized share capital of the Company (including issued and unissued share capital) were consolidated into 1 Class A Ordinary Share, par value of US$10.00 per share, and that every 10 Class B Ordinary Shares, par value of US$1.00 per share in the authorized share capital of the Company (including issued and unissued share capital) were consolidated into 1 Class B Ordinary Share, par value of US$10.00 per share. As a consequence of the reverse stock split, fractional shares were rounded up to the next whole share, resulting in the creation of an additional 8,018 Class A Ordinary Shares.

On February 21, 2023, the Company was merged with Aptorum Group Cayman Limited, a newly established wholly owned subsidiary of the Company, whereby the Company is the surviving company on the terms of the plan of merger. According to the plan of merger, the par value of its Class A and Class B Ordinary Shares are changed from USD10 to USD0.00001.

On March 31, 2023, the Group issued 70,430 Class A Ordinary Shares to a majority of the share option holders. This issuance served as an exchange for their share options and facilitated the reversal of deferred cash bonus payables owed to these holders (See Note 10).

On March 31, 2023, the Group also issued 65,770 fully vested Class A Ordinary Shares to certain employees and external consultants. The grant date fair value of each of the shares was $2.68 based on grant date quoted market price.

On June 28, 2023, the Group entered into a securities purchase agreement with 4 investors. Pursuant to the securities purchase agreement, the investors are purchasing a convertible note in the original principal amount of $3,000,000 (the “June 2023 Note”). The whole proceeds from the June 2023 Note was used to settle a related party loan. The June 2023 Note is unsecured, convertible into the Company’s restricted Class A Ordinary Shares at the Note holders’ option. The June 2023 Notes have a maturity date of 12 months subject to the investors extension, a bullet interest rate of 7% per annum, and a conversion price of $3.00 per Class A Ordinary share. The Company shall have an obligation to repay the principal amount and interest of the June 2023 Note on the maturity date in cash or in unregistered Class A Ordinary Shares or a combination of such at the Company’s discretion. Immediately following the issuance of June 2023 Note, the June 2023 Note was fully converted into 1,000,000 Class A Ordinary Shares.

For the year ended December 31, 2023, the Group issued 1,250,000 Class A Ordinary Shares to convertible note holders upon conversion (See Note 15).

For the year ended December 31, 2024 and 2023, the Group issued 427,060 and 791 Class A Ordinary Shares to share option holders as a result of exercise of options, respectively.

For the year ended December 31, 2024, the Group issued 446,842 Class A Ordinary Shares to Class B Ordinary Shares holders upon conversion.

On January 2, 2025, the Company entered into a certain securities purchase agreement (the “Securities Purchase Agreement”) with certain non-affiliated institutional investors (the “Purchasers”) pursuant to which the Company sold 1,535,000 Class A ordinary shares of the Company (the “Shares”), par value $0.00001 per share (the “Ordinary Shares”) at a per share price of $2.00 in a registered direct offering, for gross proceeds of $3,070,000 (the “January 2025 Offering”) and the net proceeds after deducting the related expense is $2,699,200. The Securities Purchase Agreement was fully executed on January 3, 2025.

On October 14, 2025, the Company closed an offering of 1,000,000 Class A ordinary shares at a purchase price of $2.00 per unit, with each unit consisting of one Class A ordinary share and two restricted warrants (the “Investor Warrants”, see Note 20) to purchase one Class A ordinary share each, for aggregate gross proceeds of $2,000,000 (the “October 2025 Offering”). Cash issuance costs are $284,001 and the net proceeds from the October 2025 Offering were approximately $1,716,000.

Of the $2,000,000 gross proceeds, $996,000 was allocated to the liability-classified Investor Warrants at their fair value (see Note 20), with the residual $1,004,000 allocated to the equity-classified Class A ordinary shares.

In connection with the October 2025 Offering, the Company issued warrants to purchase 60,180 Class A ordinary shares to the placement agent’s designees (the “Placement Agent Warrants”) at an exercise price of $2.50 per share. The Placement Agent Warrants had a grant-date fair value of $23,606 (see Note 17) which was treated as an issuance cost of the offering.

Cash issuance costs of $284,001 and the Placement Agent Warrant fair value of $23,606 were allocated between the liability and equity instruments in proportion to the allocation of proceeds ($141,433 and $11,756, respectively, to the warrant liability, expensed as incurred; and $142,568 and $11,850, respectively, to equity, charged to additional paid-in capital).

Holders of Class A Ordinary Shares and Class B Ordinary Shares have the same rights except for the following: (i) each Class A Ordinary Share is entitled to one vote while each Class B Ordinary Share is entitled to ten votes; and (ii) each Class B Ordinary Share is convertible into one Class A Ordinary Share at any time while Class A Ordinary Shares are not convertible under any circumstances.

DiamiR Biosciences Corp. [Member]

Ordinary Shares [Line Items]

ORDINARY SHARES

NOTE 10 — STOCKHOLDERS’ EQUITY

Stock-Based Compensation

The Company maintains stock option plans, under which shares are available for issuance of stock-based awards under terms established by the board of directors. Through November 30, 2025, awards under the plans generally consisted of stock options with exercise prices equal to the estimated fair market value of the Company’s common stock, vesting and service conditions of 18 months to three years without market or performance conditions and ten-year lives, and to restricted stock units with performance conditions. As of May 31, 2025, 600,000 shares remain available for future grant under the 2024 Stock Option Plan.

In the six months ended November 30, 2025, stock-based compensation expense amounted to $0. In the six months ended November 30, 2024, stock-based compensation expense amounted to $20,418, which is included in research and development expenses. As of November 30, 2025, unrecognized stock-based compensation expense related to options for which vesting is considered probable was $0.

As of November 30, 2025, unrecognized stock-based compensation expense related to options for which vesting is not considered probable was $1,093,712. As of November 30, 2025, the grant-date fair value and unrecognized compensation expense related to restricted stock units for which vesting is not considered probable was $652,080.

Founder Contribution

In six months ended November 30, 2025 and 2024, its founders made contributions to the Company in the form of a loans with interest rates below market. The Company recorded a discounts on the loans of $12,694 and $24,970 in the six months ended November 30, 2025 and 2024, respectively, as additional paid-in capital.

Warrant

In the six months ended November 30, 2024, the holder agreed to exchange 29,336 warrants to purchase shares of our common stock exercisable at a price of $5.87 per share, for 29,336 shares of our Common Stock in the event of a public offering of securities by the Company prior to January 1, 2025. The warrant expired in the year ended May 31, 2025, in accordance with its terms.

NOTE 11 — STOCKHOLDERS’ EQUITY

The Company was capitalized by its two founders with a cash contribution by one of its founders of $250,000 for 2,200,000 shares of common stock and a non-cash contribution by the other founder for 2,000,000 shares of common stock. The non-cash contribution consisted of all of the founders’ rights, title, and interest in any intellectual property, proprietary property or other property of a similar nature related to the business to be conducted by the Company involving methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases.

Founder Contributions

In the years ended May 31, 2025 and 2024, its founders also made contributions to the Company in the form of below market interest rates on loans and in the form of uncompensated services. the Company recorded discounts on founder notes payable of $34,692 and $35,063 respectively, as additional paid-in capital.

Warrant

Concurrent with the issuance of a note payable settled prior to the year ended May 31, 2024, the Company issued a warrant for 29,336 shares of the Company’s common stock at an exercise price of $5.87 per share. The warrant expired in the year ended May 31, 2025, in accordance with its terms.

Stock Option Plans

The Company maintains stock option plans, under which shares are available for issuance of stock-based awards under terms established by the board of directors. Through May 31, 2025, awards under the plans generally consisted of options with exercise prices equal to fair market value, vesting and service conditions of 18 months to three years without market or performance conditions and ten-year lives. Options granted in the year ended May 31, 2024 for an aggregate of 246,000 shares are subject to vesting conditions related to research and financing milestones. As of May 31, 2025, 600,000 shares remain available for future grant under the 2024 Stock Option Plan. The number of shares available under the 2024 Stock Option Plan will increase by 2% per year or such lower number of shares as may be determined by the Company’s board of directors.

The following is an analysis of the stock option activity under the Plans:

	Number		Weighted Average Exercise Price		Weighted Average Remaining Life
Outstanding May 31, 2023	557,450		$	6.04
Granted	153,000			0.01
Exercised	—			—
Expired or forfeited	(198,500	)		4.95
Outstanding May 31, 2024	511,950		$	4.66
Granted	—			—
Exercised	—			—
Expired or forfeited	—			—
Outstanding May 31, 2025	511,950		$	4.66	5.5 years
Exercisable May 31, 2025	263,450		$	4.96	4.0 years

The weighted average grant-date fair value of stock options granted during the years ended May 31, 2024 was $7.00, based on the following weighted average assumptions:

	2024
Expected term in years	10
Expected volatility	81	%
Risk-free interest rate	4.1	%
Expected dividend yield	0	%

In the year ended May 31, 2024, the Company modified the terms of certain of its outstanding stock options representing an aggregate of 140,000 shares. These modifications included a reduction in exercise prices from $7.01 per share to $0.01 per share and the addition of performance and vesting conditions, not currently considered probable of achievement, related to corporate transactions.

In the year ended May 31, 2025, stock-based compensation expense amounted to $24,312, which is included in research and development expenses. In the year ended May 31, 2024, stock-based compensation expense amounted to $194,846, of which $182,912 is included in research and development expenses and $11,934 is included in general and administrative expenses. As of May 31, 2025, unrecognized stock-based compensation expense related to options for which vesting is considered probable was $0. As of May 31, 2025, unrecognized stock-based compensation expense related to options for which vesting is not considered probable was $1,093,712.

In the year ended May 31, 2023, the Company issued 132,000 restricted stock units, vesting upon a change in control or public listing of the Company’s common stock. In the year ended May 31, 2024, concurrent with the modification of stock options described above, the Company terminated outstanding restricted stock units representing 44,000 shares. Vesting of the units is not considered probable and no compensation expense has been recognized through the year ended May 31, 2025. The grant-date fair value and unrecognized compensation expense as of May 31, 2025 related to the restricted stock units amounts to $652,080.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Consolidated Statements of Operations and Comprehensive Loss - USD ($)

6 Months Ended

12 Months Ended

Nov. 30, 2025

Nov. 30, 2024

Dec. 31, 2025

May 31, 2025

Dec. 31, 2024

May 31, 2024

Dec. 31, 2023

Revenue

Revenue

$ 431,378

Operating expenses

Cost of healthcare services

(420,812)

Research and development expenses

(352,879)

(2,195,161)

(5,198,329)

General and administrative fees

(573,059)

(669,486)

(1,930,637)

Legal and professional fees

(1,062,346)

(803,285)

(2,538,161)

Other operating income (expenses)

170,756

(272,609)

(1,067,690)

Total operating expenses

(1,817,528)

(3,940,541)

(11,155,629)

Other (expense) income, net

Loss on investments in marketable securities, net

(9,266)

Unrealized gain from fair value change of the long-term investments, net

6,431,088

Impairment loss of long-term investment

(1,000,000)

(77,200)

Interest expense, net

(95,713)

(146,924)

(121,145)

Gain on disposal of subsidiaries

703

Issuance cost allocated to warrant liability

(153,189)

Change in fair value of warrant liability

690,000

Government subsidies

928,461

123,015

Sundry income

564

36,784

Total other income (expense), net

441,098

(217,196)

6,383,276

Income taxes

Net loss

(1,376,430)

(4,157,737)

(4,340,975)

Net income (loss) attributable to non-controlling interests

13,160

(110,069)

1,516,328

Other comprehensive (loss) income

Exchange differences on translation of foreign operations

(181,472)

99,785

(44,430)

Other comprehensive (loss) income

(181,472)

99,785

(44,430)

Comprehensive loss

(1,557,902)

(4,057,952)

(4,385,405)

Comprehensive (loss) income attributable to non-controlling interests

(13,160)

110,069

(1,516,328)

Comprehensive loss attributable to the shareholders of Aptorum Group Limited

(1,544,742)

(4,168,021)

(2,869,077)

Net loss attributable to Aptorum Group Limited

$ (1,363,270)

$ (4,267,806)

$ (2,824,647)

Net loss per share attributable to Aptorum Group Limited

Basic (in Dollars per share)

^[1]

$ (0.19)

$ (0.78)

$ (0.62)

Net loss per common share, diluted (in Dollars per share)

^[1]

$ (0.19)

$ (0.78)

$ (0.62)

Weighted-average shares outstanding

Basic (in Shares)

^[1]

7,351,784

5,453,103

4,521,133

Diluted (in Shares)

^[1]

7,351,784

5,453,103

4,521,133

DiamiR Biosciences Corp

Revenue

Revenue

$ 130,355

$ 442,820

$ 631,729

$ 1,319,531

Operating expenses

Cost of healthcare services

93,016

Research and development

197,029

401,208

650,591

1,156,860

General and administrative

776,292

274,404

624,388

614,074

Total operating costs and expenses

1,066,337

675,612

1,274,979

1,770,934

Loss from operations

(935,982)

(232,792)

(643,250)

(451,403)

Other (expense) income, net

Other income

408,638

Interest expense, net

(57,157)

(38,839)

82,046

48,599

Total other income (expense), net

351,481

(38,839)

82,046

48,599

Net loss before income taxes

(584,501)

(271,631)

(725,296)

(500,002)

Income taxes

(174,546)

10,901

17,939

114,403

Net loss

(409,955)

$ (282,532)

(743,235)

(614,405)

Other comprehensive (loss) income

Net loss attributable to Aptorum Group Limited

$ (409,955)

$ (743,235)

$ (614,405)

Net loss per share attributable to Aptorum Group Limited

Basic (in Dollars per share)

$ (0.09)

$ (0.06)

$ (0.17)

$ (0.14)

Net loss per common share, diluted (in Dollars per share)

$ (0.09)

$ (0.06)

$ (0.17)

$ (0.14)

Weighted-average shares outstanding

Basic (in Shares)

4,440,891

Diluted (in Shares)

4,440,891

Service revenue | DiamiR Biosciences Corp

Revenue

Revenue

$ 130,355

Grant revenue | DiamiR Biosciences Corp

Revenue

Revenue

$ 442,820

$ 531,729

$ 1,319,531

Other revenue | DiamiR Biosciences Corp

Revenue

Revenue

$ 100,000

[1]	All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED’s 1 for 10 reverse stock split, which was effective on January 23, 2023.

Other Receivables and Prepayments - Schedule of Other Receivables and Prepayments (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Schedule of Other Receivables and Prepayments [Abstract]
Prepaid insurance	$ 17,490	$ 17,794
Prepaid service fee	44,810	50,538
Rental deposits	71,823	4,206
Other receivables		4,545
Other deposits	5,510	8,233
Total	$ 139,633	$ 85,316

Net Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Details) - USD ($)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Numerator:

Net loss attributable to Aptorum Group Limited

$ (1,363,270)

$ (4,267,806)

$ (2,824,647)

Denominator:

Basic weighted average shares outstanding

^[1]

7,351,784

5,453,103

4,521,133

Diluted weighted average shares outstanding

^[1]

7,351,784

5,453,103

4,521,133

Net loss per share attributable to Aptorum Group Limited(1)

Basic loss per share

^[1]

$ (0.19)

$ (0.78)

$ (0.62)

Diluted loss per share

^[1]

$ (0.19)

$ (0.78)

$ (0.62)

[1]	All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED’s 1 for 10 reverse stock split, which was effective on January 23, 2023.

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

+ Details

Going Concern

12 Months Ended

Dec. 31, 2025

Going Concern [Abstract]

GOING CONCERN

2. GOING CONCERN

The Group reported a net loss of $1,376,430 and net operating cash outflow of $1,836,546 for the year ended December 31, 2025 and had negative working capital of $1,001,299 as of December 31, 2025. In addition, the Group had an accumulated deficit of $73,792,798 as of December 31, 2025. The Group’s operating results for future periods are subject to numerous uncertainties and it is uncertain if the Group will be able to reduce or eliminate its net losses for the foreseeable future. If management is not able to generate significant revenues from its product candidates currently in development, the Group may not be able to achieve profitability. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Group’s cost structure. In connection with the Group’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that these conditions raise substantial doubt about the Group’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.

If the Group is unable to generate sufficient funds to finance the working capital requirements of the Group within the normal operating cycle of a twelve-month period from the date of these consolidated financial statements are issued, the Group may have to consider supplementing its available sources of funds through the following sources:

• other available sources of financing from banks and other financial institutions or private lender; and

• equity financing.

The Group can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to the Group, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material adverse effect on the Group and would materially adversely affect its ability to continue as a going concern.

The Group’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Group will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Income Taxes - Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate [Abstract]
Net loss before tax (in Dollars)	$ (1,376,430)	$ (4,157,737)	$ (4,340,975)
Net loss before tax, percentage	100.00%	100.00%	100.00%
Hongkong statutory income tax rate, percentage	16.50%	16.50%	16.50%
Provision for income tax benefit at Hong Kong statutory income tax rate (16.5%), Amount (in Dollars)	$ (227,110)	$ (686,027)	$ (716,261)
Provision for income tax benefit at Hong Kong statutory income tax rate (16.5%), Percent	16.50%	16.50%	16.50%
Domestic tax effects
Non-taxable income (in Dollars)	$ (13,907)	$ (5,477)	$ (1,071,774)
Non-taxable income, percentage	1.00%	0.10%	24.70%
Non-deductible expenses (in Dollars)		$ 195	$ 98,704
Non-deductible expenses, percentage	0.00%	0.00%	(2.30%)
Change in valuation allowance (in Dollars)	$ 223,918	$ 702,123	$ 1,705,603
Change in valuation allowance, percentage	(16.30%)	(16.90%)	(39.30%)
Foreign tax effects
-Statutory tax rate difference between Cayman and Hong Kong (in Dollars)	$ 16,128	$ (9,191)	$ (5,078)
-Statutory tax rate difference between Cayman and Hong Kong	(1.20%)	0.20%	0.10%
Other foreign jurisdictions (in Dollars)	$ 917	$ (1,623)	$ (11,185)
Other foreign jurisdictions	0.00%	0.10%	0.30%
Effective income tax expense (in Dollars)
Effective income tax expense

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

May 31, 2025

Income Taxes [Line Items]

Schedule of Income/(Loss) Before Income Tax Expense

Income/(loss) before income tax expense is attributable to the following geographic locations:

	Year ended December 31, 2025			Year ended December 31, 2024			Year ended December 31, 2023
Hong Kong	$	(1,409,614	)	$	(3,944,692	)	$	(1,297,897	)
Singapore		111,972			(252,611	)		(2,956,296	)
Other jurisdictions		(78,788	)		39,566			(86,782	)
Loss before income tax expense	$	(1,376,430	)		(4,157,737	)		(4,340,975	)

Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate

The reconciliation of income taxes expenses computed at the Hong Kong statutory tax rate applicable to income tax expense is as follows:

	Year ended December 31, 2025					Year ended December 31, 2024					Year ended December 31, 2023
Net loss before tax	$	(1,376,430	)	100	%	$	(4,157,737	)	100	%	$	(4,340,975	)	100	%
Hongkong statutory income tax rate		16.5	%				16.5	%				16.5	%
Provision for income tax benefit at Hong Kong statutory income tax rate (16.5%)		(227,110	)	16.5	%		(686,027	)	16.5	%		(716,261	)	16.5	%
Domestic tax effects
Non-taxable interest income		(13,907	)	1.0	%		(5,477	)	0.1	%		(1,071,774	)	24.7	%
Non-deductible expenses		—		0.0	%		195		0.0	%		98,704		(2.3	)%
Change in valuation allowance		223,918		(16.3	)%		702,123		(16.9	)%		1,705,603		(39.3	)%
Foreign tax effects
Cayman
– Statutory tax rate diﬀerence between Cayman and Hong Kong		16,128		(1.2	)%		(9,191	)	0.2	%		(5,078	)	0.1	%
Other foreign jurisdictions		917		0.0	%		(1,623	)	0.1	%		(11,185	)	0.3	%
Effective income tax expense	$	—		—		$	—		—		$	—		—

Schedule of Income Taxes Paid

Income taxes paid by jurisdiction is as follows:

	Year ended December 31, 2025		Year ended December 31, 2024		Year ended December 31, 2023
Hong Kong	$	—	$	—	—
Singapore		—		—	—
Other jurisdictions		—		—	—
Total income taxes paid	$	—		—	—

Schedule of Deferred Tax Assets and Liabilities

The following represents the tax effect of each major type of temporary difference.

	December 31, 2025			December 31, 2024
Deferred tax asset:
Net operating losses carryforwards	$	15,365,786		$	15,107,318
Depreciation and amortization		86,843			128,896
Impairment loss on assets		537,830			537,830
Total Deferred tax asset		15,990,459			15,774,044
Valuation allowance		(15,990,459	)		(15,774,044	)
Deferred tax asset, net of valuation allowance	$	—		$	—

Schedule of Changes in Valuation Allowance

Changes in valuation allowance are as follows:

	December 31, 2025			December 31, 2024			December 31, 2023
Balance as of January 1	$	15,774,044		$	17,407,156		15,705,088
Additions		223,918			702,123		1,705,603
Disposal		(7,503	)		(2,335,235	)	(3,535	)
Balance as of December 31	$	15,990,459		$	15,774,044		17,407,156

DiamiR Biosciences Corp. [Member]

Income Taxes [Line Items]

Schedule of Income Taxes Expenses Computed at the Hong Kong Statutory Tax Rate

For the years ended May 31, 2025 and 2024, a reconciliation of the Company’s effective tax rate to the statutory U.S. Federal rate is as follows:

	2025		2024
Income taxes at Federal statutory rate	21.0	%	21.0	%
Discounts and interest on notes	(2.4	)%	(2.1	)%
Financing costs	(4.3	)%	—	%
State taxes	—	%	(4.2	)%
Other	(2.3	)%	(1.2	)%
Change in valuation allowance	(14.3	)%	(36.3	)%
Income tax provision	(2.3	)%	(22.9	)%

Schedule of Deferred Tax Assets and Liabilities

The Company’s deferred tax assets and liabilities consist of the following at May 31, 2025 and 2024:

	May 31, 2025			May 31, 2024
Deferred tax assets:
Tax benefit of net operating loss carry-forward (NOL)	$	351,453		$	247,637
FIN48 reduction in NOL		(269,420	)		(219,793	)
Stock compensation		351,136			346,030
Research and development expenses		422,170			372,544
Other		1,152			2,432
Total deferred tax assets:		856,490			748,850
Deferred tax liabilities		(8,152	)		(4,583	)
Net deferred tax assets:		848,338			744,267
Valuation allowance for deferred tax assets		(848,338	)		(744,267	)
Deferred tax assets, net of valuation allowance	$	—		$	—

Schedule of Provision For Income Taxes

For the years ended May 31, 2025 and 2024, the provision for income taxes consisted of the following:

	2025		2024
Current:
Federal	$	16,483	$	112,947
State		1,456		1,456
Total current		17,939		114,403
Deferred:
Federal		—		—
State		—		—
Total deferred		—		—
Total	$	17,939	$	114,403

Schedule of Unrecognized Tax Benefits

The Company recognizes a tax benefit from an uncertain tax position when it is more-likely-than-not that it will be sustained upon examination by tax authorities.

Unrecognized tax benefits, May 31, 2023	$	217,239
Gross increases – tax positions in current period		155,305
Unrecognized tax benefits, May 31, 2024		372,544
Gross increases – tax positions in current period		49,626
Unrecognized tax benefits, May 31, 2025	$	422,170

Lease (Tables)

12 Months Ended

Dec. 31, 2025

May 31, 2025

Lease (Tables) [Line Items]

Schedule of Operating Leases Obligation

The discount rates reflect the estimated incremental borrowing rate, which includes an assessment of the credit rating to determine the rate that the Group would have to pay to borrow, on a collateralized basis for a similar term, an amount equal to the lease payments in a similar economic environment.

	For the year ended December 31, 2025			For the year ended December 31, 2024			For the year ended December 31, 2023
Lease cost
Operating lease cost		—			50,520		252,345
Short-term lease cost		—			3,374		65,221
Total lease cost	$	—		$	53,894		317,566

Other information
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	98,448		$	120,824		389,365
Weighted-average remaining lease term – operating leases		0.2 years			1.2 years		1.9 years
Weighted-average discount rate – finance leases		—	%		—	%	—	%
Weighted-average discount rate – operating leases		8.0	%		8.0	%	8.0	%

Schedule of Maturity Analysis of Operating Leases Liabilities

The maturity analysis of operating leases liabilities as of December 31, 2025 is as follows:

	December 31, 2025
Remaining periods ending December 31,
2026	24,573
Total future undiscounted cash flow	24,573
Less: Discount on operating lease liabilities	(145	)
Present value of operating lease liabilities	24,428

DiamiR Biosciences Corp. [Member]

Lease (Tables) [Line Items]

Schedule of Operating Leases Obligation

Supplemental cash flow information and non-cash activity related to leases include the following in the years ended May 31:

	2025		2024
Cash paid on operating lease liabilities	$	42,052	$	40,827
Right of use assets acquired under operating leases	$	39,083	$	37,319

Schedule of Maturity Analysis of Operating Leases Liabilities

Minimum lease payments under leases with terms greater than one year are as follows:

Year	Amount
Year ending May 31, 2026	$	43,313
Year ending May 31, 2027		25,703
Total		69,016
Less imputed interest		(4,935	)
Lease liability	$	64,081

Schedule of Lease Terms and Discount Rates

Lease terms and assumed discount rates are as follows:

	May 31, 2025		May 31, 2024
Average lease term	1.6 years		1.6 years
Discount rate	10	%	10	%

Income Taxes - Schedule of Changes in Valuation Allowance (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Changes in Valuation Allowance [Abstract]
Balance as of January 1	$ 15,774,044	$ 17,407,156	$ 15,705,088
Additions	223,918	702,123	1,705,603
Disposal	(7,503)	(2,335,235)	(3,535)
Balance as of December 31	$ 15,990,459	$ 15,774,044	$ 17,407,156

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

12 Months Ended

Nov. 30, 2025

May 31, 2025

DiamiR Biosciences Corp. [Member]

Schedule of Prepaid Expenses and Other Current Assets [Line Items]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	November 30, 2025		May 31, 2025
Advances to suppliers	$	—	$	45,252
Other		5,704		1,397
Total	$	5,704	$	46,649

Prepaid expenses and other current assets consist of the following:

	May 31, 2025		May 31, 2024
Deferred costs of equity financing	$	—	$	114,000
Advances to suppliers		45,252		—
Other		1,397		6,139
Total	$	46,649	$	120,139

Leases - Schedule of Supplemental Cash Flow Information and Non Cash Activity Related Lease (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	12 Months Ended
	May 31, 2025	May 31, 2024
Leases [Line Items]
Cash paid on operating lease liabilities	$ 42,052	$ 40,827
Right of use assets acquired under operating leases	$ 39,083	$ 37,319

Organization

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Organization [Line Items]

ORGANIZATION

1. ORGANIZATION

The consolidated financial statements include the financial statements of Aptorum Group Limited (the “Company”) and its subsidiaries. The Company and its subsidiaries are hereinafter collectively referred to as the “Group”.

The Company, formerly known as APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September 13, 2010 under the laws of the Cayman Islands with limited liability.

The Company researches and develops life science and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics Limited (“Aptorum Therapeutics”) and its indirect subsidiary companies.

On July 14, 2025 the Group and DiamiR Biosciences Corp. (“DiamiR”), have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger. The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger. Under the terms of the merger agreement and subject to stockholder approval, the Company will re-domicile to the state of Delaware prior to the closing of the merger (“Domestication”), and following the Domestication, acquire all of the outstanding capital stock of DiamiR in exchange for a number of shares of its common stock which will represent approximately 70% of the outstanding common stock of the Group, with the current equity holders of the Group retaining 30% of the common stock immediately following the consummation of the merger. The merger agreement has been approved by the boards of directors of both companies, and is subject to stockholder approval of both companies and other customary closing conditions.

Concurrently with the execution of the Merger Agreement, DiamiR and Aptorum Therapeutics, entered into a management services agreement, pursuant to which, Aptorum Therapeutics shall pay a monthly service fee and reimburse expenses to DiamiR in exchange for the officers and employees of DiamiR providing services to Aptorum Therapeutics to develop a diagnostic test for early detection and monitoring of progression of glioblastoma until the earlier of the closing of the Merger or December 31, 2025, and the respective agreement is extended to March 31, 2026, and then further extended to June 30, 2026. In addition, concurrently with the execution of the Merger Agreement, DiamiR, DiamiR LLC, a wholly owned subsidiary of DiamiR, the Company and Aptorum Therapeutics entered into an intellectual property license agreement (“Licensing Agreement”), pursuant to which DiamiR and DiamiR LLC shall license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics in exchange for upfront and periodic payments and royalties until the earlier of the closing of the Merger or December 31, 2025, the respective agreement have extended to March 31, 2026, and then further extended to June 30, 2026. Ian Huen, the Group’s Chairman and CEO, who beneficially owns approximately 87% of the Group’s total voting power, signed a voting and support agreement simultaneously with the execution of the Merger Agreement, pursuant to which he agreed to vote in favor of the transactions contemplated in the Merger Agreement.

Below summarizes the list of the major subsidiaries consolidated as of December 31, 2025:

Name	Incorporation date	Ownership	Place of incorporation	Principle activities
Aptorum Therapeutics Limited (“ATL”)	June 30, 2016	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED	May 16, 2017	100%	Hong Kong	Provision of management services to its holding company and fellow subsidiaries
Paths Innovations Limited	April 15, 2019	100%	Cayman Islands	Investment holding company
Paths Diagnostics Pte. Limited	June 5, 2019	75%	Singapore	Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited	June 30, 2017	80%	Cayman Islands	Research and development of life science and biopharmaceutical products

DiamiR Biosciences Corp. [Member]

Organization [Line Items]

ORGANIZATION

NOTE 1 — ORGANIZATION AND PRINCIPAL ACTIVITIES

DiamiR Biosciences Corp. (“DiamiR” or the “Company”) is a molecular diagnostic company focused on developing noninvasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s, Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology developed at the Company is based on quantitative analysis of circulating organ-enriched microRNAs in plasma. Short-term objectives of the Company include the development of Lab-Developed tests (LDTs) under CLIA guidelines based on the identified miRNA signatures. The tests will be used for screening, patient stratification, as well as disease and treatment monitoring. The Company’s patent portfolio includes United States patents, issued between 2014 and 2024 and set to expire between 2030 and 2038, and certain foreign counterparts, in seven patent families.

The Company was incorporated in 2014 and also operates through its wholly-owned subsidiary, DiamiR, LLC, which was incorporated as a limited liability company in Delaware in 2009. In 2014, the Company entered into a Share Exchange Agreement with DiamiR, LLC, pursuant to which the Company acquired 100% of the issued and outstanding units of DiamiR, LLC in a combination of entities under common control.

In July 2025, the Company entered into a definitive merger agreement with Aptorum Group Limited, a publicly traded Cayman Islands company (“Aptorum”). Pursuant to the merger agreement, if completed, shareholders of the Company would receive shares of the acquirer’s common stock in a share exchange. Accounting for the merger, if consummated, is not complete. Under the merger agreement, the Company’s outstanding convertible notes are expected to be converted to shares of common stock. Concurrent with the execution of the merger agreement, the companies entered into a management service agreement and a license agreement through the earlier of the closing of the merger or December 31, 2025 under which the Company will provide certain development services. In December 2025, the management service agreement and license agreement were extended through the earlier of the closing of the merger or March 31, 2026.

NOTE 1 — ORGANIZATION AND PRINCIPAL ACTIVITIES

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Schedule of Property and Equipment [Line Items]
Property, plant and equipment, gross	$ 4,784,728	$ 4,784,728
Less: accumulated depreciation	4,784,728	4,784,728
Property and equipment, net
Computer equipment [Member]
Schedule of Property and Equipment [Line Items]
Property, plant and equipment, gross	69,291	69,291
Furniture, fixture, and office and medical equipment [Member]
Schedule of Property and Equipment [Line Items]
Property, plant and equipment, gross	32,435	32,435
Leasehold improvements [Member]
Schedule of Property and Equipment [Line Items]
Property, plant and equipment, gross	108,187	108,187
Laboratory equipment [Member]
Schedule of Property and Equipment [Line Items]
Property, plant and equipment, gross	4,335,722	4,335,722
Motor vehicle [Member]
Schedule of Property and Equipment [Line Items]
Property, plant and equipment, gross	$ 239,093	$ 239,093

Subsequent Events (Details) - DiamiR Biosciences Corp. [Member] - Subsequent Event [Member] - USD ($)	Jul. 07, 2025	Jun. 30, 2025
Subsequent Events [Line Items]
Closing price of common stock	$ 500,000
Warrant exercise price (in Dollars per share)	$ 0.01
Warrant exercise term	5 years
Gross proceeds	$ 4,000,000
Received cash fee	250,000
Lieu of a number of warrants	$ 250,000
Convertible Notes [Member]
Subsequent Events [Line Items]
Face amount		$ 150,000

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	Nov. 30, 2025	May 31, 2025	May 31, 2024
Property and Equipment, Net [Line Items]
Total property and equipment		$ 105,344	$ 105,344
Accumulated depreciation		(85,315)	(64,487)
Property and equipment, net	$ 17,195	$ 20,029	40,857
Laboratory equipment [Member]
Property and Equipment, Net [Line Items]
Estimated Life		5 years
Total property and equipment		$ 88,388	88,388
Furniture [Member]
Property and Equipment, Net [Line Items]
Estimated Life		7 years
Total property and equipment		$ 11,780	11,780
Computer equipment [Member]
Property and Equipment, Net [Line Items]
Estimated Life		3 years
Total property and equipment		$ 5,176	$ 5,176

Leases - Schedule of Minimum Lease Payments (Details) - DiamiR Biosciences Corp. [Member]	May 31, 2025 USD ($)
Leases [Line Items]
Year ending May 31, 2026	$ 43,313
Year ending May 31, 2027	25,703
Total	69,016
Less imputed interest	(4,935)
Lease liability	$ 64,081

Long-Term Investment (Tables)

12 Months Ended

Dec. 31, 2025

Long-Term Investment [Abstract]

Schedule of Carrying Value of the Non-Marketable Investments Held

	December 31, 2025									December 31, 2024
	Cost basis		Upward adjustments		Impairment			Carrying value		Cost basis		Upward adjustments		Impairment			Carrying value
Investment A(1)	$	2,558,886	$	12,539,960	$	—		$	15,098,846	$	2,558,886	$	12,539,960	$	—		$	15,098,846
Investment B(2)		1,000,000		—		(1,000,000	)		—		1,000,000		—		(1,000,000	)		—
Investment C		520,821		—		(520,821	)		—		520,821		—		(520,821	)		—
	$	4,079,707	$	12,539,960	$	(1,520,821	)	$	15,098,846	$	4,079,707	$	12,539,960	$	(1,520,821	)	$	15,098,846

As of December 31, 2025 and 2024, this investment was pledged for a convertible note issued to a related party (Note 15).

Schedule of Unrealized Gains and Losses

	Year ended December 31, 2025		Year ended December 31, 2024			Year ended December 31, 2023
Upward adjustments(1)	$	—	$	—		$	6,431,088
Impairment(2)		—		(1,000,000	)		—
Total unrealized (loss) gain from fair value change of non-marketable investments, net	$	—	$	(1,000,000	)	$	6,431,088

As of December 31, 2025 and 2024, this investment was pledged for a convertible note issued to a related party (Note 15).

Variable Interest Entity

12 Months Ended

Dec. 31, 2025

Variable Interest Entity [Abstract]

VARIABLE INTEREST ENTITY

13. VARIABLE INTEREST ENTITY

The Company consolidates VIEs in which the Group has a variable interest and is determined to be the primary beneficiary. This determination is based on whether the Group has a variable interest (or combination of variable interests) that provides the Company with (a) the power to direct the activities that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses or right to receive benefits that could be potentially significant to the VIE. The Group continually reassesses whether it is the primary beneficiary of a VIE throughout the entire period the Group is involved with the VIE.

On December 30, 2021, three of the Group’s subsidiaries, Libra Sciences Limited (“Libra”, formerly known as Aptorum Pharmaceutical Development Limited), Mios Pharmaceuticals Limited (“Mios”) and Scipio Life Sciences Limited (“Scipio”), issued Class A and Class B ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share of economic benefit of the respective company, while each Class B ordinary share is entitled to 10 votes and 0.001 share of economic benefit of the respective company. Following such share issuances, the Group lost its majority voting rights in each of these three companies and only holds 48.33%, 48.39% and 48.36% economic interest in Libra, Mios and Scipio, respectively. However, the Group still holds a majority of each of these three company’s outstanding Class A ordinary shares and therefore will absorb/receive portions of these subsidiaries’ expected losses or residual returns. In addition, none of these three companies have sufficient equity to sustain its own activities, and they have two classes of ordinary shares which have different rights, benefits and obligations. We determined that all these three companies are variable interest entities (“VIE”). On December 31, 2021, Libra, Mios and Scipio further issued Class A ordinary shares to the Group in exchange of certain projects licenses. Upon these share issuances, the Group was holding 97.27% economic interest and 31.51% voting power in Libra, 97.93% economic interest and 36.17% voting power in Mios, and 97.93% economic interest and 35.06% voting power in Scipio, respectively.

We have considered each of these entity’s Memorandum and Article of Association and their respective board of directors (the sole director of each of Mios and Scipio is an executive director of the Group), and determined that we have the power to manage and make decisions that affect Mios and Scipio’s research and development activities, which activities most significantly impact Mios and Scipio’s economic performance. However, we do not have such power over Libra’s research and development activities, which activities most significantly impact Libra’s economic performance. Accordingly, we determined that we are the primary beneficiary of Mios and Scipio, but not the primary beneficiary of Libra.

In November 2024, the Group acquired 10,000 Class A Ordinary Shares and 5,850,000 Class B Ordinary Shares of Scipio, achieving control over the entity. As a result of this acquisition, Scipio is no longer classified as a VIE under the Group and it became a subsidiary under the Group.

In October 2024, Mios was dissolved and ceased operation and it was deemed disposed by the Group.

As at the year ended December 31, 2025 and 2024, the asset and liability of the consolidated VIE is both zero.

The Group’s maximum exposure to loss from its involvement with unconsolidated VIE represents the estimated loss that would be incurred if the VIE is liquidated, so that the fair value of the equity investment in VIE is zero and the amounts due from the VIE have to be fully impaired.

Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Schedule of Intangible Assets [Line Items]
Gross carrying amount	$ 423,858	$ 423,858
Less: accumulated amortization	423,858	423,858
Intangible assets, net
Prepaid patented licenses [Member]
Schedule of Intangible Assets [Line Items]
Gross carrying amount	200,000	200,000
Less: accumulated amortization	200,000	200,000
Intangible assets, net
Computer software [Member]
Schedule of Intangible Assets [Line Items]
Gross carrying amount	223,858	223,858
Less: accumulated amortization	223,858	223,858
Intangible assets, net

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Non-Controlling Interest

12 Months Ended

Dec. 31, 2025

Non-Controlling Interest [Abstract]

NON-CONTROLLING INTEREST

18. NON-CONTROLLING INTEREST

On February 1, 2023, Aptorum Medical Limited issued 122 shares to Clark Cheng in according to the appointment agreement, decreasing the equity interest of the Company from 91% to 90%. As a result, a total deficit of $67,766 was reclassified from additional paid-in capital to non-controlling interests within the Group’s consolidated financial statements for the years ended December 31, 2023.

Lease

12 Months Ended

Dec. 31, 2025

May 31, 2025

Lease [Line Items]

LEASE

14. LEASE

As of December 31, 2025, the Group has a long-term operating lease for laboratories with remaining term expiring in 2026 and a remaining lease term of 0.2 years. Weighted average discount rates used in the calculation of the operating lease liability is 8%. The discount rates reflect the estimated incremental borrowing rate, which includes an assessment of the credit rating to determine the rate that the Group would have to pay to borrow, on a collateralized basis for a similar term, an amount equal to the lease payments in a similar economic environment.

	For the year ended December 31, 2025			For the year ended December 31, 2024			For the year ended December 31, 2023
Lease cost
Operating lease cost		—			50,520		252,345
Short-term lease cost		—			3,374		65,221
Total lease cost	$	—		$	53,894		317,566

Other information
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	98,448		$	120,824		389,365
Weighted-average remaining lease term – operating leases		0.2 years			1.2 years		1.9 years
Weighted-average discount rate – finance leases		—	%		—	%	—	%
Weighted-average discount rate – operating leases		8.0	%		8.0	%	8.0	%

For the years ended December 31, 2025, the Group did not recognize any impairment losses and loss on disposal of right-of-use assets.

For the year ended December 31, 2024, an impairment loss of $144,051 on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of a right-of-use asset related to a lease of laboratory may not be recoverable.

For the year ended December 31, 2023, an impairment loss of $200,916 on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of a right-of-use asset related to a lease of clinic may not be recoverable. Additionally, the Group early terminated a lease agreement for a right-of-use asset relating to an office, which resulted in a recognized loss on early termination of the right-of-use asset totaling $31,030 in other operating expenses.

The maturity analysis of operating leases liabilities as of December 31, 2025 is as follows:

	December 31, 2025
Remaining periods ending December 31,
2026	24,573
Total future undiscounted cash flow	24,573
Less: Discount on operating lease liabilities	(145	)
Present value of operating lease liabilities	24,428

DiamiR Biosciences Corp. [Member]

Lease [Line Items]

LEASE

NOTE 9 — LEASES

As of May 31, 2023, the Company had a lease for laboratory space with a term of one year and a one-year Company renewal option. The Company renewed the lease on a one-year basis in each of the years ended May 31, 2024 and 2025. The Company considers exercise of its renewal options to be probable. Accordingly, it has recorded right of use assets and lease liabilities related to the lease.

The lease agreement does not provide an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments and recording lease liabilities. In determining this rate, the Company estimated the rate of interest it would pay on collateralized loans with similar payment terms, in a similar economic environment, by reference to comparable lessee companies.

Supplemental cash flow information and non-cash activity related to leases include the following in the years ended May 31:

	2025		2024
Cash paid on operating lease liabilities	$	42,052	$	40,827
Right of use assets acquired under operating leases	$	39,083	$	37,319

Lease terms and assumed discount rates are as follows:

	May 31, 2025		May 31, 2024
Average lease term	1.6 years		1.6 years
Discount rate	10	%	10	%

Minimum lease payments under leases with terms greater than one year are as follows:

Year	Amount
Year ending May 31, 2026	$	43,313
Year ending May 31, 2027		25,703
Total		69,016
Less imputed interest		(4,935	)
Lease liability	$	64,081

The Company also leases office space on a monthly basis. Total lease costs were $40,103 and $47,493 in the years ended May 31, 2025 and 2024, respectively

Segment Information - Schedule of Segment Revenue and Expenses (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	6 Months Ended		12 Months Ended
	Nov. 30, 2025	Nov. 30, 2024	May 31, 2025	May 31, 2024
Segment Reporting Information [Line Items]
Revenue	$ 130,355	$ 442,820	$ 631,729	$ 1,319,531
Research and development
Research and development			650,591	1,156,860
Other R&D				2,236
General and administrative
General and administrative			624,388	614,074
Patents			44,363	30,167
Depreciation	9,772	10,155	20,828	20,052
Offering costs			150,526
Rent and facilities			53,483	55,600
Other			35,918	86,204
Interest expense			82,046	48,599
Income taxes	(174,546)	$ 10,901	17,939	114,403
Net loss	$ (409,955)		(743,235)	(614,405)
Salaries and benefits [Member]
Research and development
Research and development			449,344	692,875
General and administrative
General and administrative			105,761	117,883
Consultants and contractors [Member]
Research and development
Research and development			176,935	278,837
General and administrative
General and administrative			213,509	292,234
Stock based compensation [Member]
Research and development
Research and development			24,312	182,912
General and administrative
General and administrative				$ 11,934

Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of the Group’s Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)	Dec. 31, 2025 USD ($)
Financial liabilities:
Warrant liabilities	$ 306,000
Total	306,000
Level 1 [Member] \| Fair Value, Recurring [Member]
Financial liabilities:
Warrant liabilities
Total
level 2 [Member] \| Fair Value, Recurring [Member]
Financial liabilities:
Warrant liabilities
Total
Level 3 [Member] \| Fair Value, Recurring [Member]
Financial liabilities:
Warrant liabilities	306,000
Total	$ 306,000

- Definition

Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.

+ References + Details

Long-Term Deposits

12 Months Ended

Dec. 31, 2025

Long-Term Deposits [Abstract]

LONG-TERM DEPOSITS

9. LONG-TERM DEPOSITS

Long-term deposits as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Rental deposits	$	—	$	71,823
	$	—	$	71,823

Property and Equipment, Net

12 Months Ended

Dec. 31, 2025

May 31, 2025

Property and Equipment, Net [Line Items]

PROPERTY AND EQUIPMENT, NET

7. PROPERTY AND EQUIPMENT, NET

Property and equipment as of December 31, 2025 and 2024 consisted of:

	December 31, 2025		December 31, 2024
Computer equipment	$	69,291	$	69,291
Furniture, fixture, and office and medical equipment		32,435		32,435
Leasehold improvements		108,187		108,187
Laboratory equipment		4,335,722		4,335,722
Motor vehicle		239,093		239,093
		4,784,728		4,784,728
Less: accumulated depreciation		4,784,728		4,784,728
Property and equipment, net	$	—	$	—

Depreciation expenses for property, plant and equipment amounted to $nil, $235,827 and $1,041,234 for the years ended December 31, 2025, 2024 and 2023 respectively.

For the year ended December 31, 2025, no impairment loss was recorded.

For the year ended December 31, 2024, an impairment loss relating to laboratory equipment, computer equipment, and furniture, fixture, and office equipment amounted to $1,421,782 and $5,520 were recorded in research and development expenses and other operating expenses, respectively, as the Group considered that the carrying amount of these property and equipment may not be recoverable.

For the year ended December 31, 2023, an impairment loss relating to the office and medical equipment, and computer equipment related to the Hong Kong healthcare services amounted to $28,128, was recorded in other operating expenses, as the Group considered that, with the termination of the healthcare services, the carrying amount of these property and equipment are not recoverable and are fully impaired.

For the years ended December 31, 2025 and 2024, the Group recorded $nil and $58,621 gain on disposal of medical equipment in other operation expenses, respectively. For the year ended December 31, 2023, the Group recorded $79,822 of loss on disposal of laboratory equipment, and furniture, fixture, and office and medical equipment in other operating expenses.

DiamiR Biosciences Corp. [Member]

Property and Equipment, Net [Line Items]

PROPERTY AND EQUIPMENT, NET

NOTE 6 — PROPERTY AND EQUIPMENT, NET

Property and equipment, net, consists of the following:

	Estimated Life	May 31, 2025			May 31, 2024
Laboratory equipment	5 years	$	88,388		$	88,388
Furniture	7 years		11,780			11,780
Computer equipment	3 years		5,176			5,176
Total property and equipment			105,344			105,344
Accumulated depreciation			(85,315	)		(64,487	)
Property and equipment, net		$	20,029		$	40,857

Depreciation expense was $20,828 and $20,052 for the years ended May 31, 2025 and 2024, respectively.

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	Nov. 30, 2025	May 31, 2025	May 31, 2024
Schedule of Prepaid Expenses and Other Current Assets [Line Items]
Deferred costs of equity financing			$ 114,000
Advances to suppliers		45,252
Other	5,704	1,397	6,139
Total	$ 5,704	$ 46,649	$ 120,139

Lease (Details) - USD ($)	12 Months Ended
Lease (Details) - USD ($)	Dec. 31, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024	Dec. 31, 2023
Leases [Line Items]
Weighted average remaining lease term	2 months 12 days		1 year 2 months 12 days		1 year 10 months 24 days
Operating lease weighted average discount rates	8.00%		8.00%		8.00%
Impairment loss of right-of-use assets			$ 144,051		$ 200,916
Lease cost			$ 53,894		317,566
DiamiR Biosciences Corp. [Member]
Leases [Line Items]
Weighted average remaining lease term		1 year 7 months 6 days		1 year 7 months 6 days
Operating lease weighted average discount rates		10.00%		10.00%
Lease term				1 year
Lease term renewal		1 year		1 year
Lease cost		$ 40,103		$ 47,493
Office [Member]
Leases [Line Items]
Impairment loss of right-of-use assets					$ 31,030

Summary of Significant Accounting Policies (Tables)

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Summary of Significant Accounting Policies [Line Items]

Schedule of Fair Value Hierarchy of the Group’s Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

	As of December 31, 2025
	Fair Value Measurement at the Reporting Date using
	Quoted price in active markets for identical assets Level 1		Significant other observable inputs Level 2		Significant unobservable inputs Level 3		Total
Financial liabilities:
Warrant liabilities		—		—		306,000		306,000
Total	$	—	$	—	$	306,000	$	306,000

Schedule of Estimated Useful Lives

Depreciation of property and equipment is provided using the straight-line method over their estimated useful lives:

Computer equipment		3 years
Furniture, fixture, and office and medical equipment		5 years
Leasehold improvements		Shorter of the remaining lease terms or 5 years
Laboratory equipment		5 years
Motor vehicle		5 years

DiamiR Biosciences Corp. [Member]

Summary of Significant Accounting Policies [Line Items]

Schedule of Contract Assets and Deferred Revenues

Contract assets and deferred revenues related to contracts with customers consist of the following as of November 30, 2025 and May 31, 2025:

	Contract assets						Contract liabilities Deferred revenue
	Contract costs		Unbilled revenue		Total		Contract liabilities Deferred revenue
May 31, 2024	$	—	$	—	$	—	$	—
Net change due to billings		—		—		—		43,982
Revenue recognized		—		—		—		—
May 31, 2025		—		—		—		43,982
Net change due to billings		—		86,373		86,373		—
Revenue recognized		—		86,373		86,373		43,982
November 30, 2025	$	—	$	—	$	—	$	—

Contract assets and deferred revenues related to contracts with customers consist of the following as of May 31, 2025 and May 31, 2024:

	Contract assets				Contract liability
	Contract costs		Unbilled revenue		Total		Deferred revenue
May 31, 2023	$	—	$	—	$	—	$	—
Net change due to billings		—		—		—		—
Revenue recognized		—		—		—		—
May 31, 2024		—		—		—		—
Net change due to billings		—		—		—		43,982
Revenue recognized		—		—		—		—
May 31, 2025	$	—	$	—	$	—	$	43,982

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2025	Nov. 30, 2025	May 31, 2025	Dec. 31, 2024	May 31, 2024
DiamiR Biosciences Corp
Ordinary shares, par value (in Dollars per share)		$ 0.001	$ 0.001		$ 0.001
Ordinary shares, shares authorized (in Shares)		100,000,000	100,000,000		100,000,000
Ordinary shares, shares issued (in Shares)		4,440,891	4,440,891		4,440,891
Ordinary shares, shares outstanding (in Shares)		4,440,891	4,440,891		4,440,891
Preferred stock, par value (in Dollars per share)		$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized (in Shares)		10,000,000	10,000,000		10,000,000
Preferred stock, shares issued (in Shares)
Preferred stock, shares outstanding (in Shares)
Class A Ordinary Shares
Ordinary shares, par value (in Dollars per share)	$ 0.00001			$ 0.00001
Ordinary shares, shares authorized (in Shares)	9,999,996,000,000			9,999,996,000,000
Ordinary shares, shares issued (in Shares)	6,346,823			3,811,823
Ordinary shares, shares outstanding (in Shares)	6,346,823			3,811,823
Class B Ordinary Shares
Ordinary shares, par value (in Dollars per share)	$ 0.00001			$ 0.00001
Ordinary shares, shares authorized (in Shares)	4,000,000			4,000,000
Ordinary shares, shares issued (in Shares)	1,796,934			1,796,934
Ordinary shares, shares outstanding (in Shares)	1,796,934			1,796,934

Commitments and Contingencies

6 Months Ended

12 Months Ended

Nov. 30, 2025

Dec. 31, 2025

May 31, 2025

Commitments and Contingencies [Line Items]

COMMITMENTS AND CONTINGENCIES

21. COMMITMENTS AND CONTINGENCIES

Contingent Payment Obligations

As of December 31, 2025, the Group does not have any non-cancellable purchase commitments.

The Group has contingency payment obligations under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or milestone is met.

Milestone payments are due upon achievements of specific conditions, such as Investigational New Drugs (“IND”) filing or U.S. Food and Drug Administration (“FDA”) approval, first commercial sale of the licensed products, or other achievements. The aggregate amounts of the contingent milestone payments that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as of December 31, 2025 are below:

	Amount
Drug molecules: up to the conditions and milestones of
From entering phase 1 to before first commercial sale		920,000
First commercial sale		800,000
Net sales amount more than certain threshold in a year		7,000,000
Subtotal	$	8,720,000

For the years ended December 31, 2025, 2024 and 2023, the Group incurred $nil, $61,123 and $50,000 milestone payments under license agreements, respectively. For the years ended December 31, 2025, 2024 and 2023, the Group did not incur any royalties or research and development funding, respectively.

Legal proceedings

The Group is party to a lawsuit initially filed on notice on September 3, 2024, by Karen Cheung (“Plaintiff”) in the Supreme Court of the State of New York, County of New York (“State Court Action”) (Index No. 654541/2024), which sought relief arising from (i) violations of the federal Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 § U.S.C. 1961(c), (ii)conspiracy to violate RICO, 18 U.S.C. § 1961(d), (iii) fraud, (iii) breach of fiduciary duty, (iv) negligent misrepresentation, (v) unjust enrichment, (vi) civil conspiracy and (vii) violations of the federal Securities Act of 1933, 15 § U.S.C. 77a et. seq. On December 27, 2024, the Group filed a Notice of Removal in the U.S. District Court for the Southern District of New York (Case No.1:24-cv-09969-VSB-OTW) removing the State Court Action to federal court. On December 30, 2024, the Group filed a demand for service of the complaint on the Group. Plaintiff filed and served her Complaint on the Group on February 24, 2025, alleging claims for (i) violations of RICO 18 U.S.C. § 1962(c), (ii) conspiracy to violate RICO 18 U.S.C. § 1962(d), (iii) fraud; (iv) aiding and abetting breach of fiduciary duty, (v) unjust enrichment, and (vi) civil conspiracy. Following a motion, Plaintiff was granted leave to amend her Complaint and filed a First Amended Complaint on September 2, 2025. The parties entered into a briefing schedule on the Group’s anticipated motion to dismiss (“Motion to Dismiss”), and the Group filed its opening brief on the Motion to Dismiss on July 18, 2025. Plaintiff filed her opposition to the Motion to Dismiss on September 5, 2025, and the Company’s reply in support of the Motion to Dismiss is due on October 6, 2025. The Group continues to believe that Plaintiff’s claims have no merit. As such, the Group will continue to vigorously defend against Plaintiff’s claims. At this time, it is too early to estimate the costs and expenses of defending the lawsuit.

From time to time, the Group may be subject to certain legal proceedings, claims and disputes that arise in the ordinary course of business. Although the outcomes of these legal proceedings cannot be predicted, the Group does not believe these actions, in the aggregate, will have a material adverse impact on its financial position, results of income or liquidity.

DiamiR Biosciences Corp. [Member]

Commitments and Contingencies [Line Items]

COMMITMENTS AND CONTINGENCIES

NOTE 9 — COMMITMENTS AND CONTINGENCIES

Legal

The Company is not involved in any legal matters arising in the normal course of business. While incapable of estimation, in the opinion of the management, the individual regulatory and legal matters in which it might involve in the future are not expected to have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

Advisory Fees

In the three months ended August 31, 2025, the Company entered into a financial advisory agreement with H.C. Wainwright & Co., LLC (“Wainwright”), with Wainwright to act as exclusive financial advisor to the company in connection with the merger with Aptorum. As compensation for its services, upon the consummation of the Merger, Wainwright will receive common stock purchase warrants to purchase up to a number of shares of common stock of the combined company equal to $500,000 divided by the closing price of the combined company’s common stock on the date of consummation of the Merger, which warrants shall have an exercise price of $0.01 per share and a term of exercise of five years. In the event that the company (or the combined company) consummates one or more financing transactions, with gross proceeds of at least $4,000,000 following the execution of the Merger Agreement through and including the consummation of the Merger and within 90 days thereafter, Wainwright shall receive a cash fee of $250,000, which cash fee shall be paid in lieu of a number of warrants equal to $250,000. The Executive Director and co-founder of the company, is currently a managing director of Wainwright.

NOTE 10 — COMMITMENTS AND CONTINGENCIES

Legal

Accounts Receivable - Schedule of Accounts Receivable (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	Nov. 30, 2025	May 31, 2024
Schedule of Accounts Receivable [Line Items]
Accounts receivable net	$ 131,091	$ 89,281
Unbilled revenue from contracts with customers [Member]
Schedule of Accounts Receivable [Line Items]
Accounts receivable net	42,391
Management services revenue from Aptorum [Member]
Schedule of Accounts Receivable [Line Items]
Accounts receivable net	$ 88,700

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	May 31, 2025	May 31, 2024
Schedule of Deferred Tax Assets and Liabilities [Line Items]
Tax benefit of net operating loss carry-forward (NOL)	$ 351,453	$ 247,637
FIN48 reduction in NOL	(269,420)	(219,793)
Stock compensation	351,136	346,030
Research and development expenses	422,170	372,544
Other	1,152	2,432
Total deferred tax assets:	856,490	748,850
Deferred tax liabilities	(8,152)	(4,583)
Net deferred tax assets:	848,338	744,267
Valuation allowance for deferred tax assets	(848,338)	(744,267)
Deferred tax assets, net of valuation allowance

Basis of Presentation (Details) - DiamiR Biosciences Corp. [Member]	6 Months Ended		12 Months Ended
	Nov. 30, 2025 USD ($)	Nov. 30, 2024 USD ($)	May 31, 2025 USD ($)	May 31, 2024 USD ($)
Basis of Presentation [Line Items]
Business segment unit	1
Net loss	$ (409,955)		$ (743,235)	$ (614,405)
Net cash used in operating activities	$ (215,008)	$ (145,861)	(313,440)	(308,914)
Limited Operating [Member]
Basis of Presentation [Line Items]
Net loss			(743,235)	$ (614,405)
Net cash used in operating activities			$ (313,440)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Income Taxes - Schedule of Reconciliation of Effective Tax Rate to Statutory Federal Rate (Details) - DiamiR Biosciences Corp. [Member]	12 Months Ended
	May 31, 2025	May 31, 2024
Schedule of Reconciliation of Effective Tax Rate to Statutory Federal Rate [Line Items]
Income taxes at Federal statutory rate	21.00%	21.00%
Discounts and interest on notes	(2.40%)	(2.10%)
Financing costs	(4.30%)
State taxes		(4.20%)
Other	(2.30%)	(1.20%)
Change in valuation allowance	(14.30%)	(36.30%)
Income tax provision	(2.30%)	(22.90%)

Related Party Balances and Transactions (Details)					12 Months Ended
Related Party Balances and Transactions (Details)	Jan. 13, 2022 USD ($)	Dec. 30, 2021	Nov. 17, 2021 AUD ($)	Aug. 13, 2019 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2025 HKD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 HKD ($)	Apr. 30, 2024	Dec. 31, 2022 USD ($)
Related Party Balances and Transactions [Line Items]
Line of credit debt financing				$ 15,000,000
Line of credit maturity date	Jan. 12, 2023			Aug. 12, 2022
Line of credit period	3 years
Interest rate	10.00%				8.00%	8.00%
Undrawn line of credit amount					$ 12,000,000
Loan for the borrowers (in Dollars)			$ 4,700,000
Loans interest-bearing rate			10.00%
Line of credit amount	$ 1,000,000
Outstanding amount					500,000
Allowance for credit loss recognized							$ 1,184
Allowance for credit loss								$ 521,007
Services fees								3,205	$ 25,000
CGY Investments Limited [Member]
Related Party Balances and Transactions [Line Items]
Services fees						$ 104,000
Aeneas Management Limited [Member]
Related Party Balances and Transactions [Line Items]
Line of credit period				4 years
CGY Investments Limited [Member]
Related Party Balances and Transactions [Line Items]
Services fees					13,333
Services fees adjusted					21,949	171,200
ACC Medical Limited [Member]
Related Party Balances and Transactions [Line Items]
Services fees					13,018	101,542
Services fees adjusted					$ 18,359	$ 143,200
Compensation and Benefits Trust								$ 28,615			$ 23,275
CGY Investments Limited [Member]
Related Party Balances and Transactions [Line Items]
Voting interest										10.00%
Ian Huen [Member]
Related Party Balances and Transactions [Line Items]
Owned percentage					34.56%
Maximum [Member]
Related Party Balances and Transactions [Line Items]
Decreased ownership percentage		50.00%
Minimum [Member]
Related Party Balances and Transactions [Line Items]
Decreased ownership percentage		20.00%

Segment Information (Tables)

12 Months Ended

May 31, 2025

DiamiR Biosciences Corp. [Member]

Segment Information [Line Items]

Schedule of Segment Revenue and Expenses

Segment revenue and expenses are as follows in the years ended May 31, 2025 and 2024.

	2025			2024
Revenue	$	631,729		$	1,319,531
Research and development
Salaries and benefits		449,344			692,875
Consultants and contractors		176,935			278,837
Stock based compensation		24,312			182,912
Other R&D		—			2,236
Total research and development		650,591			1,156,860
General and administrative
Salaries and benefits		105,761			117,883
Consultants and contractors		213,509			292,234
Stock based compensation		—			11,934
Patents		44,363			30,167
Depreciation		20,828			20,052
Offering costs		150,526			—
Rent and facilities		53,483			55,600
Other		35,918			86,204
Total general and administrative		624,388			614,074
Interest expense		82,046			48,599
Income taxes		17,939			114,403
Net loss	$	(743,235	)	$	(614,405	)

Related Party Balances and Transactions (Tables)

12 Months Ended

Dec. 31, 2025

Amounts due from related parties consisted of the following as of December 31, 2025 and 2024:

	December 31, 2025			December 31, 2024
Current
Libra Sciences Limited (Note b)		522,192			522,192
Allowance for credit loss		(522,192	)		(522,192	)
Total	$	—		$	—

Amounts due to related parties consisted of the following as of December 31, 2025 and 2024:

		December 31, 2025		December 31, 2024
Current
Aeneas Group Limited (Note a)	$	79,180	$	79,180
Ian Huen		—		464
	$	79,180	$	79,644
Convertible notes to a related party
Jurchen Investment Corporation (Note 15)		3,418,500		3,238,500
Total	$	3,418,500	$	3,238,500

	Year ended December 31, 2025		Year ended December 31, 2024		Year ended December 31, 2023
Loan from related parties (Note a)
– Aeneas Group Limited	$	—	$	—	$	2,500,000

Issuance of Convertible Note to related parties (Note 15)
– Jurchen Investment Corporation	$	—	$	—	$	3,000,000

Settlement of loan from a related party through issuance of Convertible Note (Note 15)
– Aeneas Group Limited	$	—	$	—	$	3,000,000

Interest expenses (Note a and Note 15)
– Aeneas Group Limited	$	—	$	—	$	71,123
– Jurchen Investment Corporation	$	180,000	$	180,000	$	58,500
– Aenco Technologies Ltd	$	—	$	—	$	(13,234	)

Loan to related parties (Note b)
– Libra Sciences Limited	$	—	$	—	$	92,459

Loan repayment and interest received from a related party (Note b)
– Talem Medical Group Limited	$	—	$	—	$	611,641

	Year ended December 31, 2025		Year ended December 31, 2024		Year ended December 31, 2023
Interest income (Note b)
– Talem Medical Group Limited	$	—	$	—	$	4,637
– Libra Sciences Limited	$	—	$	—	$	8,963

Consultant, secondment, management and administrative services fees (Note c)
– CGY Investments Limited	$	—	$	—	$	153,640
– ACC Medical Limited	$	—	$	—	$	138,768

Administrative management services (Note d)
– Libra Sciences Limited	$	—	$	—	$	9,615

Healthcare services income
– Aeneas Management Limited	$	—	$	—	$	961

Summary of Significant Accounting Policies - Schedule of Contract Assets and Deferred Revenues (Details) - DiamiR Biosciences Corp. [Member] - USD ($)	6 Months Ended	12 Months Ended
	Nov. 30, 2025	May 31, 2025	May 31, 2024
Schedule of Contract Assets and Deferred Revenues [Line Items]
Contract assets at beginning
Contract liabilities Deferred revenue at beginning
Contract assets Net change due to billings	86,373
Contract liabilities Deferred revenue Net change due to billings
Contract assets Revenue recognized	86,373
Contract liabilities Deferred revenue Revenue recognized
Contract assets at ending
Contract liabilities Deferred revenue at ending
Contract Costs [Member]
Schedule of Contract Assets and Deferred Revenues [Line Items]
Contract assets at beginning
Contract assets Net change due to billings
Contract assets Revenue recognized
Contract assets at ending
Unbilled Revenues [Member]
Schedule of Contract Assets and Deferred Revenues [Line Items]
Contract assets at beginning
Contract assets Net change due to billings	86,373
Contract assets Revenue recognized	86,373
Contract assets at ending
Contract liabilities Deferred revenue [Member]
Schedule of Contract Assets and Deferred Revenues [Line Items]
Contract liabilities Deferred revenue at beginning	43,982
Contract liabilities Deferred revenue Net change due to billings		43,982
Contract liabilities Deferred revenue Revenue recognized	43,982
Contract liabilities Deferred revenue at ending		$ 43,982

Related Party Balances and Transactions

12 Months Ended

Dec. 31, 2025

RELATED PARTY BALANCES AND TRANSACTIONS

12. RELATED PARTY BALANCES AND TRANSACTIONS

The following is a list of a director and related parties to which the Group has transactions with:

(a) Ian Huen, the Chief Executive Officer and Executive Director of the Group since November 2023. He was a Non-executive Director from June 2022 to November 2023. Before June 2022, he was the Chief Executive Officer and Executive Director;

(b) Jurchen Investment Corporation, the holding company and an entity controlled by Ian Huen;

(d) Aeneas Group Limited, an entity controlled by Ian Huen;

(e) Aenco Technologies Ltd, an entity being 34.56% effectively owned by Ian Huen;

(f) Aeneas Management Limited, an entity controlled by Ian Huen;

(g) Libra Sciences Limited, an entity which was originally a wholly owned subsidiary of ATL. Since December 30, 2021, Libra has been turned into a related party to the Group due to the voting power owned by ATL is decreased to below 50% but more than 20%. (Note 13)

Amounts due from related parties, net

Amounts due from related parties consisted of the following as of December 31, 2025 and 2024:

	December 31, 2025			December 31, 2024
Current
Libra Sciences Limited (Note b)		522,192			522,192
Allowance for credit loss		(522,192	)		(522,192	)
Total	$	—		$	—

Amounts due to related parties

Amounts due to related parties consisted of the following as of December 31, 2025 and 2024:

		December 31, 2025		December 31, 2024
Current
Aeneas Group Limited (Note a)	$	79,180	$	79,180
Ian Huen		—		464
	$	79,180	$	79,644
Convertible notes to a related party
Jurchen Investment Corporation (Note 15)		3,418,500		3,238,500
Total	$	3,418,500	$	3,238,500

Related party transactions

Related party transactions consisted of the following for the years ended December 31, 2025, 2024 and 2023:

	Year ended December 31, 2025		Year ended December 31, 2024		Year ended December 31, 2023
Loan from related parties (Note a)
– Aeneas Group Limited	$	—	$	—	$	2,500,000

Issuance of Convertible Note to related parties (Note 15)
– Jurchen Investment Corporation	$	—	$	—	$	3,000,000

Settlement of loan from a related party through issuance of Convertible Note (Note 15)
– Aeneas Group Limited	$	—	$	—	$	3,000,000

Interest expenses (Note a and Note 15)
– Aeneas Group Limited	$	—	$	—	$	71,123
– Jurchen Investment Corporation	$	180,000	$	180,000	$	58,500
– Aenco Technologies Ltd	$	—	$	—	$	(13,234	)

Loan to related parties (Note b)
– Libra Sciences Limited	$	—	$	—	$	92,459

Loan repayment and interest received from a related party (Note b)
– Talem Medical Group Limited	$	—	$	—	$	611,641

	Year ended December 31, 2025		Year ended December 31, 2024		Year ended December 31, 2023
Interest income (Note b)
– Talem Medical Group Limited	$	—	$	—	$	4,637
– Libra Sciences Limited	$	—	$	—	$	8,963

Consultant, secondment, management and administrative services fees (Note c)
– CGY Investments Limited	$	—	$	—	$	153,640
– ACC Medical Limited	$	—	$	—	$	138,768

Administrative management services (Note d)
– Libra Sciences Limited	$	—	$	—	$	9,615

Healthcare services income
– Aeneas Management Limited	$	—	$	—	$	961

Note a: On August 13, 2019, Aptorum Therapeutics Limited (“ATL”), a wholly owned subsidiary of the Company, entered into financing arrangements with Aeneas Group Limited, a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing ATL to access up to a total $15 million in line of credit debt financing. Both line of credits have originally matured on August 12, 2022. ATL and Aeneas Group Limited has mutually agreed to extend the line of credit arrangement further four years to August 12, 2026. The interest on the outstanding principal indebtedness is at the rate of 8% per annum. ATL may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. As of the issuance date of this consolidated financial statements, the undrawn line of credit facility is $12 million.

Note b: On November 17, 2021, ATL entered into a loan agreement with Talem Medical Group Limited (the “Borrower”). According to the loan agreement, ATL granted a loan of up to AUD 4,700,000 for the Borrower for general working capital purposes of the Borrower and its subsidiaries. The loan is interest-bearing at a rate of 10% per annum and secured by the entire issued shares of Talem Medical Group (Australia) Pty Limited held by the Borrower. The loan is initially matured 6 months from the date of the first drawdown. The maturity date was extended for 6 months to the first extended maturity date, and further extended for another 6 months to the second extended maturity date. As of the date of the issuance of this consolidated financial statements, there is no outstanding balance from the Borrower following a repayment in February 2023.

On January 13, 2022, ATL entered a line of credit facility with Libra Sciences Limited to provide up to a total $1 million line of credit for its daily operation. The line of credit is originally matured on January 12, 2023, and is extended for additional 3 years. The interest on the outstanding principal indebtedness is at the rate of 10% per annum. ATL and Libra Science Limited mutually agreed to terminate the line of credit agreement effect as of March 31, 2023. All existing liabilities arising from the line of credit agreement shall remain enforceable and repayable on demand by ATL. As of the issuance date of this consolidated financial statements, $0.5 million is outstanding from Libra Sciences Limited. For the year ended December 31, 2025, 2024 and 2023, the Group has assessed that the amounts due from Libra Science Limited and its subsidiary are potentially unrecoverable, and an allowance for credit loss amounting to $nil, $1,184 and $521,007 has been recognized, respectively.

Note c: CGY Investment Limited provided certain consultancy, advisory and management services to the Group on potential investment projects related to healthcare or R&D platforms. CGY Investment Limited is initially entitled to receive HK $104,000 (approximately $13,333) per calendar month plus reimbursement; such monthly service fee is adjusted to HK$171,200 (approximately US$21,949) with effect from March 1, 2022. In August 2023, CGY Investment Limited agreed to suspend its monthly services fee from August 1, 2023. In November 2023, CGY Investment Limited and the Group reached a mutual agreement to terminate their contractual relationship.

ACC Medical Limited provided certain consultancy, advisory, and management services to the Group on clinic operations and other related projects for clinics’ business development. ACC Medical Limited is initially entitled to receive HK $101,542 (approximately $13,018) per calendar month plus reimbursement; such monthly service fee is adjusted to HK$143,200 (approximately US$18,359 per month) effective from March 1, 2022. During the year ended December 31, 2023 and 2022, ACC Medical Limited also received $28,615 and $23,275 one-off compensation respectively. The agreement was terminated on June 30, 2023.

Note d: On January 1, 2022, Aptus Management Limited (“AML”), a wholly owned subsidiary of the Company, entered into an administrative management services agreement with Libra Sciences Limited. According to the agreement, AML will provide documentation and administrative services, include but are not limited to human resources and payroll administration, general secretarial and administrative support, and accounting and financial reporting services. AML is entitled to receive a fixed amount of services fees of HKD 25,000 (approximately $3,205) per calendar month with the original expiry date on December 31, 2023. AML and Libra Sciences Limited mutually agreed to terminate the administrative management service agreement effect as of March 31, 2023.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Long-Term Deposits - Schedule of Long-Term Deposits (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Schedule of Long-Term Deposits [Abstract]
Rental deposits		$ 71,823
Total		$ 71,823